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Abstract
The Protease Inhibitor Monotherapy Versus Ongoing Triple
Therapy (PIVOT) trial: a randomised controlled trial of a
protease inhibitor monotherapy strategy for long-term
management of human immunodeficiency virus infection
Nicholas I Paton,1,2* Wolfgang Stöhr,1 Lars Oddershede,3
Alejandro Arenas-Pinto,1 Simon Walker,4 Mark Sculpher4
and David T Dunn1 on behalf of the PIVOT trial team†
1Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical
Trials and Methodology, University College London, London, UK
2Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
3Danish Centre for Healthcare Improvements, Faculty of Social Sciences and Faculty of Health
Sciences, Aalborg University, Aalborg, Denmark
4Centre for Health Economics, University of York, York, UK
*Corresponding author nick_paton@nuhs.edu.sg
†Members of the PIVOT trial team are listed in the Acknowledgements
Background: Standard-of-care antiretroviral therapy (ART) for human immunodeficiency virus (HIV)
infection uses a combination of drugs, until now considered essential to minimise treatment failure and
development of drug resistance. Protease inhibitors (PIs) are potent with a high genetic barrier to resistance
and have the potential for use as monotherapy after viral load (VL) suppression achieved on combination
therapy. However, longer-term resistance and toxicity risks are uncertain.
Objective: To compare the effectiveness, toxicity profile and cost-effectiveness of PI monotherapy with
those of standard-of-care triple therapy in a pragmatic long-term clinical trial.
Design: Open-label, parallel-group, randomised controlled trial.
Setting: Forty-three HIV clinical centres in the UK NHS.
Participants: HIV-positive adults taking standard combination ART with a suppressed VL for ≥ 6 months.
Interventions: Patients were randomised to maintain ongoing triple therapy (OT) or switch to a strategy
of physician-selected ritonavir-boosted PI monotherapy (PI-mono), with prompt return to combination
therapy in the event of VL rebound.
Main outcome measures: The primary outcome was reduction of future drug options, defined as new
intermediate-/high-level resistance to one or more drugs to which the patient’s virus was considered to
be sensitive at trial entry (non-inferiority comparison, 10% margin). Secondary outcomes included
confirmed virological rebound, serious drug- or disease-related complications, total grade 3 or 4 adverse
events (AEs), neurocognitive function change, cluster of differentiation 4 (CD4) cell count change, change
in health-related quality of life, cardiovascular risk change, health-care costs and health economic analysis.
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Results: In total, 587 participants were randomised (77% male, 68% white) to OT (n= 291) or PI-mono
(n= 296) and followed for a median of 44 months, of whom 2.7% withdrew/were lost to follow-up.
One or more episodes of confirmed VL rebound were observed in eight patients (Kaplan–Meier estimate
3.2%) in the OT group and 95 patients (35.0%) in the PI-mono group [absolute risk difference 31.8%,
95% confidence interval (CI) 24.6% to 39.0%; p< 0.001]. PI-mono patients who changed to ART after VL
rebound all resuppressed (median 3.5 weeks). The proportions with loss of a future drug option at 3 years
were 0.7% in the OT group and 2.1% in the PI-mono group (difference 1.4%, (95% CI –0.4% to 3.4%);
non-inferiority demonstrated). There were no significant differences in serious disease complications
between groups or in the frequency of grade 3 or 4 clinical AEs (16.8% OT group vs. 22% PI-mono
group; absolute risk difference 5.1%, 95% CI –1.3% to 11.5%; p= 0.12). Overall, the PI-mono strategy
was shown to be cost-effective compared with OT under most scenarios explored. PI-mono was cost
saving because of the large savings in ART drug costs while being no less effective in terms of
quality-adjusted life-years in the within-trial analysis and only marginally less effective when extrapolated
to lifetime outcomes.
Conclusions: PI monotherapy, with prompt reintroduction of combination therapy for VL rebound, was
non-inferior to combination therapy in preserving future treatment options and is an acceptable and
cost-effective alternative for long-term management of HIV infection.
Trial registration: Current Controlled Trials ISRCTN04857074.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 20, No. 21. See the NIHR Journals Library website
for further project information.
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Plain English summary
Human immunodeficiency virus (HIV) treatment uses a combination of three medicines. If treatment isnot powerful enough then the HIV virus rebounds and often becomes resistant to drugs and so the
person has fewer drug options available for the future. Protease inhibitors (PIs) are very potent and it is
very hard for the virus to develop resistance to them. Once the standard three-drug combination has
suppressed the virus, the PI alone (as ‘monotherapy’) may be able to keep the virus suppressed and
prevent resistance.
We tested this in a trial carried out in 43 clinics across the UK in which 587 HIV-positive people on
standard treatment with suppressed virus were allocated by chance (half to each group) to either continue
that standard treatment or switch to PI monotherapy. They were followed for up to 5 years to see which
group ended up worse off in terms of the number of future drug options that they had lost through
developing resistance. The trial found that people who were allocated to PI monotherapy lost very few
future drug options – no more than did those on the standard treatment. There were also some small
advantages (such as a slight reduction in long-term kidney damage).
In summary, the trial has shown that PI monotherapy with regular checking of the HIV virus level and
switch back to combination treatment if needed is an acceptable option for the long-term management of
HIV infection and is also cost-effective.
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Scientific summary
Background
Standard-of-care antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection uses a
combination of drugs, an approach until now considered essential to minimise treatment failure and
development of drug resistance. The 2013 British HIV Association (BHIVA) treatment guidelines recommend
that an initial treatment regimen should contain two nucleoside reverse transcriptase inhibitors (NRTIs)
together with a non-NRTI (NNRTI) drug (efavirenz), a ritonavir-boosted protease inhibitor (PI) [atazanavir
or darunavir (DRV)] or an integrase strand-transfer inhibitor (raltegravir). In practice, the most commonly
used third drug (on the backbone of two NRTIs) prescribed in the UK has been efavirenz.
Protease inhibitors have very high antiviral activity, have the highest genetic barrier to resistance of all HIV
drugs and are the only drugs that act at multiple steps of the HIV lifecycle, thus giving them the potential
to be used alone as monotherapy. A randomised controlled trial that examined the use of PI monotherapy
in treatment-naive patients showed clearly inferior performance with the generation of substantial drug
resistance. However, several other trials in which patients switched to PI monotherapy after achieving
full viral load (VL) suppression have produced more encouraging results, in some cases demonstrating
non-inferiority compared with standard-of-care (for a primary outcome of short-term VL suppression). However,
these trials have used a single protocol-specified PI, lopinavir/ritonavir or DRV/ritonavir, usually mandated for
both the monotherapy and the standard-of-care group (thus not resembling standard practice in the UK).
Furthermore, the trials have been based on a primary end point of short-term VL suppression (usually at
48 weeks), whereas it is the preservation of adequate future treatment options and the minimisation
of toxicity that really matter in long-term HIV care. Although data supporting longer-term meaningful
outcomes are limited, PI monotherapy is being increasingly used in clinical practice in the UK and in
some European countries.
Objective
To compare the effectiveness, toxicity profile and cost-effectiveness of PI monotherapy with those of
standard-of-care triple therapy in a pragmatic long-term clinical trial based in routine clinical care.
Design
Open-label, parallel-group, randomised controlled trial.
Setting
Forty-three HIV clinical centres in the UK NHS with wide geographical representation and including diverse
patient populations (14 centres in London, 29 outside London).
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Participants
The trial enrolled HIV-positive adults aged > 18 years who had been on ART consisting of two NRTIs and
one NNRTI or a PI for at least 24 weeks with no change in the previous 12 weeks and who had a VL of
< 50 copies/ml at, and for at least 24 weeks before, screening. The main exclusion criteria were known
major PI resistance mutation(s) on previous resistance testing; previous ART change for unsatisfactory
virological response; concomitant medication with PI interactions; and central nervous system disease,
cardiovascular disease or diabetes.
Interventions
Participants were randomised to maintain ongoing triple therapy (OT) or switch to a strategy of
physician-selected ritonavir-boosted PI monotherapy (PI-mono) with prompt return to combination
therapy (reintroduction of NRTIs, switch of PI to NNRTI discretionary) in the event of VL rebound
(defined as three consecutive tests at > 50 copies/ml, including one repeat on the first sample if available).
VL was monitored every 12 weeks.
Protease inhibitor substitution was allowed for toxicity or convenience.
Main outcome measures
The primary outcome was loss of future drug options, defined as new intermediate-/high-level resistance to
one or more drugs to which the patient’s virus was considered to be sensitive at trial entry (non-inferiority
comparison, 10% margin). The primary analysis included all resistance mutations detected, whereas a
predefined sensitivity analysis excluded resistance mutations that were detected to classes of drugs that the
patient was not receiving during the trial (and which likely were archived mutations). Secondary outcomes
included confirmed VL rebound, serious drug- or disease-related complications, total grade 3 or 4 adverse
events (AEs), neurocognitive function change (using a standardised test battery assessing five neurocognitive
domains), cluster of differentiation 4 (CD4) cell count change, change in health-related quality of life,
cardiovascular risk change, health-care costs and health economic analysis.
Results
In total, 587 participants were randomised (77% male, 68% white) to OT (n= 291) or PI-mono (n= 296)
and followed for a median of 44 months, of whom 2.7% withdrew/were lost to follow-up. One or more
episodes of confirmed VL rebound were observed in eight patients (Kaplan–Meier estimate 3.2%) in the
OT group and 95 patients (35.0%) in the PI-mono group [absolute risk difference 31.8%, 95% confidence
interval (CI) 24.6% to 39.0%; p< 0.001]. PI-mono patients who changed to combination ART after VL
rebound all resuppressed (median 3.5 weeks). The proportions of participants with loss of a future
drug option at 3 years were 0.7% in the OT group and 2.1% in the PI-mono group [difference 1.4%
(95% CI –0.4% to 3.4%); non-inferiority demonstrated]. In the prespecified sensitivity analysis, in which
mutations that were likely archived were excluded, the proportions of patients with loss of a future
drug option at the end of trial follow-up were 1.5% in the OT group and 1.0% in the PI-mono group
[difference –0.4% (95% CI –2.1% to 1.4%); non-inferiority also demonstrated]. Only one participant in
the PI-mono group developed resistance to the PI that they were taking: a participant taking atazanavir
monotherapy who developed the I50L mutation, predicted to confer high-level resistance to atazanavir.
SCIENTIFIC SUMMARY
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There were no significant differences in serious drug- or disease-related complications between the groups.
Although there were more deaths in the PI-mono group (six vs. one), these were of diverse aetiology,
often with clear non-HIV-related risk factors present, and the numerical difference was not statistically
significant. The numbers of serious adverse events and clinical grade 3 and 4 AEs did not differ between
the groups, but there were fewer total grade 3 or 4 AEs in the PI-mono group, the difference reflecting
fewer laboratory events. Fewer patients in the PI-mono group experienced an estimated glomerular
filtration rate below 60ml/minute/1.73 m2 during follow-up (10% OT group vs. 5% PI-mono group;
difference –4.6%, 95% CI –8.8% to –0.4%; p= 0.033). There were no differences between the groups in
the proportions of patients with symptomatic peripheral neuropathy, facial lipoatrophy or abdominal fat
accumulation or in the summary scores for neurocognitive function, cardiovascular disease risk or quality of
life or in the mean CD4 cell count change.
Overall, the PI-mono strategy was shown to be cost-effective compared with OT under most scenarios
explored. The PI-mono strategy was cost saving because of large savings in ART drug costs while being no
less effective in terms of quality-adjusted life-years in the within-trial analysis and only marginally less
effective with modelling.
Conclusions
Protease inhibitor monotherapy, with regular VL monitoring and prompt reintroduction of combination
therapy for VL rebound, was non-inferior to combination therapy in preserving future treatment options
and is an acceptable and cost-effective alternative for long-term management of HIV infection.
Trial registration
This trial is registered as ISRCTN04857074.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Human immunodeficiency virus epidemiology and care in the UK
At the end of 2012 there were an estimated 100,000 people living with human immunodeficiency virus
(HIV) in the UK, of whom approximately 80% have been diagnosed and seen for HIV-related care. The
annual number of new HIV diagnoses made in the UK continues to rise, with 6360 new cases in 2012,1
and as more people receive effective treatment the number of deaths continues to fall. Thus, the number
of people receiving treatment and the already substantial burden on the NHS will continue for the
foreseeable future. The cost of providing care and treatment to people living with HIV in the UK increased
by about 600% from 1997 to 2010, when £762M was spent, mainly on antiretroviral therapy.2
Principles of antiretroviral therapy
A range of drugs are available that are active in blocking the replication of HIV. Current HIV treatment
guidelines recommend a combination of two drug classes for the initiation and maintenance of
antiretroviral therapy (ART).3,4 The principle of combining drugs with different mechanisms of action to
increase potency and reduce the selection of drug-resistant mutants is common to the treatment of many
infectious diseases. However, the need for combination therapy for HIV may be reduced after the initial
period of treatment, once viral load (VL) has been suppressed and the risk of de novo resistance
generation diminishes.
Recommendations for the threshold at which HIV treatment should be started differ internationally, with
the current US treatment guidelines4 recommending starting all HIV-infected individuals on treatment,
regardless of their cluster of differentiation 4 (CD4) cell count, to reduce the risk of disease progression,
and the UK guidelines3 recommending starting at a CD4 cell count of 350 cells/mm3. This is based
predominantly on data from large cohorts which show that starting ART at CD4 cell counts of
> 500 cells/mm3 was associated with slower HIV disease progression measured by acquired immunodeficiency
syndrome (AIDS) events, HIV-associated mortality or all-cause mortality.5,6 However, substantive evidence is now
available from a large randomised controlled trial (RCT), the Strategic Timing of AntiRetroviral Treatment (START)
trial, that demonstrates that initiating ART at CD4 cell counts of > 500 cells/mm3 is of benefit.7 Aside from
potential benefits to the individual, early initiation of ART has been shown to effectively reduce HIV sexual
transmission and may diminish population-level incidence of HIV infection.8 Once started, treatment needs to be
continued indefinitely – the Strategies for Management of Antiretroviral Therapy (SMART) trial showed inferior
outcomes with treatment interruption, even at high CD4 cell counts.9
As a result of the move towards extending therapy exposure (start earlier and continue indefinitely) is the
realisation that patients are now facing the prospect of taking ART for decades. Maximising long-term
durability, preserving a viable sequence of future drug options and minimising long-term side effects are
becoming increasingly important considerations.
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New strategic approaches
Much of the current pharmaceutical company-driven research as well as investigator-initiated research is
now designed to look at switching drugs or compare regimens for toxicity or tolerability advantages. The
search for cost-effective approaches to care, including ways of containing drug costs and approaches to
simplify monitoring and follow-up, is also an important focus of current research.
The availability of effective and well-tolerated newer drug options that act on different targets, such as
integrase inhibitors, has not only increased the treatment options available but also led to re-examination
of the paradigm of care [treatment with triple therapy, consisting of two nucleoside reverse transcriptase
inhibitors (NRTIs) and a non-NRTI (NNRTI) or protease inhibitor (PI)] that has changed little in the last
decade. The availability of more treatment options may have also allowed some flexibility to accept a small
risk of treatment failure in a regimen that has fewer side effects or that effectively preserves long-term
treatment options in the vast majority.
Thus, research into more innovative uses of current drugs, as well as ways of combining or sequencing
drugs to maximise long-term outcomes (preserving viable treatment options, minimising toxicity,
minimising cost), is increasingly important. Given that treatment interruption is not a sensible option,
treatment simplification studies form an increasingly important aspect of the HIV treatment research
agenda, not only for individual patients but also for health-care policy.2,10,11 The most promising candidates
for treatment simplification are undoubtedly the PIs.
Previous trials of protease inhibitor monotherapy
Protease inhibitors have very high antiviral activity, have the highest genetic barrier to resistance of all HIV
drugs and are the only drugs that act at multiple steps of the HIV lifecycle, thus giving them the potential to
be used alone as monotherapy.12 A RCT that examined the use of PI monotherapy for treatment-naive
patients showed clearly inferior performance, with the generation of substantial resistance.13 However,
other trials in which patients switch to PI monotherapy after achieving full VL suppression have been
more successful. These trials have generally used lopinavir (LPV)/ritonavir and darunavir (DRV)/ritonavir
monotherapy and have evaluated non-inferiority based on VL suppression in plasma at weeks 48 or 96
after switching from combination antiretroviral therapy (cART). Results have been generally favourable,
although several studies have failed to demonstrate non-inferiority compared with standard-of-care.
Table 1 summarises the published RCTs on ritonavir-boosted PI monotherapy as a simplification strategy.
Small single-arm studies (n= 30–36) have explored ritonavir-boosted atazanavir simplification in patients
effectively suppressed on cART, showing effective preservation of virological suppression in 64–80% of
patients with no evidence of selection of PI-resistance mutations in those who developed VL rebound.28–30
A systematic review and meta-analysis of RCTs identified 10 trials involving 1189 patients comparing three
different PIs used as monotherapy against a standard regimen of a PI plus two NRTIs.31 With the most
conservative approach (VL < 50 copies/ml on two consecutive measurements), the risk ratios for effective
viral suppression at 48 weeks for PI monotherapy compared with cART were 0.94 [95% confidence
interval (CI) 0.89 to 1.00] in the intention-to-treat analysis and 0.93 (95% CI 0.90 to 0.97) in the
per-protocol analysis. Reintroduction of cART in 44 patients with virological failure led to de novo viral
suppression in 93%.
Given the contradictory findings and the small size of the trials, PI monotherapy has not been widely
adopted in HIV treatment guidelines. Only the European guidelines32 consider PI monotherapy an option
and then only for selective patient groups.
INTRODUCTION
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TABLE 1 Summary of RCTs of PI monotherapy as a switch strategy in patients with virological suppression
Study
n (monotherapy
vs. other)
Drug vs.
comparator Eligibility End point Results
Arribas 2005,14
Pulido 2008,15,16
(OK study)
21 vs. 21 LPV/r vs. LPV/r plus
two NRTIs
Experienced without PI failure
VL < 50 copies/ml for > 6 months
LPV/r plus two NRTIs for > 1 month
VL < 500 copies/ml at week 48
(ITT, M or change= F)
Failure = VL >500 copies/ml × 2
that could not resuppress
(<50 copies/ml) with NRTIs
No difference in virological suppression
between arms at week 48 (81% and 95% in
patients on LPV/r monotherapy and LPV/r plus
two NRTIs respectively; p= 0.34)
No major PI mutations were found even after
4 years’ follow-up
Pulido 2008,15
Arribas 200917
(OK04 study)
103 vs. 102 LPV/r vs. LPV/r plus
two NRTIs
Experienced without PI failure
VL < 50 copies/ml for > 6 months
LPV/r plus two NRTIs for > 1 month
VL < 500 copies/ml at week 48
(ITT, M or change= F)
Failure = VL >500 copies/ml × 2
that could not resuppress
(<50 copies/ml) with NRTIs
No difference in virological suppression
between arms by week 48 (94% and 90% in
patients on LPV/r monotherapy and LPV/r plus
two NRTIs respectively) with upper limit of
95% CI for difference of 3.4%
Using < 50 copies/ml, 85% and 90% of
patients on LPV/r monotherapy and LPV/r plus
two NRTIs, respectively, had an undetectable
VL at week 48 (p= 0.31; upper limit of
95% CI for difference of 14%)
By week 96, 87% on monotherapy (n = 100)
and 78% on triple therapy (n = 98; 95% CI
–20% to +1.2%) showed effective virological
suppression
Using < 50 copies/ml, 77% and 78% of
patients on LPV/r monotherapy and LPV/r plus
two NRTIs, respectively, had an undetectable
VL at week 96
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TABLE 1 Summary of RCTs of PI monotherapy as a switch strategy in patients with virological suppression (continued )
Study
n (monotherapy
vs. other)
Drug vs.
comparator Eligibility End point Results
Nunes 200918
(KalMo study)
30 vs. 30 LPV/r vs. continued
HAART
No history of VF
VL < 80 copies/ml for > 6 months
CD4 cell count of > 200 cells/mm3
VL < 80 copies/ml at week 96
(ITT, M= F)
No difference in virological suppression
between arms by week 96 (80.0% and 86.6%
in patients on LPV/r monotherapy and LPV/r
plus two NRTIs respectively; p= 0.48)
There was one virological failure (defined as a
VL < 500 copies/ml) in each arm. No major
PI mutations were found
Meynard 201019
(KALESOLO
study)
87 vs. 99 LPV/r vs. continued
HAART
Experienced
VL < 50 copies/ml for ≥ 6 month
VL < 50 copies/ml at week 48 LPV/r monotherapy did not achieve
non-inferiority vs. cART for maintaining
plasma VL at < 50 copies/ml
No major PI mutations were found
Gutmann 201020
(MOST study)
29 vs. 31 LPV/r vs. continued
HAART
Experienced
CD4 cell count of ≥ 100 cells/mm3
VL < 50 copies/ml for ≥ 6 months
Treatment failure in the CNS or
genital compartment (2 × VL
> 400 copies/ml)
Trial ended prematurely when six patients on
monotherapy demonstrated VF in plasma
Cahn 201121 41 vs. 39 LPV/r vs. LPV/r plus
two NRTIs
Experienced
No history of VF
HAART for ≥ 6 months
VL < 50 copies/ml for ≥ 3 months
VL < 200 copies/ml at day 360 No difference in virological suppression
between arms by day 360 (80% and 86.6% in
patients on LPV/r monotherapy and LPV/r plus
two NRTIs respectively; p= 0.611)
Using < 50 copies/ml, 92% and 95% of
patients on LPV/r monotherapy and LPV/r plus
two NRTIs, respectively, had an undetectable
VL at day 360 (p= 0.671)
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Study
n (monotherapy
vs. other)
Drug vs.
comparator Eligibility End point Results
Arribas 2010,22
Clumeck 2011,23
Arribas 201224
(MONET study)
127 vs. 129 DRV/r vs. DRV/r
plus two NRTIs
Experienced
HAART plus two NRTIs plus either
NNRTI or PI at screening
No previous use of DRV
VL < 50 copies/ml for ≥ 6 months
No previous VF
Proportion with VL
< 400 copies/ml at week 48
Treatment failure: 2 × VL
>50 copies/ml; discontinuation
of randomised therapy (time to
loss of virological response);
stopping DRV/r or starting NRTIs
in the monotherapy arm; or
stopping NRTIs in the control
arm (switches in NRTIs
permitted)
Non-inferiority demonstrated at week 48 in the
per-protocol and ITT and by switch= failure
analyses (86.2% vs. 87.8%, 84.3% vs. 85.3%
and 93.5 vs. 95.1% in the monotherapy and
triple therapy arms respectively)
Non-inferiority not demonstrated at week 96 in
ITT analysis
7/8 with detectable viraemia resuppressed with
NRTI intensification
47 genotyped (20 in monotherapy arm): only
one patient per arm had any evidence of
genotypic resistance; both patients regained
suppression without change in therapy
By week 144, 69% and 75% of patients on
monotherapy and triple therapy, respectively,
had a VL of <50 copies/ml (ITT switch= failure);
these values were 84% and 83.5% if switches
were not considered failures
continued
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TABLE 1 Summary of RCTs of PI monotherapy as a switch strategy in patients with virological suppression (continued )
Study
n (monotherapy
vs. other)
Drug vs.
comparator Eligibility End point Results
Katlama 2010,25
Valantin 201226
(MONOI study)
112 vs. 133 DRV/r vs. DRV/r
plus two NRTIs
Experienced
DRV naive
VL < 50 copies/ml at screening
VL < 400 copies/ml for
≥ 18 months
No PI failure
CD4 cell count nadir of
> 50 cells/mm3
All patients suppressed on DRV/r
prior to randomisation
Proportion with VL of
< 400 copies/ml at week 48
Treatment failure: 2 × VL
> 400 copies/ml; treatment
modification; withdrawal
Non-inferiority demonstrated at week 48 in
the per-protocol analysis (94% and 99% of
patients on DRV/r monotherapy and triple
therapy, respectively, had undetectable VL;
90% CI for the difference –9.1 to 0.8%)
Non-inferiority not demonstrated at week 48
in ITT analysis
No resistance to PI emerged by week 48
No difference in virological suppression
between arms by week 96 (88% and 84% in
patients on DRV/r monotherapy and triple
therapy respectively; p= 0.42)
Echeverria 201027 17 vs. 11 SQV/r vs. continued
HAART
Experienced
VL < 50 copies/ml for ≥ 3 months
No history of VF
VF at week 48 Only one patient from the SQV/r group
experienced virological failure at week 48.
A similar mean increase in CD4 cell count was
observed in both groups at week 48
CNS, central nervous system; DRV/r, darunavir/ritonavir; HAART, highly active antiretroviral therapy; ITT, intention to treat; ITT, M= F, intention-to-treat analysis, for which missing values are
treated as failure; LPV/r, lopinavir/ritonavir; M or change= F, missing values or treatment change regarded as failure; MOST, Monotherapy Switzerland/Thailand; VF, virological failure.
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Virological and resistance concerns over protease
inhibitor monotherapy
A proportion of patients may not be able to maintain full viral suppression on PI monotherapy and, if not
addressed, there is the theoretical risk that ongoing viral replication may lead to the selection of resistance
mutations. However, the trials summarised in Table 1 as well as observational studies have shown that
the selection of major PI mutations in patients with detectable viraemia while on PI monotherapy occurs
only rarely.33,34 In addition, complete concordance between circulating and cell-associated virus genotypes
has been reported in patients on DRV monotherapy, with no major DRV-selected resistance mutations
in peripheral blood mononuclear cells (PBMCs), offering additional reassurance that exposure to PI
monotherapy, at least with DRV, may not compromise future antiretroviral treatment options.35
Although resistance is rare, several studies have shown that some mutations at the gag cleavage site
might reduce sensitivity to PI-based regimens. In the MONOI trial (n= 255),36 nine participants developed
virological failure (defined as VL > 400 copies/ml in two consecutive samples) but major DRV-selected
mutations could not be demonstrated in any of them using standard sequencing. However, by doing protease
gene clonal analysis, the authors found that the virus of one of the nine patients with virological failure
presented minority variants, with DRV resistance mutations at positions 32, 47 and 50 but no mutations in
the gag region.
Although trials have usually shown very similar rates of VL suppression with PI monotherapy, there is a
theoretical concern that there may be ongoing low-level HIV replication that could cause disease
pathology. In both the MONET37 and MONOI38 trials no difference in the change from baseline of level of
proviral deoxyribonucleic acid (DNA) (cellular integrated HIV-1 DNA) in PBMCs was observed between
patients on DRV monotherapy and those on triple therapy. Furthermore, in an observational study,39 no
difference in tonsil viral replication was observed between patients on NNRTI-based cART and patients on
either DRV/r or LPV/r, but proviral DNA levels were found more frequently in patients on cART. Thus, there
is no evidence for occult viral replication when patients have an undetectable VL on PI monotherapy.
Other concerns with protease inhibitor monotherapy
As a consequence of effective viral suppression, dementia and serious neurocognitive impairment that
were frequently seen in patients with advanced HIV disease not receiving effective ART have become
relatively rare in recent years.40,41 Despite this, high rates of more subtle cognitive dysfunction in HIV-infected
subjects are being increasingly described, with neurocognitive impairment rates approaching 50% in some
cohorts. Several factors have been implicated in the evolution of neurocognitive impairment in the highly
active antiretroviral therapy (HAART) era, including older age, a low nadir CD4 cell count, chronic hepatitis C
virus (HCV) co-infection and possibly the use of antiretroviral regimens with poor central nervous system (CNS)
penetration.42 The penetration of PIs into the CNS is variable and generally inferior to that of the other main
drug classes, thus raising the concern about the possibility of neurocognitive deterioration on PI monotherapy.
Prior to this trial, this has not been systematically investigated with formal neurocognitive testing.
Data from RCTs have not shown consistent evidence for any excess risk of CNS adverse events (AEs) in
patients on DRV and LPV monotherapy, although detectable HIV RNA in cerebrospinal fluid (CSF) of
symptomatic patients has been reported.43 The Monotherapy Switzerland/Thailand (MOST) trial20 was
stopped prematurely when six patients on LPV/ritonivir monotherapy developed virological failure in
peripheral blood. CSF samples were available for five of these patients and detectable VL was also
confirmed in these. However, the results of the MOST trial are not in agreement with data generated in
previous studies and, as the study was interrupted, its findings are difficult to interpret.44 Furthermore,
cross-sectional data showed that, compared with patients on cART, effectively suppressed patients on
PI monotherapy did not show any higher rate of neurocognitive impairment.45
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Possible benefits of protease inhibitor monotherapy
Ritonavir-boosted PI monotherapy may reduce the risk of long-term toxicity associated with NRTIs and, in
some cases, NNRTIs. In addition, PI monotherapy may possibly reduce the risk of long-term failure because
of the high genetic barrier to resistance (compared with NRTIs and NNRTIs) and a better profile of
preserved drug options for the future. Previous RCTs have not shown major differences in safety
parameters between PI monotherapy and cART.
A further advantage is likely to be the reduction in treatment costs, although this may be offset by more
frequent VL rebounds in patients on PI monotherapy leading to additional costs to health services. PI
monotherapy as a strategy may be potentially cost saving if it can be implemented in a large group of
patients on ART.2
Rationale for this trial
The previous randomised trials of PI monotherapy summarised earlier have shown high rates of short-term
VL suppression, sometimes meeting non-inferiority criteria, but have not been of sufficient size and
duration to address definitively the effects on long-term drug resistance, clinical disease progression and
drug toxicity in clinical practice.17,24,25,31,46 This trial was designed to be different in a number of respects
from the previously completed or ongoing pharma-sponsored studies:
1. Whereas other studies have examined the effect of PI monotherapy per se, this trial was designed to
examine the effectiveness of a strategy that includes prompt switch back to standard-of-care when
PI monotherapy does not maintain full virological suppression of < 50 copies/ml.
2. Whereas previous or ongoing studies were/are focused on specific PI drugs and specified comparator
regimens, this trial allows drug selection according to patient/physician preference and selection or
switching of PIs for maximising tolerability; it is therefore more relevant to clinical practice.
3. Whereas other studies were of relatively short duration (1–2 years), this trial set out to have a relatively
long-term follow-up perod (up to 5 years), which is important for assessing long-term consequences of
this strategy.
4. Whereas other studies have focused on short-term VL end points (reflecting their commercial origin and
single drug focus), this trial has an end point of clinical drug resistance, chosen to be most relevant to
the long-term goal of maintaining effective treatment regimens.
The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial was designed as a
pragmatic RCT to evaluate relevant long-term outcomes in patients following a PI monotherapy strategy
in routine clinical care centres across the UK.
The main trial objectives were to:
1. determine whether or not a strategy of switching to PI monotherapy is non-inferior to continuing triple
drug therapy (the standard-of-care) in terms of the proportion of patients who maintain all of their
available drug treatment options after at least 3 years of follow-up
2. compare the safety and toxicity of PI monotherapy with those of standard-of-care triple therapy over
3–5 years
3. assess the cost-effectiveness of PI monotherapy after 3 years’ follow-up and to extrapolate to lifetime
follow-up.
INTRODUCTION
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Chapter 2 Methods
This open-label randomised parallel-group trial (registered as ISRCTN04857074) was performed in43 centres in the UK (sites listed in Acknowledgements).
Trial entry criteria
The trial enrolled HIV-positive adults aged > 18 years who had been on ART comprising two NRTIs and
one NNRTI or one PI for at least 24 weeks with no change in the previous 12 weeks, who had a VL
of < 50 copies/ml at and for at least 24 weeks before screening (one ‘blip’ to < 200 copies/ml allowed
during this period if followed by two or more tests with a result of < 50 copies/ml), who had a CD4 cell
count of > 100 cells/mm3 at screening and who were willing to continue with their current ART or change
according to the randomised allocation. Exclusion criteria were known major PI resistance mutation(s) on
previous resistance testing (if performed; not mandated), previous ART change for unsatisfactory virological
response (change for toxicity prevention/management or convenience permitted), PI allergy, concomitant
medication with PI interactions, current or anticipated requirement for radiotherapy or cytotoxic chemotherapy,
treatment for acute opportunistic infection within the previous 3 months, current or planned pregnancy, active
substance abuse or psychiatric illness (that would, in the opinion of the investigator, prevent compliance with
the protocol or assessments), history of HIV encephalopathy with a current deficit of > 1 in any domain of the
Neuropsychiatric AIDS Rating Scale (NARS),47,48 history of cardiovascular disease (CVD), 10-year absolute
coronary heart disease risk of > 30% or risk of > 20% with diabetes or a family history of premature ischaemic
heart disease/stroke,49 insulin-dependent diabetes mellitus, active/planned HCV treatment, hepatitis B virus
(HBV) surface antigen positive at screening or since HIV diagnosis (unless HBV DNA < 1000 copies/ml while
off HBV-active drugs) or a fasting plasma glucose > 7.0mmol/l at screening.
We chose to exclude patients with active substance use or psychiatric illness that was thought likely to
prevent compliance with the protocol because we thought that it was paramount to conduct a definitive
trial that answered the question of the risks for long-term treatment options arising from VL rebound and
this would require very high levels of trial retention. We excluded patients with a high risk of CVD because
of the concern that PIs may add to that risk, and it seemed inappropriate to randomise patients with CVD
who were stable on relatively low-risk NNRTI-based regimens to a new regimen that might increase that
risk. Most of the other inclusion and exclusion criteria are standard.
The protocol was approved by the Cambridgeshire 4 Research Ethics Committee and the Medicines and
Healthcare products Regulatory Agency (MHRA) and all participants provided written informed consent.
Randomisation and treatment strategies
Participants were randomly assigned in a 1 : 1 ratio to maintain ongoing triple therapy (OT) or switch to
ritonavir-boosted PI monotherapy (PI-mono). In the OT group, patients were managed using triple
combination therapy regimens with changes allowed for toxicity, convenience or protocol-defined
confirmed VL rebound (see Assessments). In the PI-mono arm, patients were switched to a single ritonavir-
boosted PI (physician choice but ritonavir-boosted DRV 800mg/100mg once daily or ritonavir-boosted LPV
400mg/100mg twice daily were recommended). Patients switching from a NNRTI-based regimen continued
on NRTIs for the first 2 weeks. PI substitution was allowed for toxicity or convenience. The strategy required
prompt reintroduction of NRTIs (switch of PI to NNRTI discretionary) in the event of protocol-defined
confirmed VL rebound (see Assessments), and patients were subsequently managed on combination therapy
for the remainder of the trial. Subsequent switches for toxicity, convenience or VL failure were allowed, as for
the OT group. The hypothesis was that PI-mono would be non-inferior to OT.
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Randomisation was stratified by centre (nine groups) and baseline ART regimen (PI vs. NNRTI). The
computer-generated, sequentially numbered randomisation list (permuted blocks of varying size) was
preprepared by the trial statistician. Screening forms were faxed to a central trials unit, eligibility was
confirmed and, on receipt of a baseline visit form, randomisation was performed by the trial manager who
could access the next number but not the whole list.
Assessments
Study visits at baseline, weeks 4 and 8 (PI-mono only), week 12 and at every 12 weeks thereafter included
assessment of clinical status, medication adherence (standardised questions), VL and CD4 cell count as well
as safety blood tests (measured at the site laboratory). Visits at baseline, week 12, week 48 and every
48 weeks thereafter included additional assessments of 10-year CVD risk,49 neurocognitive function
(described below), symptomatic peripheral neuropathy (Brief Peripheral Neuropathy Screen)50,51 and quality
of life [self-completed Medical Outcomes Study HIV Health Survey (MOS-HIV)].52
Neurocognitive testing was performed by designated research staff at each study site after receiving
appropriate training by the co-ordinating centre. The training procedures included a face-to-face session,
a training video and practice of the tests with at least five work colleagues before being allowed to assess
study participants, followed by yearly revision. Five cognitive domains were explored with three different
tests: verbal learning and memory were assessed using Hopkins Verbal Learning Test – Revised (HVLT-R),53
fine motor skills were assessed using the Grooved Pegboard Test54 and attention and executive function
were assessed using Colour Trails Tests 1 and 2 respectively.55 Test performance was considered invalid if
participants decided to abandon the test before completion, if investigators failed to comply with standard
procedures according to the instructions, or if the test was interrupted because of external factors. In
addition, all scores were centrally monitored and extreme results were investigated and excluded if
considered to be related to any of the situations listed above. Only participants with complete cognitive
testing results available were included in the analyses. Raw scores for each cognitive test were transformed
to z-scores using the manufacturers’ normative data53–55 adjusted for age (all tests) and years of education
(Colour Trails Tests) by subtracting the mean and dividing by the standard deviation (SD) of test scores in
reference populations. For the Grooved Pegboard Test the z-score was obtained by taking the average
of the z-scores for the dominant and non-dominant hands. A summary score was then calculated for each
patient by averaging the z-scores of the five tests [neurocognitive performance z-score 5 (NPZ-5)].
Clinical and laboratory events were classified by each site according to standard diagnostic criteria in the
protocol [based on Centers for Disease Control and Prevention (CDC) criteria for AIDS;56 INSIGHT criteria
for serious non-AIDS events;57 and Division of AIDS (DAIDS) criteria for AEs]58 and were reviewed by an
independent physician at the trial co-ordinating centre. The estimated glomerular filtration rate (eGFR) was
calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.59
If VL was detectable at ≥ 50 copies/ml at any visit, the test was repeated (on the same sample if available
or on a fresh sample draw if not). If the VL was < 50 copies/ml, routine follow-up resumed; if the VL was
≥ 50 copies/ml, adherence counselling was performed and the patient returned for a confirmatory VL test at
least 4 weeks from the date of the first sample. If the VL was < 50 copies/ml on the confirmatory test,
routine follow-up resumed; if the VL was ≥ 50 copies/ml (i.e. third consecutive test) this met the protocol
definition of confirmed VL rebound and the patient was required to change therapy and a repeat VL test
was performed 4 weeks later.
Genotypic resistance testing was performed on all confirmed VL rebound samples and on rebound samples
that did not meet this definition but preceded treatment switch. Genotypic testing was carried out
at site laboratories and was repeated at the central laboratory if local sequencing was unsuccessful.
Drug susceptibility prediction used the Stanford algorithm.60 When resistance mutations were identified,
comparison was made with any pre-trial genotypic testing reports.
METHODS
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The primary outcome was loss of future drug options, defined as new intermediate-/high-level resistance to
one or more drugs in contemporary use to which the patient’s virus was considered to be sensitive at trial
entry. Contemporary use was determined by current UK treatment guidelines,3 with saquinavir added as
this was taken by some participants during the trial. Interim data were reviewed approximately annually by
an Independent Data Monitoring Committee (IDMC).
Secondary outcomes were the occurrence of serious drug or disease-related complications (death, serious
AIDS-defining illness, serious non-AIDS-defining illness); the total number of grade 3 and 4 AEs; confirmed
virological rebound (defined as above); CD4 cell count change from baseline; neurocognitive function change
from baseline; cardiovascular risk change from baseline; and health-related quality of life (HRQoL) change from
baseline (mental and physical health summary scores on the MOS-HIV questionnaire).
Additional specified safety outcomes included assessment of facial lipoatrophy, abdominal fat accumulation,
peripheral neuropathy and eGFR.
Health-care costs were evaluated and a full health economic analysis performed as described in Chapter 4.
Sample size determination and statistical analysis
Assuming that 97% of patients in the OT group would maintain all future drug options (i.e. remain free
of new resistance mutations) over 3 years,16,22,25 we estimated that approximately 280 patients per group
would be required to demonstrate non-inferiority of PI-mono, defined by the upper limit of the 95% CI
(two-sided) for the difference in the proportion of patients who maintain all future drug options over
3 years (OT – PI-mono) being < 10% with 85% power and allowing 10% loss to follow-up. The 10%
non-inferiority margin was chosen based on US Food and Drug Administration (FDA) guidance.61,62
All comparisons were as randomised (intention to treat). Statistical tests presented are two-sided and test
the null hypothesis of no difference between randomised groups. The absolute difference between the
groups in the reduction of future drug options was estimated using Kaplan–Meier analysis, with the 95% CI
(two-sided) derived using bootstrap methods. The primary analysis included all new resistance mutations seen
that conferred intermediate-/high-level drug resistance, but a sensitivity analysis was predefined in which loss
of drug options was restricted to classes to which the patient was exposed during the trial (i.e. excluded
mutations that were likely archived).
For secondary end points, binary outcome variables were compared between groups using the chi-squared
test or Fisher’s exact test and using logistic regression models for adjusted analyses; for continuous
variables groups were compared using mean change from baseline and the t-test/linear regression [change
was from baseline to the last available visit at which a measurement was performed or after week 144
(patients without such data were not included)]. Time-to-event outcomes were tested using a log-rank test.
Poisson regression was used to compare incidence rates. Global tests of difference between randomised
groups taking into account data at all follow-up time points were performed using generalised estimating
equations (GEEs) (independent correlation structure, binomial or normal distribution as appropriate).
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Patient and public involvement in the research
Given that this was a large UK-based trial looking at the long-term treatment of people living with HIV
infection, it was considered critical from the outset to have involvement from the HIV community.
An important consideration was that, in view of the cost-saving potential of the monotherapy approach,
it was possible that the trial could at some stage be misrepresented as a cost-saving initiative and this
perception might damage the trial. It was felt that engagement of the community was essential for
maintaining the focus on the potential patient benefits, such as toxicity reduction, and ensuring that this
message came across to the people in the trial as well as more broadly. The measures to engage the
community are outlined briefly below.
The chief investigator approached the UK Community Advisory Board (UK-CAB), a network for community
HIV treatment advocates, and asked for an opportunity to discuss the trial design at its meetings. He
presented the trial design on two occasions and obtained useful feedback that resulted in a number of
suggestions being incorporated in the final protocol (e.g. the suggestion to include therapeutic drug
monitoring of PI levels at the first visit following randomisation in the PI-mono group).
At these meetings and in follow-up correspondence with UK-CAB, the chief investigator explained about
the roles of the Trial Steering Committee (TSC) and the IDMC and requested that UK-CAB provide
a representative on each of these committees. A lay summary of the roles was produced as well as a
description of the attributes that would be desired in those selected. UK-CAB organised an election
process and a nominee for each of the two committees was selected.
The IDMC community representative attended all of the IDMC meetings and contributed to the discussion
of the blinded data throughout the course of the trial.
The TSC community representative attended all of the TSC meetings and provided input into the final
study protocol and all subsequent key decisions made during the course of the trial, including the approval
of the study amendments, decisions on the viability of substudies, the decision to increase the sample size
and include more sites in the UK and discussions around classification of end points in the final analysis.
The TSC representative also fed back to the chief investigator any concerns that were circulating in the
community or any community discussions (usually not directly related to the trial) about PI monotherapy
that might impact on the trial and which needed to be addressed.
In parallel with engagement with UK-CAB and its nominated representatives, the trial team engaged with
the African Eye Trust, a community group focused on the support of African HIV-positive patients, who
represent a substantial proportion of the infected community in the UK. This community group organised
workshops at regional sites that talked generally about clinical trials but which also specifically mentioned
the PIVOT trial design and the opportunity that it presented for members of the community to participate
in a trial. The trial was also featured in an article in the African Eye Voice magazine. Members of the
African Eye Trust also helped patients who expressed an interest in the trial to understand the trial
requirements and processes. This engagement likely contributed to the substantial representation of
African patients in the trial (see Chapter 3), which is unusual for HIV trials conducted in the UK, Europe
and North America, where enrolment tends to be dominated by white men who have sex with men.
Once the trial was complete, all participants were invited to hear about the results at a meeting that
immediately followed (in the same afternoon) the results meeting for investigators. The study team, as well
as several site investigators, were available to help patients interpret the findings and to answer questions
about the study. This meeting was held before the formal release of the results at a major international
HIV conference the following week. Participants provided very positive feedback and were highly
appreciative of the opportunity to hear and discuss the results before their release at the conference.
METHODS
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Chapter 3 Results of the clinical trial
Trial recruitment
Recruitment to the trial commenced on 4 November 2008 with a target of 400 patients. In July 2009
the sample size was increased to 570 patients as emerging data from other studies22,25 indicated that
event rates for the primary end point would likely be lower than first estimated. Recruitment ended on
28 July 2010 with 587 participants recruited from 43 sites across the UK (Figure 1). Study visits ended on
1 November 2013.
Baseline characteristics of the study participants
Participant characteristics were similar between groups at baseline (Table 2). The median time on previous
ART was 4 years and 53% were on a NNRTI-containing regimen at baseline.
Trial follow-up and withdrawal
The median duration of trial follow-up was 44 months (maximum 59 months); 1% died and 2.7% were
withdrawn/lost to follow-up before the end of the trial (Figure 2).
Treatment and adherence
In the PI-mono group, the initial choice of PI was DRV (80%), LPV (14%) or another boosted PI (6%);
58% were still taking PI monotherapy at the end of the trial (23% reintroduced combination therapy
for VL rebound, 4% reintroduced combination therapy for VL rebound not meeting protocol criteria,
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FIGURE 1 Trial recruitment.
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TABLE 2 Baseline characteristics
Characteristics OT (n = 291) PI-mono (n = 296) Total (n = 587)
Demographic and clinical characteristics
Age (years)
Median (IQR) 43 (37–49) 45 (39–50) 44 (38–49)
Range 23–75 23–67 23–75
Mode of infection, n (%)
MSM 175 (60) 176 (59) 351 (60)
Heterosexual 108 (37) 108 (36) 216 (37)
Other 8 (3) 12 (4) 20 (3)
Female, n (%) 64 (22) 73 (25) 137 (23)
Ethnicity, n (%)
White 206 (71) 195 (66) 401 (68)
Black 73 (25) 90 (30) 163 (28)
Other 12 (4) 11 (4) 23 (4)
HCV antibody positive, n (%) 7 (2) 14 (5) 21 (4)
HIV disease status
Previous AIDS-defining illness, n (%) 59 (20) 57 (19) 116 (20)
Nadir CD4 cells/mm3, median (IQR) 181 (90–258) 170 (80–239) 178 (86–250)
Baseline CD4 cells/mm3, median (IQR) 512 (386–658) 516 (402–713) 513 (392–682)
Baseline HIV VL undetectable, n (%) 276 (95) 279 (94) 555 (95)
Duration of VL undetectable (months), median (IQR) 36 (17–62) 38 (22–66) 37 (20–63)
ART history
Years since ART start, median (IQR) 3.9 (2.0–6.4) 4.2 (2.4–6.9) 4.0 (2.2–6.7)
Number of drugs ever received, median (IQR) 5 (3–6) 4 (3–6) 4 (3–6)
NNRTI at entry, n (%)
Any 157 (54) 157 (53) 314 (53)
Efavirenz 115 (40) 115 (39) 230 (39)
Nevirapine 42 (14) 39 (13) 81 (14)
Etravirine 0 (0) 3 (1) 3 (1)
PI at entry, n (%)
Any 134 (46) 139 (47) 273 (47)
Atazanavir 59 (20) 59 (20) 118 (20)
LPV 28 (10) 49 (17) 77 (13)
DRV 24 (8) 13 (4) 37 (6)
Saquinavir 16 (5) 15 (5) 31 (5)
Fosamprenavir 7 (2) 3 (1) 10 (2)
NRTIs at entry, n (%)
Any 291 (100) 296 (100) 587 (100)
Emtricitabine/tenofovir 190 (65) 180 (61) 370 (63)
Lamivudine/abacavir 80 (27) 82 (28) 162 (28)
Other 21 (7) 34 (11) 55 (9)
IQR, interquartile range; MSM, men who have sex with men.
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5% reintroduced combination therapy for toxicity, 7% reintroduced combination therapy for other
reasons/unknown and 2% never started monotherapy). Overall, 72% of follow-up time was spent on
monotherapy. Self-reported adherence to study medication was high; across all visits, 93% of participants
in the OT group and 92% of participants in the PI-mono group reported not missing any ART doses in the
last 2 weeks (p= 0.51).
Virological rebound and resuppression
One or more episodes of confirmed VL rebound were observed in eight patients (Kaplan–Meier estimate
3.2%) in the OT group and 95 patients (35.0%) in the PI-mono group (absolute risk difference 31.8%,
95% CI 24.6% to 39.0%; p< 0.001). The rate of rebound while on monotherapy was highest in the
first year (24 per 100 person-years vs. 6 per 100 person-years thereafter; Figure 3).
There was no difference in the rate of rebound by PI in the PI-mono group [14 (95% CI 11 to 17),
8 (95% CI 4 to 17) and 12 (95% CI 5 to 27) rebounds per 100 person-years for DRV, LPV, and other PIs
respectively; p= 0.52 for overall comparison between groups]. The median peak VL at first episode of
rebound on monotherapy was 526 copies/ml; of the 91 patients with subsequent VL tests, 22 (24%)
resuppressed spontaneously and 69 (76%) resuppressed a median of 3.5 weeks after changing ART.
Figure 4 shows the time to first VL below 50 copies/ml (mid-point between the last test with a VL above
50 copies/ml and the first test with a VL below 50 copies/ml) for patients at the time of first rebound who
were taking PI monotherapy. Outcomes by type of treatment switch are shown in Figure 5.
Randomised (n = 587)
Excluded (n = 108)
• Previous ART change due to 
unsatisfactory VL response, n = 30
• VL > 50 copies/ml at screening 
or last 24 weeks, n = 28
• Did not return after screening, n = 19
• Not on 2NRTIs+NNRTI/PI regimen, n = 8
• Had other reasons, n = 29 
• (6 had multiple reasons) 
Patients assessed for eligibility (n = 695)
Allocated to ongoing triple therapy (n = 291)
• Received allocated therapy, n = 291
• Did not receive allocated therapy, n = 0
Allocated to PI monotherapy (n = 296)
• Received allocated therapy, n = 290
• Did not receive allocated therapy, n = 6
Developed AE after switch from NNRTI to 
   PI and never stopped NRTIs, n = 2
Died before end of trial follow-up (n = 1)
Complete withdrawal or lost to follow-up (n = 11)
Died before end of trial follow-up (n = 6)
Complete withdrawal or lost to follow-up (n = 5)
Included in primary analysis (n = 291) Included in primary analysis (n = 296)
• Patient decision, n = 4
FIGURE 2 Consolidated Standards of Reporting Trials (CONSORT) diagram.
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PI mono
(n = 296)
No change ART
(n = 26) 
First rebound
(n = 95)  
Added NRTIs
only
(n = 47)
Resuppressed (following ART change)
(n = 69; 100%)
Changed to
NRTIs and
NNRTI
(n = 18)
Changed 
PI only
(n = 2) 
Other
[No ART to cART
(1); on cART,
added fourth
drug (1)]
(n = 2)   
Resuppressed
(spontaneously)
(n = 22) 
Outcome unknown
(rebound detected
at last trial visit;
no new resistance
mutations detected)
(n = 4)
Resuppressed
(spontaneously)
(n = 6)
No change ART
(n = 7) 
Second rebound 
(n = 8)
Second rebound 
(n = 7)
Added NRTIs only
(n = 4) 
No change ART
(n = 4) 
Outcome unknown
(rebound detected
at last trial visit or
penultimate visit;
no new resistance
mutations detected)
(n = 2)
Resuppressed
(spontaneously)
(n = 2)
Resuppressed
(following ART
change)
(n = 4; 100%)
Outcome unknown
(rebound detected
at last trial visit;
no new resistance
mutations detected)
(n = 1) 
FIGURE 5 Outcome of VL rebound episodes in the PI-mono group.
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Resistance and loss of future drug options
The proportion of patients with loss of future drug options at 3 years, the primary outcome, was 0.7%
in the OT group and 2.1% in the PI-mono group [difference 1.4% (–0.4% to +3.4%); non-inferiority
criterion met; Table 3]. PI-mono was also non-inferior in prespecified secondary analyses including the loss
of drug options during the full trial follow-up period and excluding loss of options attributed to mutations
likely to be archived (as described in the following paragraph).
One participant on atazanavir monotherapy developed the I50L mutation (as a mixture with wild type),
conferring high-level atazanavir resistance. An isolated L90M mutation was detected in two patients on
DRV monotherapy; both resuppressed with the reintroduction of NRTIs. This mutation, possibly archived,
does not affect DRV sensitivity but confers resistance to saquinavir and thus met the end point definition.
NRTI or NNRTI mutations were detected in three patients in the PI-mono group, likely archived from
previous treatment. In the OT group, three patients had loss of future drug options to drug classes that
they were taking and one, taking a PI-based regimen, had NNRTI mutations that were likely archived
(Tables 3 and 4).
Serious drug- or disease-related complications
There were no differences in serious drug- or disease-related complications (death, AIDS-defining illness,
serious non-AIDS-defining illness) (Tables 5–7). Causes of death (one in the OT group, six in the PI-mono
group) were diverse and none was considered to be related to the treatment strategy (see Table 6).
TABLE 3 Primary outcome: loss of future drug options – summary results
Loss of future drug optionsa OTb PI-monob PI-mono – OTc
At 36 months, n (%) 21,2 (0.7) 65–10 (2.1) 1.4% (−0.4% to 3.4%)
At the end of the trial, n (%) 41–4 (1.8) 65–10 (2.1) 0.2% (−2.5% to 2.6%)
At the end of the trial, limited to drug classes given
during the trial (excluding likely archived resistance), n (%)
31–3 (1.5) 35–7 (1.0) −0.4% (−2.1% to 1.4%)
3TC, lamivudine; ABC, abacavir; ATV, atazanavir; EFV, efavirenz; ETV etravirine; FPV fosamprenavir; FTC, emtricitabine;
NVP nevirapine; RPV, rilpivirine; SQV, saquinavir; TDF, tenofovir; TPV tipranavir; ZDV, zidovudine.
a Loss of future drug options is defined as new intermediate-/high-level resistance to one or more drugs in contemporary
use (treatment options listed in the British HIV Association (BHIVA) 2012 treatment guidelines,63 with SQV added) to
which the patient’s virus was considered to be sensitive at trial entry.
b Numbers in superscript refer to individual patients meeting the primary end point (more detail provided in Table 4):
(1) OT group, received ABC, 3TC, ATV; detected 118I, 179D, 184V, 84V; lost 3TC, FTC, SQV, FPV, TPV; (2) OT group,
received TDF, FTC, RPV; detected 100I, 103N, 184V, 71V; lost 3TC, FTC, NVP, EFV, ETV, RPV; (3) OT group, received
TDF, FTC, ETV, NVP, ETV; detected 184V/I, 65R, 138A, 181C, 221Y, 230L; lost 3TC, FTC, ABC, TDF, NVP, EFV, ETV, RPV;
(4) OT group, received TDF, FTC, DRV; detected 106A; lost NVP, EFV (likely archived resistance); (5) PI-mono group,
received ATV; detected 20T, 50L/I, 71T; lost ATV; (6) PI-mono group, received DRV; detected 90M; lost SQV (possibly
archived resistance); (7) PI-mono group, received DRV; detected 90M; lost SQV (possibly archived resistance); (8) PI-mono
group, received DRV; detected 103N; lost NVP, EFV (likely archived resistance); (9) PI-mono group, received DRV;
detected 103N; lost NVP, EFV (likely archived resistance); (10) PI-mono group, received DRV; detected 41L, 215D;
lost ZDV (likely archived resistance).
c The absolute difference between the groups was estimated using Kaplan–Meier analysis, with the 95% CI (two-sided)
derived using bootstrap methods.
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TABLE 4 Detailed treatment history, VL rebound and resistance test results in cases meeting the definition of the primary end point, loss of future drug optionsa
Patient
Cumulative ART
exposure before trial
entry Time of
resistance test
(trial week)b
Cumulative ART exposure
during the trialc VL (copies/ml)
at time of
resistance test
Drug-resistance mutations
presentd Drugs with reduced susceptibilitye
NRTI, NNRTI PI NRTI, NNRTI,II PI RT PRO NRTI NNRTI PI
OT group
1 ZDV, 3TC,
NVP, ABC
ATV –89 – – – 118I, 179D – – – –
70 ABC, 3TC ATV 33,300 118I, 179D, 184V 84V 3TCH, FTCH – SQVH, TPVI,
ATVI, FPVH
185 TDF, FTC, RAL
(3TC, ABC)
DRV
(ATV)
4100 118I, 179D – – – –
2 d4T, TDF, EFV,
FTC
DRV –286 – – – – 71V – – –
193 TDF, FTC, RPV (DRV) 1500 100I, 103N, 184V 71V 3TCH, FTCH NVPH, EFVH,
ETVI, RPVI
–
3 ddI, 3TC, EFV,
FTC, TDF
161 TDF, FTC, ETV
(EFV, NVP)
(DRV) 60 138A, 184V/I – 3TCH, FTCH – –
167 TDF, FTC, ETV
(EFV, NVP)
(DRV) 5400 65R, 138A, 181C,
184V/I, 221Y, 230L
– 3TCH, FTCH,
ABCH, TDFI
NVPH, EFVH,
ETVH, RPVH
–
4 3TC, ABC LPV,
SQV
–179 – – – – – – – –
51 TDF, FTC DRV 2300 106A – – NVPH, EFVI –
continued
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TABLE 4 Detailed treatment history, VL rebound and resistance test results in cases meeting the definition of the primary end point, loss of future drug optionsa (continued )
Patient
Cumulative ART
exposure before trial
entry Time of
resistance test
(trial week)b
Cumulative ART exposure
during the trialc VL (copies/ml)
at time of
resistance test
Drug-resistance mutations
presentd Drugs with reduced susceptibilitye
NRTI, NNRTI PI NRTI, NNRTI,II PI RT PRO NRTI NNRTI PI
PI-mono group
5 FTC, TDF, EFV – –165 – – – – 71T – – –
48 – ATV 23,400 – 20T, 50L/I,
71T
– – ATVH
57 – ATV 3300 – 20T, 71T – – –
61 – ATV 2400 – 71T – – –
6 ZDV, 3TC,
ABC, EFV
LPV 155 – DRV 200 – 90M – – SQVI
7 FTC, TDF, EFV – 73 – DRV 300 – 71I, 90M – – SQVI
8 3TC, ABC, EFV – 82 – DRV < 20 103N – – NVPH, EFVH –
9 ZDV, 3TC,
FTC, TDF, NVP
SQV –290 – – – – 11I – – –
83 – DRV 1100 103N – – NVPH, EFVH –
10 ZDV, 3TC LPV 17 – DRV 300 41L, 215D – ZDVI – –
3TC, lamivudine; ABC, abacavir; ATV, atazanavir; d4T, stavudine; ddl, didanosine; EFV, efavirenz; ETV, etravirine; FPV, fosamprenavir; FTC, emtricitabine; NVP, nevirapine; PRO, protease;
RAL, raltegravir; RPV, rilpivirine; RT, reverse transcriptase; SQV, saquinavir; TDF, tenofovir; TPV tipranavir; ZDV, zidovudine.
a Drugs used for < 28 days are not reported.
b A negative value refers to the timing of a pre-trial resistance test relative to randomisation (usually obtained before the start of ART if performed).
c Shown is the cumulative drug exposure between randomisation and the time of performing the resistance test. PI-mono patients continued NRTIs for the first 14 days after randomisation
(drugs not shown). Drugs taken during the trial but discontinued prior to the resistance test are shown in parentheses.
d Drug-resistance mutations limited to those used in the Stanford algorithm.57
e Drug susceptibility determined from the Stanford algorithm.57 List limited to drugs that are included as treatment options in the British HIV Association (BHIVA) 2012 treatment guidelines,
with the addition of SQV. Superscript denotes the level of predicted resistance: I= intermediate, H= high.
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TABLE 5 Safety outcomes summary table
Serious drug- or disease-related complications OTa (n= 291)
PI-monoa
(n= 296)
Difference
(95% CI) (%)b p-value
Total, n (%) 8 (2.8) 15 (5.1) 2.3 (–0.8 to 5.4) 0.15
Death, n (%) 1 (0.3) 6 (2) 1.7 (–0.3 to 3.6) 0.12
AIDS-defining event, n (%) 1 (0.3) 1 (0.3) 0.0 (–1.3 to 1.3) 1
Serious non-AIDS-defining event, n (%) 7 (2.4) 12 (4.1) 1.6 (–1.2 to 4.5) 0.26
a Number (percentage) of patients experiencing the specified event during the entire trial follow-up period. p-Values are
from chi-squared or exact tests.
b Risk difference: PI-mono –OT.
TABLE 6 Causes of death, risk factors and HIV disease status during trial follow-up prior to the presentation of the
terminal condition
Patient
(group)
Cause of death
(week of presentation
of terminal condition) Clinical history and risk factors
HIV disease status from trial entry
to presentation of terminal condition
1 (OT) Metastatic
adenocarcinoma,
probable lung origin
(week 20)
58-year-old male; 40 pack per
year history of smoking; presented
with a right thigh mass; mediastinal
and adrenal mass on CT
CD4 525 cells/mm2 at baseline; VL
suppressed from randomisation to
presentation of the terminal condition
2 (PI-mono) Trauma, presumed suicide
(week 17)
47-year-old male; no history of
depression
CD4 215 cells/mm2 at baseline; VL
suppressed from randomisation to death
3 (PI-mono) Pulmonary embolism
(week 51)
40-year-old female; hospitalisation
for encephalitis (weeks 40–50);
pulmonary embolism secondary to
deep-vein thrombosis
CD4 333 cells/mm2 at baseline; VL
rebound week 36 because of
non-adherence; resuppressed partially
with reintroduction of combination
therapy
4 (PI-mono) Breast carcinoma,
recurrent (week 7)
54-year-old female; angiosarcoma
of the breast 2 years before study
entry treated by mastectomy
CD4 550 cells/mm2 at baseline; VL
suppressed from randomisation to
presentation of the terminal condition
5 (PI-mono) Small-cell lung carcinoma
(week 178)
59-year-old male; smoker for
30 years; presented with headache;
lung mass on CT, biopsy showed
small-cell carcinoma of the lung
CD4 208 cells/mm2 at baseline; VL
suppressed from randomisation to
presentation of the terminal condition
6 (PI-mono) Glioblastoma (week 66) 61-year-old male; non-smoker;
presented with headache at
week 66; brain mass on CT, biopsy
showed high-grade glioblastoma
CD4 468 cells/mm2 at baseline; VL
rebound weeks 25–32 (< 300 copies/ml).
Resuppressed with addition of TDF/FTC
thereafter
7 (PI-mono) Anal carcinoma (week 80) 56-year-old male; smoker; anal
mass detected; biopsy showed
squamous cell carcinoma
CD4 319 cells/mm2 at baseline; VL
rebound weeks 24–43
(max. 815 copies/ml). Resuppressed
with addition of TDF/FTC thereafter
CT, computerised (axial) tomography; FTC, emtricitabine; TDF, tenofovir.
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Serious adverse events and grade 3/4 clinical events
The number of serious adverse events (SAEs) overall and by category and the number of SAEs that were
considered to be related to ART did not differ between the groups (Tables 8–10). However, there
were fewer total grade 3 or 4 AEs in the PI-mono group (see Table 8), the difference reflecting fewer
laboratory events (Table 11).
TABLE 7 Serious AIDS- and non-AIDS-defining events
Event OT (n= 291) PI-mono (n= 296)
Serious AIDS-defining events
AIDS encephalopathy 1
Cytomegalovirus colitis 1
Serious non-AIDS-defining events
Acute pancreatitis 1
Facial wasting 1
Myocardial infarction 1
Renal failure 1
Malignancy 5 10
Anal squamous cell carcinoma 1a
CNS (glioblastoma) 1a
Hodgkin’s disease 1
Lung (small-cell carcinoma) 1a
Metastatic carcinoma (angiosarcoma, unknown primary) 1a 1a
Prostate cancer 2 1
Renal cell carcinoma 1
Skin carcinoma (variousb) 1 4
a Causing death.
b Basal cell carcinoma (OT, n= 1; PI-mono, n= 1); carcinoma in situ (PI mono, n= 2); squamous cell carcinoma
(PI-mono, n= 1).
TABLE 8 Serious adverse events and grade 3/4 AEs
Event OTa (n= 291) PI-monoa (n= 296) Difference (95% CI) (%)b p-value
SAE, n (%) 45 (15) 56 (19) 3.5 (–2.6 to 9.6) 0.27
Grade 3/4 AE, n (%) 159 (55) 137 (46) –8.4 (–16.4 to –0.3) 0.043
a Number (percentage) of patients experiencing the event specified at least once during the entire trial follow-up period.
b Risk difference: PT-mono –OT.
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TABLE 9 Serious adverse events by category of event
Event OT (n= 291)a PI-mono (n= 296)a
Total events 61 75
Death 1 6
Life-threatening 4 2
Caused/prolonged hospitalisation 58 67
Disability/incapacity 0 2
Congenital anomaly/birth defect 0 0
Other 4 5
a Number of events in each category.
Note
There is overlap of categories meaning that some events are in more than one category.
TABLE 10 Adverse events that were considered to be related to ART
Event OT (n= 291)a PI-mono (n= 296)a Difference (95% CI) (%) p-valueb
Total 6 (2.1) 3 (1.0) –1.0 (–3.2 to 1.1) 0.34
Death 0 0
SAE 2 0
Grade 3/4 AE 3 3
SAE plus grade 3/4 AE 1 0
a Total number (percentage) of patients with any event considered as possibly, probably or definitely related to ART based
on independent review at the co-ordinating centre. The numbers of events are shown for the individual categories.
b The p-value was calculated for a Fisher’s exact test for the proportion of patients affected.
DOI: 10.3310/hta20210 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 21
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Paton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
23
Renal toxicity
Fewer patients in the PI-mono group experienced an eGFR of < 60ml/minute/1.73m2 during follow-up
(Table 12) and there was a trend towards a reduced decline in eGFR in the PI-mono group (Figure 6),
although the difference at the end of the trial was marginal (see Table 12). There was no evidence of
serious clinical consequences: the only case of end-stage renal failure occurred in the PI-mono group in
a patient with pre-existing chronic renal impairment at trial entry.
Differences in the numbers ever having an eGFR of < 60ml/minute/1.73 m2 as well as in the mean change
from baseline were similar when values were calculated using the Cockcroft–Gault equation64 instead of
the CKD-EPI formula.59
TABLE 11 Grade 3/4 AEs by clinical and laboratory category
Event OT (n= 291)a PI-mono (n= 296)a Difference (95% CI) (%)b p-valuec
Clinical events
Total 49 (17) [78] 65 (22) [91] 5.1 (–1.3 to 11.5) 0.12
Cardiovascular 8 (3) [11] 7 (2) [7] –0.4 (–2.9 to 2.2) 0.77
Respiratory 5 (2) [5] 11 (4) [11] 2.0 (–0.6 to 4.6) 0.14
Gastrointestinal 12 (4) [15] 7 (2) [8] –1.8 (–4.6 to 1.1) 0.23
Hepatic 2 (1) [2] 3 (1) [3] 0.3 (–1.4 to 2.1) 1.00
Renald 2 (1) [2] 3 (1) [3] 0.3 (–1.4 to 2.1) 1.00
CNSe 9 (3) [10] 17 (6) [20] 2.7 (–0.7 to 6.0) 0.12
Skin 7 (2) [7] 9 (3) [9] 0.6 (–2.0 to 3.3) 0.64
Other 20 (7) [26] 24 (8) [30] 1.2 (–3.0 to 5.5) 0.57
Laboratory events
Total 131 (45) [158] 97 (33) [117] –12.2 (–20.1 to –4.4) 0.002
Phosphate decreased 73 (25) 37 (13) –12.6 (–18.8 to –6.3) < 0.001
Bilirubin increased 44 (15) 21 (7) –8.0 (–13.1 to –3.0) 0.002
Lipids increased 22 (8) 39 (13) 5.6 (0.7 to 10.5) 0.026
Haematological 8 (3) 5 (2) –1.1 (–3.4 to 1.3) 0.38
Other 7 (2) 11 (4) 1.3 (–1.5 to 4.1) 0.36
a Number (percentage) of patients with a given type of grade 3 or 4 AE and the total number of events in each category.
Recurrent laboratory events in the same patient were counted as a single event.
b Absolute differences in the proportions of patients affected in each group.
c p-values were calculated for chi-squared or Fisher’s exact tests for the proportion of patients affected.
d Renal events were nephrolithiasis and pyelonephritis in the OT group and renal cell carcinoma, end-stage renal failure
(progression of existing chronic renal impairment present at study entry) and acute renal impairment (transient,
accompanying episode of pneumonia) in the PI-mono group.
e CNS events were depression and/or suicidal ideation (n= 4), anxiety/stress (n= 2), headache (n= 2), psychosis (n= 1) and
normal-pressure hydrocephalus (n= 1) in the the OT group and depression and/or suicidal ideation (n= 9), anxiety/stress
(n= 1), headache (n= 2), myasthenia gravis (n= 1), psychosis (n= 2), psychiatric symptoms (unspecified) (n= 1),
meningioma (n= 1), glioblastoma (n= 1), head injury (n= 1) and convulsion (n= 1) in the PI-mono group.
RESULTS OF THE CLINICAL TRIAL
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Fewer patients in the PI-mono group experienced a phosphate level of < 0.65mmol/l (p< 0.001;
see Table 11). Patients allocated to the OT group had on average slightly lower serum phosphate levels
over the whole follow-up period than patients allocated to the PI-mono group (unadjusted GEE for global
difference in mean change, p= 0.017; Figure 7). There was, however, no significant difference in mean
change from baseline to the last available visit, with measurement at or after week 144 (difference
PI-mono –OT adjusted for baseline value: +0.02mmol/l, 95% CI –0.01 to +0.05; t-test p= 0.48).
Patients allocated to the OT group had on average a slightly higher urine protein–creatinine ratio over
the whole follow-up period than patients allocated to the PI-mono group (unadjusted GEE for global
difference in mean change after log10 transformation, p= 0.021; Figure 8). Patients in the OT group also
had a larger urine protein–creatinine ratio at the last available visit with measurement at or after
week 144 (p= 0.026).
85
90
95
100
105
110
M
e
a
n
 a
b
so
lu
te
 e
G
F
R
 (
m
l/
m
in
u
te
/1
.7
3
 m
2
)
[C
K
D
-E
P
I;
 p
o
in
tw
is
e
 (
9
5
%
 C
I)
]
0
1
2
2
4
3
6
4
8
6
0
7
2
8
4
9
6
1
0
8
1
2
0
1
3
2
1
4
4
1
5
6
1
6
8
1
8
0
1
9
2
2
0
4
2
1
6
2
2
8
2
4
0
Weeks
OT
PI-mono
FIGURE 6 Absolute eGFR over time.
TABLE 12 Number of patients with an eGFR of < 60ml/minute/1.73m2 during follow-up and mean change in eGFR
from baseline to the last visit
Outcome OT (n= 291)
PI-mono
(n= 296) Difference (95% CI)a p-value
Estimated GFR < 60ml/minute/1.73m2, n/N (%)b 28/290 (10) 15/296 (5) –4.6% (–8.8% to –0.4%) 0.033
Mean change (ml/minute/1.73m2), mean (SE) –5.13± 0.67 –3.83± 0.66 1.30 (–0.55 to 3.15) 0.09
a Difference in mean change or risk difference: PI-mono –OT.
b New episodes after baseline.
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In total, 65/271 (24%) in the OT group and 42/270 (16%) in the PI-mono group, respectively, ever had a
urine protein–creatinine ratio of > 200mg/g (difference –8.4%, 95% CI –15.1% to –1.8%; p= 0.014),
including single increased values (cut-off not prespecified).
Peripheral neuropathy and lipodystrophy
Proportions of patients with symptomatic peripheral neuropathy, facial lipoatrophy and abdominal fat
accumulation did not differ between the groups during follow-up (Table 13 and Figure 9).
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Cardiovascular disease risk
There was no difference in Framingham risk score65 between the groups over the whole follow-up period
(unadjusted GEE for global difference in mean change, p= 0.56) (Figure 10). The mean [standard error
(SE)] change in risk score for a CVD event over the next 10 years, from baseline to the last available visit,
with measurement at or after week 144, was +1.3% (0.3%) and +1.6% (0.3%) in the OT and PI-mono
groups, respectively; the difference between the groups adjusted for baseline values was 0.3%
(95% CI –0.6% to 1.1%; t-test p= 0.52). In total, 9/281 (3%) in the OT group and 16/288 (6%) in the
PI-mono group, respectively, ever newly had a CVD risk of > 30% after baseline (difference 2.4%,
95% CI –1.0% to 5.7%; p= 0.17).
TABLE 13 Peripheral neuropathy and lipodystrophy outcomes
Outcome OT (n= 291)
PI-mono
(n= 296)
Difference
(95% CI) (%)a p-value
Symptomatic peripheral neuropathy, n/N (%)b 44/283 (15.5) 46/289 (15.9) 0.4 (–5.6 to 6.3) 0.90
Facial lipoatrophy, n/N (%)c 23/282 (8.2) 35/289 (12.1) 4.0 (–1.0 to 8.9) 0.12
Abdominal fat accumulation, n/N (%)d 47/274 (17.2) 57/277 (20.6) 3.4 (–3.1 to 10.0) 0.30
a Absolute difference (PI-mono –OT).
b Symptomatic peripheral neuropathy on one or more of the post-baseline scheduled follow-up assessments (irrespective
of status at baseline).
c Facial lipoatrophy present at one or more of the post-baseline scheduled follow-up assessments (irrespective of status at
baseline) as assessed by the doctor or nurse.
d Abdominal fat accumulation at the last available assessment compared with baseline (irrespective of status at baseline),
self-assessed by the patient.
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FIGURE 9 Symptomatic peripheral neuropathy prevalence over time.
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CD4 cell count change
There was no difference in CD4 cell count between groups over the whole follow-up period (unadjusted
GEE for global difference in mean change, p= 0.91) (Figure 11). Mean (SE) change from baseline to the
last available visit, with measurement at or after week 144, was +93 (10) cells/mm3 in the OT group and
+109 (9) cells/mm3 in the PI-mono group; the difference between the groups adjusted for baseline values
was +16 (95% CI –11 to +42) cells/mm3 (t-test p= 0.30).
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FIGURE 10 Absolute CVD risk over time (estimated using the Framingham equation).
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Neurocognitive function
There was no difference between the groups in the change in mean NPZ-5 score on the neurocognitive
function tests (Figures 12 and 13). The mean (SE) change from baseline to the last available visit, with
measurement at or after week 144, was +0.53± 0.04 and +0.52± 0.04 in the OT and PI-mono groups,
respectively; the difference between the groups adjusted for baseline value was –0.01 (95% CI –0.11 to
0.09; t-test p= 0.94).
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FIGURE 12 Absolute NPZ-5 score over time.
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Quality of life
Changes in the mental and physical health summary scores from baseline to the last study visit were
calculated from the responses on the MOS-HIV questionnaire, with imputation of missing data on
individual subscales. Changes from baseline were relatively small in both groups and there was no
significant difference between the groups (Table 14).
TABLE 14 Quality of life: MOS-HIV questionnaire
Quality of life, summary score OT (n= 291) PI-mono (n= 296) Difference (95% CI)a p-value
Mental health, mean change –0.75± 0.57 –1.82± 0.54 –1.07 (–2.61 to 0.47) 0.17
Physical health, mean change –0.76± 0.53 –1.17± 0.46 –0.41 (–1.79 to 0.98) 0.56
a Difference in mean change: PI-mono –OT.
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Chapter 4 Health economics analysis
Outline of the analysis
The objective of the health economics analysis was to investigate the cost-effectiveness of the strategy
of switching to PI monotherapy compared with continuing triple therapy in HIV-1-infected patients. The
cost-effectiveness analysis considered costs from a NHS perspective (2012 GBP) and health outcomes in terms
of quality-adjusted life-years (QALYs) for each treatment group from the PIVOT trial. The base-case analysis
was a within-trial analysis and had a 3-year (156-week) time horizon. Secondary analyses modelled lifetime
costs and outcomes. All analyses were performed using individual patient-level data on resource use and
HRQoL from the PIVOT trial. Table 15 provides a description of the data collected for the economic evaluation.
Missing data on costs and QALYs were handled using multiple imputation (MI) and regression analysis was
used to adjust for baseline covariates. When one option generated additional mean QALYs at a higher
mean cost, comparative results were presented as incremental cost-effectiveness ratios (ICERs) by dividing
the difference in mean costs by the difference in mean QALYs.66 The cost-effectiveness of PI-mono was
assessed by comparing ICERs to the cost-effectiveness threshold range of £20,000–30,000 per QALY
defined by the National Institute for Health and Care Excellence (NICE).67 All analyses were conducted on
an intention-to-treat basis. All costs and QALYs accrued beyond the first year were discounted at an
annual rate of 3.5%.67
TABLE 15 Data collected for the economic evaluation during the PIVOT trial
Category Description of data collected Time points
HRQoL The European Quality of Life-5 Dimensions 3 Level (EQ-5D-3L) health
questionnaire
Baseline and
every 12 weeks
ART drug costs Generic names of ART drugs used as well as dosage, quantity and
duration of usage
Every 12 weeks
Cost of visits to HIV clinics Scheduled visits to HIV clinics every 12 weeks in the PI-mono group and
an additional scheduled appointment within the first 12 weeks after
initiation of monotherapy (frequency considered necessary for routine
clinical care on monotherapy)
Every 12 weeks
Scheduled visits every 24 weeks in the OT group (frequency considered
necessary for routine clinical care on triple therapy)
Additional unscheduled visits for both groups
Includes the cost of usual laboratory tests and additional resistance tests
in the PI-mono group
Cost of hospital services Visits to non-HIV outpatient clinics or accident and emergency
departments
Every 12 weeks
Inpatient admissions, including length of stay and reason for admission
Primary care costs Visits to general practitioners Every 12 weeks
Trial protocol-driven costs Measurement of PI concentration in the PI-mono group, required by the
trial protocol
Every 12 weeks
Visits to HIV clinics that are not expected to be part of routine clinical
practice, required by the trial protocol
Neurocognitive testing, required by the trial protocol
Cost of concomitant drugs Generic names of cholesterol-lowering agents used as well as dosage,
quantity and duration of usage
Every 12 weeks
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Health-care resource usage
Data on resource use were collected at scheduled visits every 12 weeks. In addition to the scheduled visits
every 12 weeks, which patients in both trial arms attended, two additional visits were scheduled at
weeks 4 and 8 for the PI-mono group. The recording of resource use was based on patients’ recollections
since the last visit. As patients were asked to recall their use of health-care resources since the last visit it
was assumed that visits that followed one or more omitted visits captured all of the use since the last
recorded visit. The use of the following types of resources was recorded: ART use, HIV clinic visits, visits to
accident and emergency or non-HIV outpatient clinics, general practitioner (GP) visits, hospital inpatient
stays and use of concomitant drugs. The use of ART was recorded by clinical staff, whereas the length of
any interruptions in ART treatment was based on the patients’ own recollections. Concomitant drugs
included all cholesterol-lowering agents as the use of these was expected to differ a priori.68 The patients
attending the scheduled visit at week 4 post randomisation were assumed to have their PI drug
concentration measured, as per protocol. No further PI drug concentration measurements were assumed
to be performed. No attempts were made to distinguish visits that were HIV related from those that were
not. In both groups the costs of all visits were included in the calculations. The total resource consumption
among the complete cases is summarised in Table 16 along with the corresponding unit costs.
TABLE 16 Use of health-care resources within 3 years’ follow-up for complete cases
Resource type
PI-mono (n= 266) OT (n= 254)
Unit cost and
sourceaMean (SD)
Median
(IQR)
Used by,
n (%) Mean (SD)
Median
(IQR)
Used by,
n (%)
ART drug use at the 3-year follow-up visit
Monotherapy 162 (60.9) 4 (1.6) Various69,70
Any triple
therapy use
104 (39.1) 250 (98.4) Various69,70
No use 0 (0) 0 (0) £0
Routine HIV clinic
visits
16.60 (3.74) 15 (4) 266 (100) 8.31 (3.9) 7 (3) 254 (100) PI-mono:
£411.81;71,[CA]
OT: £40471
Primary care
GP visits 6.24 (6.16) 5 (7) 244 (91.7) 6.06 (6.06) 4.75 (6) 234 (92.1) £5372
Hospital services
Outpatient clinic
or A&E visits
3.7 (5.39) 2 (5) 188 (70.7) 4.49 (7.19) 2 (4) 194 (76.4) £106.2071
Inpatient
admissions
0.368 (0.83) 0 (0) 60 (22.6) 0.311 (0.79) 0 (0) 50 (19.7) Various71
Trial protocol-driven resource use
Neurocognitive
testing
3.81 (0.56) 4 (0) 265 (99.6) 3.82 (0.58) 4 (0) 252 (99.2) £32.9472–75
PI drug
concentration
measurements
0.974 (0.16) 1 (0) 259 (97.4) 0 (0) 0 (0) 0 (0) £60CA
Non-routine HIV
clinic visits
0.98 (0.24) 1 (0) 255 (95.9) 6.69 (0.67) 7 (0) 254 (100) PIM: £411.81;71,[CA]
OT: £40471
Concomitant drug use at the 3-year follow-up visit
Cholesterol-
lowering agents
59 (22.2) 35 (13.8) Various70
A&E, accident and emergency; CA, clinical advice; IQR, interquartile range.
a The term ‘various’ indicates that a variety of prices was used; rather than listing them all, the source from which they
were drawn is presented.
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Costs
Resource use estimates were obtained from the PIVOT trial and unit costs were obtained from routinely
published national cost sources: the British National Formulary (BNF),70 the Department of Health’s
Commercial Medicines Unit’s Electronic Market Information Tool,69 the Personal Social Services Research
Unit report on the unit costs of health and social care72 and NHS reference costs71 (see Table 16).
All analyses assume that no costs of ART drugs are incurred in periods of interrupted treatment.
Furthermore, potential ART drug waste from switching drug combinations before a package had been
finished was not registered and therefore not estimated. All six categories of health-care resources
consumed were included in the base-case analysis of costs accrued within 3 years. As such, the base case
also includes the resource use that could mainly be attributed to the trial protocol (see Table 16).
Quality-adjusted life-years
The QALY is a generic measure of health that combines effects of interventions on both life expectancy
and HRQoL and their side-effects and is defined as a year lived with full health.66 To calculate the total
QALYs gained per patient the length of life was weighted by the HRQoL. During the PIVOT trial, HRQoL
was measured at baseline and at each scheduled follow-up visit using the three-level version of the
European Quality of Life-5 Dimensions (EQ-5D-3L).76 Responses were converted into the EQ-5D-3L index
score using weights based on the UK value set.77
Missing data
Multiple imputation using chained equations was used to handle missing data on costs and outcomes.78–80
The use of MI requires a less strong assumption regarding the missingness mechanism than the
assumption needed to perform complete-case analysis. When complete-case analysis is performed in the
presence of missing data it is assumed that there is no underlying relationship between missing values
and any observed or unobserved variables; that is, that values are missing completely at random.81 In
contrast, MI requires that missing data can be assumed to be missing at random conditional on values of
observed variables but not on any unobserved variables.81 As such, missing data were handled using MI.
A total of 20 imputations (m= 20) was performed as previous research suggested that m= 20 would
improve efficiency in the presence of 10–30% missing data.82 The model imputed HRQoL scores, ART drug
costs, primary care costs, secondary care costs, the cost of HIV clinic visits and the cost of concomitant
drug use at each 12-week time point. To further inform the imputation model the following auxiliary
variables were included: age, gender, ethnic origin, baseline CD4 cell count, history of diabetes, smoking
status, history of coronary artery disease, years of education, years since diagnosis, number of days off
work between each time point and an indicator of whether patients were receiving a NNRTI-based or a
PI-based regimen prior to randomisation. The imputation model performed predictive mean matching to
handle the bounded and skewed nature of costs and HRQoL scores. In predictive mean matching the
specified covariates are used to estimate a predictive model but, instead of replacing missing values with
the model-predicted values, the nearest observed value is used to fill the missing value. By applying
predictive mean matching, predictions that lie outside the bounds of each variable were avoided.83
However, the distribution of imputed values will often closely match that of the observed values. Following
the use of MI to generate estimates that replace missing values, the uncertainty of these values is
incorporated in the estimation of mean costs and QALYs using a method commonly known as Rubin’s rule.84
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Regression analyses of costs and quality-adjusted life-years
Regression methods were used to obtain the incremental estimates of costs and QALYs between treatment
groups while adjusting for the baseline characteristics that were selected a priori. A generalised linear model
(GLM) was chosen as it offers a flexible framework to handle adjustment for baseline covariates when the
distribution of the dependent variable is right skewed.85 However, QALYs are usually left skewed.86 Therefore,
to be able to adjust the QALYs gained for baseline covariates, the QALY decrement was estimated. The QALY
decrement is defined as the maximum QALYs that could possibly be accrued within the time frame minus the
actual QALYs gained. Because the distribution of QALYs was left skewed, the distribution of QALY decrements
was right skewed. Hence the GLM for right-skewed (gamma) distributions was a good match for both cost
regressions and regressions of QALY decrements. An identity link function was applied to assume an additive
effect of covariates on costs and QALY decrements.85 Costs and QALY decrements were adjusted for the
following baseline covariates: age, gender, ethnic origin, time since HIV diagnosis, history of diabetes, smoking
status, history of coronary artery disease and CD4 cell count. In the regression of QALY decrements, the
baseline HRQoL score was also included, as failure to do so may bias estimates in the presence of an imbalance
in baseline HRQoL score between the treatment groups.87 Regression analysis and MI of missing values was
conducted in Stata version 12.1 (StataCorp, College Station, TX, USA).
Scenario analyses
Several scenario analyses were conducted to assess the impact of uncertainty on the cost-effectiveness
results and to strengthen the external validity of the results; these are summarised in Table 17.
Scenarios 1a–f were constructed to incorporate potential reductions in the price of ARTs. Scenarios 1a–d
assumed 10%, 20%, 30% and 40% reductions in the price of all ARTs respectively. Scenario 1e assumed
a 10% reduction in the price of ART drugs in the PI-mono group and a 30% reduction in the price of ART
drugs in the OT group. This scenario was constructed to explore the impact that generic versions of
frequently used triple therapy drugs could be speculated to have on the cost-effectiveness of PI-mono
compared with OT. Scenario 1f applied information about the current prices being paid, which was
obtained through clinical advice with a HIV pharmacist in a major NHS trust.
TABLE 17 Alternative scenarios investigated
Scenario Element Base case Variation for the sensitivity analysis
1 Costs All unit costs for ART drugs were drawn from the
Department of Health Commercial Medicines
Unit’s Electronic Market Information Tool69 and
the BNF70
1a: 10% reduction in all ART drug costs
1b: 20% reduction in all ART drug costs
1c: 30% reduction in all ART drug costs
1d: 40% reduction in all ART drug costs
1e: 30% reduction in ART drug costs for the
OT group and 10% reduction in the PI-mono
group
1f: Estimated reductions obtained from
personal communication with HIV
pharmacist
2 Costs All cost categories included The costs that were deemed attributable to
the trial protocol were excluded
3 Missing
data
Data assumed to be missing at random; analysis
therefore conducted on imputed data
Data assumed to be missing completely at
random; analysis therefore conducted on the
complete-case data
4 Mortality All patients included The six patients who died within 3 years
were excluded from the analysis
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In scenario 2 the costs of trial protocol-driven resource consumption were excluded as they might not be
a part of routine clinical practice. PI monotherapy patients may need a stricter monitoring regimen than
patients on triple therapy to ensure that combination therapy can be reintroduced promptly if a VL
rebound occurs. The base case assumes that both PI-mono patients and OT patients attend scheduled HIV
clinic visits every 12 weeks. Although this is considered reasonable in a routine clinical setting for PI
monotherapy patients, it would be considered excessive for patients on triple therapy. Patients on triple
therapy may only routinely attend scheduled HIV clinic visits every 24 weeks and the additional visits
which the OT patients were subject to during the PIVOT trial were therefore considered to incur trial
protocol-driven costs. This means that the trial protocol-driven consumption of health-care resources is
higher in the OT group than in the PI-mono group. In scenario 2, these trial protocol-driven costs are
excluded to assess the cost-effectiveness of PI monotherapy in a routine clinical setting. Hence scenario
2 assumes that PI-mono patients attend the HIV clinic every 12 weeks, whereas OT patients attend every
24 weeks. Furthermore, neurocognitive testing and PI drug concentration measurements conducted for the
trial were excluded entirely.
In scenario 3 a complete-case analysis was performed to assess the impact of MI on the estimate of
incremental costs and QALYs. GLM regression was also used in the complete-case analysis to adjust for
baseline covariates. However, in the complete-case analysis QALY decrements could not be adjusted
for history of diabetes and history of coronary artery disease because none of the complete cases was
characterised by these at baseline. This was not considered to be a major issue as the restricted model for
QALY decrements in the complete-case analysis was nested in the full model.
Scenario 4 addressed the within-trial mortality. The patients who died within 3 years (described in Chapter 3)
were excluded from the analysis as it was considered unlikely that within-trial mortality was caused by
treatment allocation. In total, six patients were removed from the data set after MI was performed. GLM
regression of costs and QALY decrements was then performed using the remaining 291 PI-mono patients and
290 OT patients.
Subgroup analysis
In the PIVOT trial the randomisation of patients was stratified by whether ART treatment before
randomisation was a PI-based or a NNRTI regimen. The stratification was carried out to ensure that equal
numbers of patients from each stratum were randomised to each of the treatment groups because
previous treatment was expected to impact on the success of the PI-mono strategy. This expected
heterogeneity in treatment success is also likely to impact on costs and QALYs. Therefore, an exploratory
subgroup analysis was conducted to investigate whether previous treatment regimen could be identified
as a source of heterogeneity.88 The subgroup analysis was performed by adding the previous regimen
(PI based or NNRTI based) as a covariate and adding an interaction term between allocated treatment
group (PI-mono or OT) and previous treatment regimen in regression models for costs and QALYs. As such,
the subgroup analysis assumes that the impact of other covariates is independent of previous treatment.
Modelling lifetime costs and quality-adjusted life-years
The validity of the base case within the trial analysis for assessing cost-effectiveness relies on the assumption
that no differences in costs or QALYs between the treatment groups persist beyond the trial follow-up
period. As this can be considered a strong assumption, exploratory extrapolation was performed to assess
the impact of differences persisting beyond the trial period. Two scenarios, A and B, were considered to
model the future costs and QALYs by treatment group.
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Scenario A assumed that PI-mono patients switch back to combination therapy 3 years post randomisation
and that there is no difference in mortality between treatment groups; that is, the survival rates are equal
in the trial and survival curves are assumed to be parallel following the end of the trial. Therefore, scenario A
excluded from the analysis the patients who died within 3 years’ follow-up, as in scenario 4 of the sensitivity
analysis. Patient-specific life expectancies were calculated using a predictive model from the UK Collaborative
HIV Cohort (UK CHIC) study89 and data on mortality in the UK general population from the Office for National
Statistics.90 May et al.89 have estimated life expectancy conditional on CD4 cell count and defined three groups:
< 100, 100–199 and 200–350 cells/mm3. The CD4 cell count measured at the closest point to the final 3-year
follow-up visit was used to allocate the trial participants into these three groups to estimate patient-specific
life expectancy conditional on age and CD4 cell count. The life expectancy of patients with a CD4 cell count
of > 350 cells/mm3 was estimated based on the group with a CD4 cell count of 200–350 cells/mm3. Each
patient’s future HRQoL score was calculated from the HRQoL score at the final 3-year follow-up visit, with
declining health over time being captured using an annual decrement per year of –0.00029.91 QALYs were
then calculated from the patient-specific life expectancy and HRQoL score. As this scenario assumes that
PI-mono patients switch to OT at the end of the trial, the mean total cost per year in the OT group during the
PIVOT trial was applied in both groups.
Scenario B assumed that all patients stay on the treatment that they were receiving at the end of the trial.
As an extension of this assumption, it was assumed that any within-trial difference in mortality rate would
continue beyond the trial follow-up period. In other words, a hazard ratio of 3.3 for all-cause mortality of
PI-mono compared with OT was assumed to continue beyond the 3-year follow-up, allowing the survival
curves to diverge at a constant rate. Life expectancy for OT patients was modelled in the same manner
as in scenario A, whereas the hazard ratio for mortality within 3 years’ follow-up was applied for patients
in the PI-mono group to obtain life expectancy. However, the PI-mono patients who have switched back to
triple therapy are assumed to have the same increased mortality rate as those still on PI monotherapy. To
inform estimates of future costs, the within-trial costs between week 108 and week 156 were used. By the
end of the 3-year follow-up period approximately 40% of PI-mono patients had switched back to triple
therapy (see Table 16). By using the costs accrued during the final 48 weeks to inform future costs, the
cost savings from PI monotherapy are diminished because many patients had switched back to triple
therapy. At the patient level, costs accrued in the 48 weeks from week 108 to week 156 were inflated to
reflect an entire year and applied as the annual cost of treatment until death. As such, scenario B was
constructed to assess the cost-effectiveness of PI-mono under much less favourable assumptions for
PI-mono; that is, a high mortality rate among PI-mono patients.
Probabilistic sensitivity analysis
The uncertainty surrounding the decision to adopt PI monotherapy was assessed using probabilistic sensitivity
analysis (PSA) for every scenario. The PSA captures the uncertainty in all parameters jointly to estimate the
probability of a treatment being cost-effective for a given cost-effectiveness threshold. The variance–covariance
matrices from the regressions of costs and QALY decrements were extracted and entered in Microsoft Excel®
2010 (Microsoft Corporation, Redmond, WA, USA). The PSA was performed by taking 10,000 random draws
from the distribution of the covariates in the regressions of costs and QALY decrements. The Cholesky
decomposition was applied to ensure an appropriate covariance in the random draws. The 10,000 random
draws were then used to present cost-effectiveness acceptability curves.86 These were used to assess the
probability of PI-mono being cost-effective across a range of cost-effectiveness thresholds.92
Results
Missing data
Missing data was not a major issue during the PIVOT trial. The EQ-5D-3L index score had the lowest number
of available data, but none of the categories of HRQoL or resource use had > 20% missing values (Table 18).
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TABLE 18 Percentages of available data on HRQoL and resource use
Time point
EQ-5D-3L index score ART drugs HIV clinic visits Primary care Hospital Services Trial protocol driven Concomitant drugs
PI-mono OT PI-mono OT PI-mono OT PI-mono OT PI-mono OT PI-mono OT PI-mono OT
Baseline 97.6 98.3 NA NA NA NA NA NA NA NA NA NA NA NA
12 weeks 95.6 92.1 100.0 99.3 100.0 99.3 100.0 99.3 99.3 98.6 100.0 100.0 100.0 99.3
24 weeks 94.6 91.1 99.7 99.3 98.3 98.6 98.3 98.6 98.3 98.6 100.0 100.0 99.7 99.3
36 weeks 91.6 89.3 99.7 99.0 97.6 96.6 97.6 96.6 97.6 96.6 100.0 100.0 99.7 99.0
48 weeks 92.6 91.4 99.3 98.6 97.6 96.9 97.6 96.9 97.6 96.9 100.0 100.0 99.3 98.6
60 weeks 92.2 88.3 99.0 98.6 98.3 97.3 98.3 97.3 98.3 97.3 100.0 100.0 99.0 98.6
72 weeks 91.9 90.7 99.0 98.3 96.6 96.2 96.6 96.2 96.6 96.2 100.0 100.0 99.0 98.3
84 weeks 90.9 88.3 98.6 98.3 96.3 95.9 96.3 95.9 96.3 95.9 100.0 100.0 98.6 98.3
96 weeks 90.2 91.8 99.0 97.9 96.6 96.2 96.6 96.2 96.6 96.2 100.0 100.0 99.0 97.9
108 weeks 88.2 82.5 99.0 97.9 97.0 95.9 97.0 95.9 97.0 95.9 100.0 100.0 99.0 97.9
120 weeks 89.9 88.3 98.6 97.9 97.0 96.2 97.0 96.2 97.0 96.2 100.0 100.0 98.6 97.9
132 weeks 89.9 87.3 98.0 97.9 96.3 95.2 96.3 95.2 96.3 95.2 100.0 100.0 98.0 97.9
144 weeks 87.8 89.0 98.6 97.6 95.9 95.2 95.9 95.2 95.9 95.2 100.0 100.0 98.6 97.6
156 weeks 82.4 80.0 98.3 96.9 95.9 93.8 95.9 93.8 95.9 93.8 100.0 100.0 98.3 96.9
NA, not applicable.
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Health-related quality of life
The missing values were handled using MI and the results are presented in Table 19. No marked difference
in EQ-5D-3L index score was observed during the 156 weeks of follow-up in the PIVOT trial.
Costs
Missing values of costs were multiply imputed for each category at each time point. The degree of missing
data for each of the six categories of health-care resources is shown in Table 18. The costs accrued within
3 years are shown by category in Table 20.
TABLE 19 Health-related quality of life (EQ-5D-3L index score) within the 3-year follow-up period
Time point PI-mono (n= 296, m= 20), mean (SE) OT (n= 291, m= 20), mean (SE)
Baseline 0.8772 (0.0102) 0.8716 (0.0111)
12 weeks 0.8512 (0.0130) 0.8481 (0.0135)
24 weeks 0.8601 (0.0137) 0.8672 (0.0128)
36 weeks 0.8585 (0.0134) 0.8617 (0.0129)
48 weeks 0.8369 (0.0145) 0.8328 (0.0146)
60 weeks 0.8398 (0.0144) 0.8389 (0.0150)
72 weeks 0.8433 (0.0143) 0.8418 (0.0153)
84 weeks 0.8497 (0.0140) 0.8564 (0.0135)
96 weeks 0.8209 (0.0156) 0.8312 (0.0141)
108 weeks 0.8418 (0.0134) 0.8479 (0.0144)
120 weeks 0.8317 (0.0155) 0.8553 (0.0131)
132 weeks 0.8226 (0.0161) 0.8544 (0.0138)
144 weeks 0.8194 (0.0153) 0.8343 (0.0146)
156 weeks 0.8145 (0.0164) 0.8326 (0.0156)
Multiple imputation (m= 20) using chained equations was used to handle missing values of HRQoL at every time point.
TABLE 20 Unadjusted costs accrued within 3 years by category
Cost category
PI-mono (n= 296, m= 20) OT (n= 291, m= 20)
Mean (SE) (£) % of total Mean (SE) (£) % of total
ART drugs 14,335.31 (286.52) 62.5 21,954.84 (255.39) 74.9
HIV clinic visits 6648.38 (100.08) 29.0 3359.13 (112.04) 11.5
Primary care 325.52 (19.15) 1.4 316.26 (21.24) 1.1
Hospital services 1010.49 (120.40) 4.4 988.46 (126.55) 3.4
Trial protocol driven 574.32 (6.82) 2.5 2676.92 (25.67) 9.1
Concomitant drugs 30.71 (6.70) 0.1 27.84 (7.40) 0.1
Total 22,924.74 (354.42) 100 29,323.46 (337.72) 100
Multiple imputation (m= 20) using chained equations was used to handle missing values in each category of costs at every
time point. Cost accrued beyond the first year is discounted at an annual rate of 3.5%.
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From Table 20 it can be seen that the unadjusted incremental cost of PI-mono was –£6398.72 per patient
within 3 years. The single largest difference between the groups is in the cost of ART drugs. Considerably
more costs were incurred from HIV clinic visits in the PI-mono group. This is because the scheduled HIV
clinic visits every 12 weeks were considered to be necessary for the PI-mono strategy outside the trial
setting, whereas scheduled visits only every 24 weeks were considered necessary in the OT group.
Conservatively, even those patients who switched from PI monotherapy back to combination therapy
were considered to have scheduled visits every 12 weeks. As patients in both trial arms were seen every
12 weeks for scheduled HIV clinic visits, the additional visits in the OT group were considered to be trial
protocol-driven costs. As such, the trial protocol-driven costs are considerably higher for the OT group than
for the PI-mono group. Costs incurred from primary care, hospital services and cholesterol-lowering
treatments were comparable between groups within 3 years.
Cost-effectiveness
Base-case analysis
In the base-case analysis PI-mono was a dominant strategy as it offered, per patient, both mean cost
savings and a small mean QALY gain compared with OT. The adjusted incremental total cost of PI-mono
per patient was –£6424.11 (95% CI –£7418.84 to –£5429.38) over a 3-year period. The cost savings in
the PI-mono group were mainly attributable to the saving in ART drug costs. The adjusted regression of
QALY decrements showed that PI-mono patients gained an average of 0.0051 QALYs (95% CI –0.0479 to
0.0582) more than OT patients (Table 21). The PSA revealed that PI-mono was cost-effective in 100% of
simulations regardless of whether a £20,000 per QALY or a £30,000 per QALY cost-effectiveness threshold
was applied (Figure 14).
Scenario analyses
Overall, PI-mono remained cost-effective in all scenarios. The results were robust regarding all of the
alternative ART prices used in scenario 1. However, scenario 1e showed that introduction of generic
versions of frequently used triple-therapy drugs resulted in a 20% larger reduction in the mean ART cost
for OT and much lower cost savings for PI-mono. Scenario 2, in which PI-mono requires a stricter
monitoring regimen than OT in routine clinical practice but in which other trial protocol-driven costs were
excluded, resulted in a mean cost saving of £4307.27 per patient for PI-mono. In the complete-case
analysis performed for scenario 3, differential costs and QALYs fell in the south-west quadrant of the
cost-effectiveness scatterplot; that is, PI-mono remained cost-saving but resulted in a QALY decrement
compared with OT. However, the PSA showed that PI-mono remained cost-effective as the mean QALY
loss was small (–0.0227, 95% CI –0.0878 to 0.0424) but there were large cost savings. Under the
assumption that the observed within-trial mortality was unrelated to the allocated treatment, the six
patients who died were excluded from the analysis in scenario 4. The expected QALY gain observed in the
PI-mono group was slightly higher than in the base-case analysis as five out of the six patients who died
within 3 years’ follow-up were allocated to the PI-mono group. The results of all alternative scenarios are
summarised in Table 21.
Subgroup analysis
The results of the exploratory subgroup analysis demonstrated that PI-mono was cost-effective in both
strata. Results indicated that patients who were receiving a PI-based regimen before randomisation had
larger mean cost savings from PI-mono than those receiving a NNRTI-based regimen. Furthermore, PI-mono
might be associated with a slight QALY loss for patients receiving a NNRTI-based regimen. For both strata,
PI-mono was considered cost-effective in 100% of the simulations regardless of whether a £20,000 per
QALY or a £30,000 per QALY threshold was applied (Figure 15).
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TABLE 21 Cost-effectiveness results of all scenarios
Analysis
Incremental cost
(PI-mono –OT)
(95% CI) (£)
Incremental QALYs
(PI-mono –OT)
(95% CI) ICER (£)
Probability of being
cost-effective at threshold
of £20,000 per QALY
(£30,000 per QALY) (%)
Base-case analysis
Base case –6424.11a
(–7418.84 to –5429.38)
0.0051a
(–0.0479 to 0.0582)
PI-mono
dominant
100 (100)
Alternative scenariosb
Scenario 1a –5662.98a
(–6589.23 to –4736.73)
0.0051a
(–0.0479 to 0.0582)
PI-mono
dominant
100 (100)
Scenario 1b –4902.03a
(–5762.35 to –4041.71)
0.0051a
(–0.0479 to 0.0582)
PI-mono
dominant
100 (100)
Scenario 1c –4141.32a
(–4938.84 to –3343.79)
0.0051a
(–0.0479 to 0.0582)
PI-mono
dominant
100 (100)
Scenario 1d –3380.89a
(–4119.48 to –2642.29)
0.0051a
(–0.0479 to 0.0582)
PI-mono
dominant
100 (100)
Scenario 1e –1279.97a
(–2134.85 to –425.08)
0.0051a
(–0.0479 to 0.0582)
PI-mono
dominant
97.47 (93.84)
Scenario 1f –4245.63a
(–5085.79 to –3405.47)
0.0051a
(–0.0479 to 0.0582)
PI-mono
dominant
100 (100)
Scenario 2 –4307.27a
(–5285.24 to –3329.31)
0.0051a
(–0.0479 to 0.0582)
PI-mono
dominant
100 (100)
Scenario 3 –6417.15c
(–7393.62 to –5440.68)
–0.0227d
(–0.0878 to 0.0424)
282,641e 100 (100)
Scenario 4 –6406.41f
(–7374.08 to –5438.74)
0.0197f
(–0.0291 to 0.0685)
PI-mono
dominant
100 (100)
Subgroup analysis
PI-based
regimen at
randomisation
–9718.45a
(–11,183.1 to –8253.8)
–0.0032a
(–0.0804 to 0.0741)
3,085,027e 100 (100)
NNRTI-based
regimen at
randomisation
–7386.40a
(–8910.89 to –5861.90)
–0.0316a
(–0.1094 to 0.0462)
233,639e 100 (100)
Modelling of lifetime cost-effectiveness
Scenario A –38,248f
(–46,081 to –30,416)
–0.3884f
(–1.1299 to 0.3531)
98,475e 99.98 (98.52)
Scenario B –69,065f
(–76,212 to –61,919)
–3.2597f
(–3.8945 to –2.6249)
20,772e 63.31 (0.19)
a PI-mono (n= 296, m= 20) and OT (n= 291, m= 20).
b The details of the alternative scenarios are provided in Table 17.
c PI-mono (n= 266, m= 0) and OT (n= 254, m= 0).
d PI-mono (n= 142, m= 0) and OT (n= 130, m= 0).
e ICER in the south-west quadrant of the cost-effectiveness plane, i.e. the ICER of OT compared with PI-mono.
f PI-mono (n= 291, m= 20) and OT (n= 290, m= 20).
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FIGURE 14 Incremental cost-effectiveness scatterplot for the base-case analysis (PI-mono –OT). The green circles are
the 10,000 simulated sets of the incremental costs and QALYs of PI-mono compared with OT in the PSA for the
base-case analysis. The black line running through (0,0) in the cost-effectiveness plane is the £20,000 per QALY
threshold. As all simulations fall ‘under’ the threshold PI-mono could be considered cost-effective compared with
OT in 100% of the simulations.
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FIGURE 15 Incremental cost-effectiveness scatterplot for the subgroup analysis (PI-mono –OT). The blue circles are
the 10,000 simulated sets of incremental costs and QALYs of PI-mono compared with OT for patients receiving a
NNRTI-based regimen at randomisation, whereas the green circles are the 10,000 simulated sets of incremental
costs and QALYs for patients receiving a PI-based regimen at randomisation.
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Extrapolation
In both of the exploratory extrapolation scenarios PI-mono was cost saving but also less effective than OT.
However, the substantial cost saving associated with PI-mono in both scenarios means that PI-mono may
be cost-effective. This is because the costs saved by the use of PI-mono could generate more QALYs if
spent elsewhere than the small amount of QALYs lost to the patients on PI-mono. As PI-mono is cost saving
and less effective, the results fall in the south-west quadrant of the cost-effectiveness plane (Figure 16).
In this quadrant, the ICER can be interpreted as the difference in costs between the lower-cost intervention
(PI-mono) and the higher-cost intervention (OT), such that each additional QALY offered by OT over
PI-mono costs the ICER value. Consequently, the ICERs of £98,475 per QALY and £20,772 per QALY in
scenarios A and B, respectively, represent the ICERs of OT compared with PI-mono (i.e. the incremental
cost of OT compared with PI-mono per additional QALY generated by OT compared with PI-mono).
Therefore, at a cost-effectiveness threshold of £20,000 per QALY, PI-mono appears to be the cost-effective
option in both extrapolation scenarios, as the incremental cost per QALY generated by OT compared with
PI-mono is above the threshold in both cases. At a threshold of £30,000 per QALY, OT appears to be
cost-effective in scenario B, generating additional QALYs at a cost below the threshold, but not in scenario A.
There are two main reasons for the difference in the results of the two extrapolation scenarios. First, the lower
effectiveness of PI-mono in extrapolation scenario B is caused by the assumption that the PI-mono group has a
hazard ratio of 3.3 for all-cause mortality compared with the OT group. Second, the higher cost saving in
extrapolation scenario B is caused by the assumption that the majority of patients in the PI-mono group
continue lifelong monotherapy.
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FIGURE 16 Incremental cost-effectiveness scatterplot for the two extrapolation scenarios (PI-mono–OT). The blue circles
are the 10,000 simulated sets of incremental costs and QALYs of PI-mono compared with OT for extrapolation scenario A,
whereas the green circles are the 10,000 simulated sets of incremental costs and QALYs for extrapolation scenario B.
The black line running through (0,0) in the cost-effectiveness plane is the £20,000 per QALY threshold.
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Chapter 5 Discussion
Main trial results
We have shown that, in patients who have achieved VL suppression on combination therapy, a maintenance
strategy of PI monotherapy with reintroduction of combination therapy in the event of VL rebound was
non-inferior to combination therapy in preserving future treatment options over 3–5 years. Only one patient
developed clinically significant resistance to the PI that they were taking as monotherapy, an I50L mutation
occurring on atazanavir monotherapy. The clinical consequences of this are mitigated by the increase in
sensitivity to other PIs conferred by this mutation.93 None of the 278 patients taking DRV or LPV (the
recommended options for monotherapy, taken by the large majority of the patients in this trial) developed
resistance affecting the efficacy of these drugs. Our findings concur with earlier trials of PI monotherapy that
found little resistance but extend these results to provide the critical long-term randomised outcome data in a
large pragmatic trial needed to provide the confidence to use this option in clinical practice.17,24,25,46 We sought
resistance fastidiously, testing confirmed VL rebound samples irrespective of level of viraemia, using standard
population sequence genotypic testing. Although PI resistance may occur in other regions of the virus, such as
in the gag or env genes, or in minority species that are not detected by population assays,12 previous minority
species sequencing in patients failing PI monotherapy has found minimal resistance in excess of that detected
by population sequencing.36,37,94 Furthermore, our finding that patients with VL rebound on PI monotherapy
achieved full VL suppression without exception when switched to combination therapy (usually by
reintroduction of NRTIs) provides an important assurance that any mutations that were not detected by
population sequencing did not impact on subsequent treatment efficacy.
A higher proportion of patients in the PI-mono group experienced VL rebound. This had been expected,
although the difference was much greater than that seen in previous studies.31 VL suppression has been
the traditional outcome for comparing treatment regimens in clinical trials but is less informative in strategy
trials such as this, especially given the different impact of VL rebound on risk of drug resistance for
different drug classes. Aside from risk of resistance (shown to be minimal in this study), it is unlikely that
these brief episodes of low-level viraemia, rapidly reversed by the reintroduction of combination therapy,
would have adverse long-term effects – persistent VL levels of > 20,000 copies/ml are needed to drive HIV
disease progression.95 Indeed, there was no evidence of excess HIV disease progression in the PI-mono
group, as increases in CD4 cell counts and HIV disease-related clinical events were similar between the two
groups. Although deaths were numerically greater in the PI-mono group this was not statistically significant
as the causes were diverse and without plausible link to the drugs taken or HIV disease progression.
We therefore regard this as a chance imbalance, but will continue to follow the trial cohort to gather
further outcome data.
Fewer episodes of renal impairment were seen in the PI-mono group, as anticipated given the
well-recognised renal toxicity of NRTIs (especially tenofovir). However, close laboratory monitoring and
pre-emptive treatment changes ensure that serious renal outcomes are rare; there were no cases of
end-stage renal disease in the standard-of-care group.96 This pragmatic trial, in which clinicians were
allowed to switch drugs at clinical discretion (rather than be restricted to single protocol-mandated
regimens), provides a realistic estimate of the clinical impact of PI monotherapy in routine clinical practice
and suggests that the benefits in terms of renal toxicity would be modest. We did not find any other
clinical advantages of the PI monotherapy strategy. A potential theoretical concern expressed about
PI monotherapy has been that suboptimal drug penetration into the CNS might lead to harm.20,44
Neurocognitive testing carried out in all patients throughout the trial found no differences between the
groups. This, together with the absence of a significant excess of neurological events in the PI-mono group,
provides important reassurance that even if PI monotherapy has less brain penetration this does not lead to
important clinical consequences.
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The strengths of this trial are its size and duration (more than three times the randomised person follow-up
time of earlier studies), the low loss to follow-up rate, the pragmatic design set in routine clinical care with
flexibility in drug selection in both treatment groups and the use of a primary efficacy end point (preserving
drug options) that is relevant to long-term management. Limitations are the open-label design and the lack of
pre-ART resistance tests in some patients, which would help to rule out resistance acquired before the trial
(both limitations were unavoidable). Although the primary end point and many of the major secondary end
points were based on measured laboratory values, the possibility of bias needs to be considered in some of the
secondary end points that incorporated subjective measures as part of the assessment, in particular clinical AEs,
neurocognitive assessment and quality of life assessment.
Bias in the reporting of clinical AEs could arise from selective reporting of events by patients or selective
ascertainment by clinicians or study staff (e.g. by prompting specifically about symptoms that the researchers
believe, correctly or incorrectly, to be associated with particular treatment arms, such as neurocognitive events
in the PI-mono arm and peripheral neuropathy events in the standard-of-care arm); selective recording of
events or systematic differences in grading of those events in the medical record; or selective reporting
of events captured in the medical record in the case report form (and hence entry into the trial database). To
minimise the risk of bias we compared treatment arms using events at the more severe end of the spectrum
only (i.e. grades 3 and 4), which are less likely to go unreported by patients or unrecorded in the medical case
notes. Sites were provided with standard tables for grading events, were trained on the use of these and were
required to report all grade 3 or 4 events (or serious disease progression events or SAEs) on a separate event
form together with justification for choosing the grade. These forms were checked independently by a
clinician at the trial co-ordinating centre and any apparent misclassification was discussed with the site. Finally,
on-site monitoring was carried out at all sites, with a random selection of the medical records reviewed to
detect any events that had not been reported on the case report forms (with more detailed inspection if any
discrepancies were detected). We believe that these measures reduced any bias in the collection of clinical AEs
to a minimum, although we cannot rule it out completely. There was a trend (although not significant)
towards a greater number of reported CNS grade 3 or 4 events in the PI-mono arm, but the heterogeneous
nature of these events argues against a common aetiology; this is most likely a chance imbalance or possibly
minor residual bias towards reporting such events in the PI-mono arm. The method of conducting
neurocognitive tests was standardised and the sites were trained to follow these methods uniformly for all
patients, therefore it would be difficult for bias to be introduced by staff members performing the testing. In
general, patients were self-motivated to give their best performance on the tests and it is unlikely that any
of them deliberately modulated their performance in response to some belief about their treatment allocation.
Both treatment groups improved performance over time (as might be expected with a learning effect), with
similar changes in both groups, again suggesting that bias is unlikely. The assessment of quality of life used a
well-validated questionnaire that the patients self-completed and so this could not be influenced by site staff.
It is the patients’ perception of their condition that matters in the assessment of quality of life, and it is
academic whether that is determined by subjective opinion about the impact of the treatment that they are
taking or the direct effects caused by treatment benefits or side effects.
We believe that the pragmatic trial design, broad inclusion criteria and other strengths of the trial outlined
above mean that the results are likely to be generalisable to other settings internationally where treatment
is individualised and regular VL monitoring is performed. We excluded patients with active substance
abuse or psychiatric illness if this was considered severe enough to preclude compliance with the trial
protocol. In some clinic settings, a high proportion of patients have psychiatric comorbidity. Although
our trial findings do not strictly apply to this group, such patients might be expected to do better on
PI monotherapy given what is known (including from this trial) about PI resistance being slow to develop in
patients with episodes of VL rebound. In fact, the European HIV treatment guidelines32 (see Conclusions)
recommend these patients as a particular group to consider for PI monotherapy. We also excluded patients
with high CVD risk at baseline because of concerns that being randomised to start a PI might increase that
risk. The current British HIV Association (BHIVA) treatment guidelines97 recommend avoiding LPV in such
patients but offer no opinion on the use of DRV, the other main drug used for PI monotherapy, so this
may still represent a feasible group for treating with PI monotherapy.
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Cost-effectiveness
The results showed that switching to a strategy of PI-mono, with prompt return to combination therapy in
the event of VL rebound, was cost-effective compared with OT in most scenarios. Within 3 years there
was little difference in the mean QALYs between PI-mono and OT. PI-mono appears to be cost-effective
compared with OT as substantial resources could be freed from HIV treatment and used to improve health
outcomes for other patients. In the sensitivity analyses and extrapolation scenarios, PI-mono was cost
saving but marginally less effective than OT. In all but extrapolation scenario B at a threshold of £30,000
per QALY, PI-mono appeared to be cost-effective compared with OT. This was because the cost saving from
PI-mono could generate more health elsewhere than the small amount of health lost to PI-mono patients.
Two studies have investigated ART drug costs following PI-based monotherapy compared with the ART
drug costs of triple therapy.98,99 In both studies the estimated ART drug cost in the PI monotherapy group
was comparable to that in the present study. However, in both studies the estimated cost of ART drugs in
the combination therapy group was higher than that in the present study. The study by Restilli et al.99 also
investigated the total health-care costs of PI monotherapy patients and compared them to the total
health-care costs of patients on combination therapy using Italian administrative records. It was estimated
that the incremental cost of PI monotherapy compared with combination therapy would be –€3382 per year.
This represents an approximate cost saving of £8000 over a 3-year period, compared with the present
base-case analysis in which the cost saving was estimated to be £6424 per patient over a 3-year period.
A noticeable similarity between the present study and the study by Restilli et al.92 is that the base-case
analyses in both studies assumed that both treatment groups would attend the same number of outpatient
activities. However, this might not be the case in routine clinical practice. The present study therefore
conducted sensitivity analyses (scenario 2) to assess the cost-effectiveness of monotherapy in a situation
in which PI-mono patients are routinely followed every 12 weeks and OT patients are followed every
24 weeks. In this scenario the cost saving of PI-mono was reduced to £4307 over a 3-year period. In the
health technology assessment by Restilli et al.99 it was concluded that the evidence supported the use of
PI-based monotherapy as an alternative to combination therapy. In the study by Gazzard et al.98 the ART
drug costs of DRV/ritonavir-based monotherapy were compared with those of combination therapy from a
UK perspective. They used trial data on ART drug consumption from the MONET trial22 and did not consider
total health-care expenditure. Gazzard et al.98 estimated an annual cost saving for ART drugs of £4126
(that is £12,378 over 3 years), whereas the present study estimated the 3-year cost saving to be £7620.
However, Gazzard et al.98 also acknowledge that, although patients on combination therapy may need
scheduled visits to HIV clinics only every 6 months, patients on PI monotherapy may need to be seen every
3 months, which would reduce their estimated cost saving.
The strengths of this economic evaluation are that it presents the costs and QALYs accrued in a large
randomised trial designed to reflect routine clinical practice as closely as possible. As such, the results are
highly relevant to decision-makers.
A few limitations of the cost-effectiveness analysis should be noted. First, a within-trial cost-effectiveness
analysis is limited by the assumption that costs and outcomes do not differ between treatment groups
after the follow-up period. This is a significant assumption that might not hold in the context of managing
HIV-1-infected patients. Two extrapolation scenarios were generated to address this limitation. The results
showed that PI-mono could be considered cost-effective in both extrapolation scenarios at a £20,000
per QALY threshold. However, for a cost-effectiveness threshold of £30,000 per QALY, OT would be
considered the more cost-effective form of management.
Second, the May et al.89 data used for modelling life expectancies in extrapolation scenarios A and B are
subject to uncertainties. Notably, the data used to estimate life expectancies are extrapolated well beyond
what is observed and there is still a lack of data in the older age group where most of the mortality is in
the general population.
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Third, the analysis is limited by the manner in which data on health-care resource consumption were
collected. During the PIVOT trial, patients were asked to recall their contacts with the health-care system
since the last follow-up visit. Although there might not be an issue with data validity for patients who
attended each 12-week visit, the risk of recollection bias is likely to increase if one or more visits are
missed. However, any such recollection bias is thought to have restricted influence on the estimates of the
incremental costs. The costs of primary care, hospital services and concomitant drugs accounted for only
5–6% of the total cost and therefore any imprecision in the costs of these would have a diminished
importance in terms of the incremental cost.
Fourth, the cost-effectiveness results presented in this study are conditional on the current ART prices.
Scenarios 1a–f attempted to explore the impact that variation in ART drug prices could have on the
cost-effectiveness results. However, there is uncertainty surrounding future ART prices and these analyses
should be viewed as speculative. The ART treatment regimens taken by patients in the OT arm of the trial
were typical of the standard-of-care regimens in use at the time that the study started and of those that
continue to be used at the time of writing this report. However, a new class of drugs, integrase inhibitors,
have been developed that in some cases appear to have clear advantages over the current drugs in terms
of toxicity and possibly efficacy.100 These are now licensed for the initial treatment of HIV infection in the
UK. Although cost has limited their uptake to date, as prices fall it is likely that they will become more
widely used over the next 5–10 years, possibly becoming the dominant drugs used in treating HIV infection.
They are still required to be given in combination therapy, usually with NRTIs. The cost-effectiveness
calculations may therefore change with the shift in clinical practice in HIV therapy.
Conclusions
Although there have been a number of trials of PI monotherapy conducted previously, the majority of
which have been initiated and funded by the pharmaceutical industry, this large, long-term, strategic,
investigator-initiated and publicly funded trial is likely to be regarded as the definitive trial of PI monotherapy
because it has answered the clinically relevant long-term impact questions that previous trials were unable to
address convincingly. There are no ongoing RCTs of PI monotherapy of greater size or duration than the
PIVOT trial and it is unlikely now that any will be undertaken in the future. Additional meta-analyses may be
performed that will incorporate the PIVOT trial data to assess VL suppression rates (which we have shown to
be of limited value as an end point), but this is unlikely to affect the broad conclusion drawn from this trial,
which is that there is a higher rate of VL rebound with PI monotherapy but that this does not adversely
impact on future treatment options.
The PIVOT trial identified a numerical excess of deaths (not statistically significant) in the PI-mono arm that
were of diverse aetiology and considered to be unrelated to the treatment strategy and are most likely to be
a chance finding. Consent was obtained at the last patient visit to continue follow-up of the cohort (both
treatment groups) for a further 5 years. This will be carried out by means of annual retrospective data
collection from patient clinical case sheets/records gathered at routine clinical visits, collecting outcome data
on VL rebound episodes, drug resistance, treatment changes and major clinical events. It is likely that a
substantial proportion of patients who have been stable on PI monotherapy will choose to remain on this
strategy and so the follow-up will provide additional valuable data on longer-term outcomes. This additional
follow-up, with likely accumulation of more clinical events, may be of particular value in addressing any
residual concerns around the imbalance in the (small) number of deaths, as well as other outcome differences
between the groups that may become more pronounced with longer-term follow-up (e.g. renal function).
The impact of the PIVOT findings on HIV treatment guidelines is hard to predict at this point. Current
BHIVA treatment guidelines (2014 update, unchanged from the 2012 version)97 recommend ‘continuing
standard combination ART as the maintenance strategy in virologically suppressed patients. There are
insufficient data to recommend PI/r monotherapy in this clinical situation.’ Current European AIDS Clinical
Society (EACS) treatment guidelines (2014 edition)32 recommend that ‘PI/r monotherapy with qd DRV/r or
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bd LPV/r might represent an option in persons with intolerance to NRTIs or for treatment simplification or
in illicit drug users with documented frequent interruption of cART. Such a strategy only applies to persons
without history of failure on prior PI-based therapy and who have had HIV-VL < 50 copies/ml in at least
the past 6 months and who do not have chronic HBV.’ The PIVOT findings would support recommending
the PI-mono strategy more broadly as an acceptable treatment option for patients, but it is unclear
whether this will in fact translate into guideline changes. The belief by physicians that VL rebound is a
universally bad thing is deeply ingrained. Although it is clear from the PIVOT trial and other trials that PIs
are very robust drugs that have a very low propensity to develop resistance after short-term low-level VL
rebound, this nuanced thinking about the consequences of VL rebound may not gain traction given the
longstanding mantra about the essentiality of triple therapy to prevent VL rebound. Furthermore, guideline
panels use VL suppression and rebound rates as the unifying factor for decisions around regimens across
trials of different designs and may be uncomfortable using alternative approaches to evaluate regimen
strategies. Clear evidence of toxicity reduction with the PI-mono strategy could have represented a
compelling argument for its adoption by guideline panels, but in the absence of this the risk–benefit
assessment is more neutral. Nevertheless, the PIVOT trial has provided evidence that will increase the
confidence of physicians to use this intervention in patients who are intolerant of NRTIs. Because such
patients might have been randomised to the standard-of-care arm and be required to continue these
NRTIs, such patients were excluded from entering this trial. Particular treatment groups, such as those with
renal impairment on tenofovir, could benefit from PI monotherapy, although there may be alternatives to
tenofovir use in this situation such as the NRTI abacavir or substituting an alternative drug class such as
integrase inhibitors. Patients with challenges to adherence such as those with psychiatric illness may also
do better on PI monotherapy because of the more limited risk of resistance developing with intermittent
treatment, although that is different from the strategy we used here, which required immediate
reintroduction for treatment failure. Switching to PI monotherapy is likely to be more attractive as an
option when patients are already established on a PI-based triple therapy regimen as, in this case, the
intervention involves simply withdrawing drugs, with the benefit of reducing pill burden and with no risk
of new drug toxicity. For patients established on a NNRTI-based regimen, especially those taking a single
combination pill once a day, switching to monotherapy may increase the pill burden slightly and also runs
the risk of introducing new side effects arising from changing to a new drug class (PIs).
Although the findings of the PIVOT trial are unlikely to lead to a recommendation in clinical practice guidelines
that PI monotherapy is the preferred approach, there may be other drivers of the increased use of this
intervention. Anecdotally, many UK physicians report that they have substantial numbers of patients on
PI monotherapy in their clinical practice and the PIVOT trial findings are likely to reassure them and increase
their confidence that this is a perfectly reasonable approach. Furthermore, although clinical considerations are
paramount in drafting treatment guidelines, when there are no compelling clinical advantages of using one
ART regimen over another the relative costs often have a substantial impact on pragmatic decisions over which
regimens are used in clinical practice. Given that under most of the scenarios evaluated switching to a strategy
of PI-mono was shown to be cost-effective compared with OT for HIV-1-infected patients, this may increase
the willingness to consider this intervention in practice. However, the financial drivers are likely to be dynamic
given that a number of first-line ART drugs are coming off patent and there are increasing options for first-line
therapy with the introduction of new classes of drugs such as integrase inhibitors, which are driving down drug
costs. PIs are relatively expensive drugs to produce and it may be that combination therapy using generic drugs
from other classes eventually becomes cheaper than PI monotherapy, thus removing this potential driver of the
use of this therapy. Future combination drug prices are a key uncertainty in the cost-effectiveness analysis and
if future prices are low it may alter the cost-effectiveness results.
The PIVOT trial has shown that PI monotherapy is an acceptable alternative to standard combination ART
for long-term HIV management, with a modest benefit in terms of reducing renal toxicity. The need for
regular VL monitoring and the possible requirement to switch back to combination therapy may be
perceived as drawbacks, but this approach may nevertheless appeal to patients wishing to minimise drug
exposure. More broadly, the trial challenges the mantra that combination therapy is essential for the
management of chronic HIV infection.
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GENERAL INFORMATION
This document describes the PIVOT trial and provides information about procedures for 
entering patients into the trial. The protocol should not be used as an aide-memoire or guide 
for the treatment of other patients; every care was taken in its drafting, but corrections or 
amendments may be necessary. These will be circulated to the registered investigators in 
the trial, but centres entering patients for the first time are advised to contact the HIV
Group, Medical Research Council Clinical Trials Unit, London, to confirm they have the most 
up-to-date version. Clinical problems relating to this trial should be referred to the Chief 
Investigator.
• Compliance
The trial will be conducted in compliance with the protocol, MRC GCP, Data Protection Act 
(DPA number: Z5886415), NHS research governance and other regulatory requirements, 
as appropriate in the participating centres. 
• Sponsor
Medical Research Council, 20 Park Crescent Road, London W1B 1AL, UK.
• Funder
NHS R&D Health Technology Assessment (HTA) P rogramme, Mailpoint 728, Boldrewood, 
University of Southampton, Southampton SO16 7PX, UK.
Main Contacts
Emergency
medical
contact
Dr Nicholas Paton
MRC Clinical Trials Unit
222 Euston Road
London NW1 2DA
Email:
Tel:
Fax:
nick.paton@ctu.mrc.ac.uk
020 7670 4808
020 7670 4817
Chief
Investigator
Dr Nicholas Paton
MRC Clinical Trials Unit
222 Euston Road
London NW1 2DA
Email:
Tel:
Fax:
nick.paton@ctu.mrc.ac.uk
020 7670 4808
020 7670 4817
Trial
Statisticians
Dr David Dunn
MRC Clinical Trials Unit
222 Euston Road
London NW1 2DA
Dr Wolfgang Stöhr
MRC Clinical Trials Unit
222 Euston Road
London NW1 2DA
Email:
Tel:
Fax:
Email:
Tel:
Fax:
david.dunn@ctu.mrc.ac.uk
020 7670 4739
020 7670 4818
wolfgang.stoehr@ctu.mrc.ac.uk
020 7670 4802
020 7670 4818
Trial Virologist Professor Deenan Pillay
Centre for Virology
Royal Free and University 
College Medical School 
UCL Windeyer Institute
46 Cleveland St
London W1T 4JF
Email:
Tel:
Fax:
d.pillay@ucl.ac.uk
020 7679 9482/9490 (Office)
020 7580 5896
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Trial
Pharmacologist
Dr Saye H Khoo
Dept of Pharmacology
University of Liverpool
70 Pembroke Place
Liverpool L69 3GF
Email:
Tel:
Fax:
S.H.Khoo@liverpool.ac.uk
0151 794 5560
0151 794 5656
Health
Economist
Professor Mark Sculpher 
Centre for Health 
Economics
University of York
Heslington
York YO10 5DD
Email:
Tel:
Fax:
mjs23@york.ac.uk
01904 321440
01904 321402
External
Principal
Investigator
Professor Brian Gazzard
St Stephens Centre
Chelsea and Westminst er
Hospital
369 Fulham Road
London SW10 9NH
Email:
Tel:
Fax:
patricia.sanderson@chelwest.nhs.uk
020 8746 8239
020 8746 5611
Trial
Management
Fionna van Hooff
MRC Clinical Trials Unit
222 Euston Road
London NW1 2DA
Email:
Tel:
Fax:
fvh@ctu.mrc.ac.uk
020 7670 4843
020 7670 4817
Data Manager 
MRC Clinical Trials Unit
222 Euston Road
London NW1 2DA
Email:
Tel:
Fax:
pivot@ctu.mrc.ac.uk
020 7670 4843 
020 7670 4817
For the listing of participating institutions and clinicians please refer to Appendix 4.
RANDOMISATION
Tel:  +44 (0)20 7670 4843 (Mon - Fri, 09:00 – 17:00)
Fax: +44 (0)20 7670 4817
SUSAR NOTIFICATION
Within one working day of becoming aware of an SUSAR, please 
fax a completed SUSAR form to the MRC Clinical Trials Unit on:
Fax: +44 (0)20 7670 4817
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1. SUMMARY
1.1 Background and Aims
The current standard-of-care treatment for people living with HIV is combination
antiretroviral therapy (ART), usually consisting of 3 drugs: 2 nucleoside reverse transcriptase 
inhibitors (NRTIs) with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a 
protease inhibitor (PI). Although triple ART has a relatively high long -term success rate, a 
proportion of patients (about 4% per year) continues to experience virological failure, and 
this is often associated with complete resistance to one or more drugs (especially NRTI and 
NNRTI classes). Furthermore, long-term drug toxicity remains a concern. Additional
strategies for long-term management are needed that preserve future drug options and 
minimise toxicity. Short-term clinical trials suggest that stable patients who have had
prolonged virological suppression on combination ART can be switched successfully to PI 
monotherapy, resulting in a reduction of toxicity without increasing the risk of treatment 
failure and drug resistance.
This trial aims to determine whether a strategy of switching to PI monotherapy is non-
inferior to continuing triple -therapy, in terms of the proportion of patients who  maintain all 
the drug treatment options that were available to them at baseline after at least 3 years of 
follow-up, and to compare clinical events, safety, toxicity and health economic parameters 
between the two strategies.
1.1.1 Trial design
This is a parallel group, open -label, multi-centre, randomised controlled strategy trial. 
1.1.2 Patients to be included
400 patients will be included who are HIV-infected adults on a stable ART regimen of two 
NRTIs and one NNRTI or PI. Patients will have CD4+ T-cell counts greater than 100 cells/µL, 
and viral load (VL) less than 50 copies/ml for no less than 6 months.  Patients who have 
previously failed on a PI-containing regimen, who have PI resistance mutations, or in whom 
PIs are contraindicated will not participate.  For more details refer to section 4.
1.1.3 Trial interventions – research and control arm
Patients randomised to the PI monotherapy group will stop other ART drugs and start or 
continue only on a ritonavir-boosted PI (selection of drug at discretion of physician and
patient). Those who do not maintain complete virological suppression or who are unable to 
tolerate the PI (substitution for toxicity is allowed), will promptly switch back to their 
previous triple-therapy. Patients randomised to the control group will continue their current 
regimen. For more details refer to section 6.
1.1.4 Duration of trial
The trial will be conducted over 5 years, including an initial recruitment period estimated to 
last 12 to 18 months. All patients will continue on treatment and follow-up until close of the 
trial. For more details refer to section 7.
1.1.5 Outcome measures
Analyses will compare the 2 groups by intention to treat (ITT).
Primary outcome measure: 
Loss of future drug options defined as the occurrence of intermediate to high level resistance
to any one or more of the standard antiretroviral drugs (limited to licensed drugs in 
contemporary use) to which the patient’s virus was considered to be sensitive at trial entry. 
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PI monotherapy arm
Switch to a regimen comprising a 
single ritonavir-boosted PI
RANDOMISE
Control arm
Continue standard -of-care
triple-therapy regimen
Eligible, consenting patient on triple-therapy
Week 4 visit
Viral load and TDM
Yes
Resistance testing & 
switch back to a 
triple-therapy regimen
Confirmed VL rebound 
 >50 copies/ml?
 (At any time during
 follow -up)
No
Continue regimen 
comprising a single 
ritonavir-boosted PI 
Week 12 visit and 
12-weekly visits thereafter
Viral load, CD4+ count and 
safety measurements
Week 8 visit
Viral load 
Outcome measures
Secondary outcome measures: 
• Serious drug or disease-related complications
• Adverse events
• Virological rebound 
• CD4+ count change
• Health-related Quality of Life change
• Neurocognitive function change
• Cardiovascular  risk change 
• Health care costs
For more details refer to section 9.
1.1.6 Data recorded directly on CRFs
Clinical and routine laboratory data will be recorded on case report forms (CRFs). A copy will 
be faxed or sent to the MRC CTU for data entry and the original will be kept at the local 
centre. For more details see section 7. 
1.1.7 Organisation
Sponsor: Medical Research Council, UK. 
Funder: NHS R&D Health Technology Assessment (HTA) programme, UK.
Coordinator: Medical Research Council Clinical Trials Unit, UK.
1.2 Flow diagram
Figure 1: Trial entry, randomisation and treatment
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1.3 Trial schedule
PI monotherapy arm only
PIVOT t rial schedule
Screening
-4wks to Day 0
Day 0
(Baseline) Week 4
+/-2 wks
Week 8
+/- 2 wks
Week 12
+/- 2 wks
Subsequent
12-weekly visits
Wk 24, 36 etc
+/- 4 wks
Annual visits
Wk 48, 96, 144, 192, 
240 and final visit10
+/- 4 wks
Complete and sign Consent Form X
Medical and drug history X
Assessment of drug adherence X X X X X X
Concomitant medication X X X X X X
Symptom review / physical examination X X X X X X X
Assessment of clinical adverse events X X X X X X
Cardiovascular risk assessment X X
ECG (within last 6 months acceptable) X
Assessment of healthcare resource utilisation X X X X X X
EQ-5D health status questionnaire X X X X
Neurocognitive assessment X X X
MOS-HIV questionnaire X X X
HIV viral load1,2 X X X X X X X
CD4+ count X X X X X
Full blood count 3 X X X X X X
UEC and LFTs4 X X X X X X
Bone profile5 X X5 X5 X
Glucose (fasting) X X X X
Lipids (fasting)6 X X X X
Urine protein/creatinine ratio5 X X5 X5 X
Hepatitis B/C serology (within last 6 months acceptable) X X
Pregnancy test7 X
Plasma sample for storage8 X X X X X
PI drug concentration9 X X8 X8
Completion of CRF X X X X X X X
1 HIV viral load will be repeated on the same lab sample for any value >50 copies/ml. If >50 copies/ml confirmed on lab re-test, patient will be telephoned for adherence counselling and asked to return for 
repeat VL test at 4 weeks (window up to 6 weeks) after the first test. Repeat plasma sample for storage will be obtained at the second visit.
2 Resistance testing will be performed on a stored sample at the local laboratory in the event of 2 consecutive VL values >50 copies/ml. Resistance testing will be performed on the higher of the two samples. If 
VL results differ by less than 50 copies/ml the second sample will be used for resistance testing.
3 FBC will include Hb, WCC, neutrophil count, lymphocyte count, platelets.
4 UEC will include sodium, potassium, urea, creatinine; LFTs will include bil irubin, ALT, alkaline phosphatase.
5 Bone profile (calcium and phosphate) and urine protein/creatinine ratio will be performed quarterly only if patients are taking tenofovir.
6 Lipids will include total cholesterol, triglycerides, LDL, HDL. If elevated at Week 12, additional fasting lipid tests can be performed between the annual visit checks as needed to inform clinical management.
7 Pregnancy test in women only; can be urine or blood test, as per standard practice at site; repeated at any subsequent visi ts where pregnancy is suspected.
8 Blood sample will be stored at these visits plus any visit where a second VL sample is taken for confirmation of rebound.
9 PI drug concentration measurement can be repeated at Week 8 and/or Week 12 if Week 4 concentration is low (only in the PI monotherapy arm).
10 The final visit will be scheduled within 12 weeks before the common closing date of the trial.
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2. BACKGROUND
2.1 Introduction
At the end of 2005 there were an estimated 63,500 people living with HIV in the UK, of 
whom approximately two-thirds have been diagnosed and seen for HIV-related care. The 
annual number of new HIV diagnoses made in the UK continues to rise, with 7450 new cases 
in 2005 (1), and as more people receive effective treatment, the number of deaths continues 
to fall. Thus the number of people receiving treatment and the already substantial burden on 
the NHS will continue for the foreseeable future. 
A range of drugs are available that are active in blocking the replication of HIV. The current 
standard-of-care is the use of combination ART, usually consisting of 3 drugs: a backbone of 
2 NRTIs with either a NNRTI or a PI. Such combination therapy has been shown to be
effective in reducing viral load, preventing decline in immune function and dramatically 
decreases the risk of opportunistic infections and morbidity and mortality from HIV. 
2.2 Managing HIV as a long-term chronic disease: changes in the 
treatment paradigm
The SMART study showed inferior outcomes with treatment interruption rather than
continued ART, clearly demonstrating that ART needs to be continued indefinitely once it has 
been started (2).
Inference from the SMART data as well as consideration of cohort data has lead to a 
renewed debate on the possible merit of initiating ART even earlier in the course of disease
than is currently the case (3). A major HIV therapeutic trial will soon commence to address 
the question of whether ART should be started at CD4+ counts above 500 cells/mm3.
Consequent on the move towards extending therapy exposure (start earlier and continue 
indefinitely) is the realisation that patients are now facing the prospect of taking ART for 
decades. Considerations of maximising long -term durability, preserving a viable sequence of 
future drug options, and minimising long-term side effects are becoming increasingly
important.
Much of the current pharmaceu tical company driven research as well as investigator-initiated
research is now designed to look at switching drugs or comparing regimens for toxicity or 
tolerability advantages. The search for cost-effective approaches to care, including ways of 
containing drug costs as well as looking at approaches to simplify monitoring and follow-up
are also an important focus of current research. Several promising new drugs that act on 
different targets will soon be available (an integrase inhibitor and a CCR5 inhibito r) as well as 
better options of new drugs with potentially greater efficacy or reduced toxicity within 
existing classes. These new drugs will increase treatment options available, but will also lead 
to re-examination of the paradigm of care (treatment with triple-therapy, comprising 2 NRTIs 
and a NNRTI or PI) that has changed little in the last decade. The availability of more 
treatment options may also allow the flexibility to accept a small risk of treatment failure in a 
regimen that has fewer side effects or that effectively preserves long-term treatment options 
in the vast majority. 
Thus research into more innovative uses of current drugs, as well as ways of combining or 
sequencing drugs to maximise long-term outcomes (preserving viable treatment optio ns,
minimising toxicity, minimising cost) will become increasingly important. Given that
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treatment interruption is not a sensible option, (2) treatment simplification studies form an 
increasingly important aspect of the HIV treatment research agenda. The most promising 
candidates for treatment simplification are undoubtedly the PIs. 
2.3 Previous trials of PI monotherapy
Four randomised controlled trials of PI monotherapy were presented as abstracts at the 16th 
World AIDS Conference in Toronto in August 2006, two of which have been recently 
published in full in a peer -reviewed journal. Three of these trials investigated switching to 
lopinavir monotherapy after patients had gained full virological suppression using triple-
therapy. The largest of these studies, OK 04, enrolled 205 patients who were stable on 
triple-therapy and randomised them to switch to triple-therapy with lopinavir, or lopinavir 
monotherapy. Monotherapy was found to be non-inferior (defined with a non-inferiority
margin of 12%) to triple-therapy at 48 weeks based on proportion with VL >500 copies/ml. 
The majority of patients (89%) maintained viral suppressio n without the need for re-
induction and only two patients in this study developed primary PI mutations (4). The data 
for 96 weeks of follow-up were presented at the European AIDS Conference in October 
2007, and showed that lopinavir monotherapy continued to be non -inferior to continuing 
triple-therapy, with no further virological rebounds with PI resistance. The percentage of 
patients without therapeutic failure was 87% in the monotherapy arm and 78% in the triple-
therapy arm, and there were significantly fewer adverse events in the monotherapy arm (5).
In the second study (M03-613) presented in Toronto, 155 treatment-naïve patients were 
randomised to induction with 2 NRTIs plus lopinavir, followed after 6 months by lopinavir 
monotherapy versus standard -of-care 2 NRTIs and a NNRTI. There was no significant
difference in the rate of maintaining VL <50 copies/ml in the two groups through 96 weeks. 
Although intermittent increases in VL were seen often in the monotherapy arm, most
returned to <50 copies/ml spontaneously and only 4 patients required re-introduction of 
NRTIs. Two patients treated in the monotherapy arm developed PI resistance mutations (6).
The third study, KalMo, randomised 60 patients on stable combination therapy and with 
undetectable VL to continue existing ART or to receive lopinavir monotherapy. There was no 
difference in the proportion of patients who maintained undetectable VL in the two groups at 
48 weeks (83% in standard-of-care and 86% in monotherapy), and none of the patients in 
the PI monotherapy arm developed resistance mutations (7). Taken together these 3 
randomised controlled trials suggest that switching to lopinavir monotherapy is a viable 
treatment option in patients who have been already established on stable triple-therapy.
In contrast, the fourth study compared lopinavir monotherapy with triple-therapy in
treatment naïve patients starting therapy for the first time and found a high proportion of 
patients had low level viraemia in the monotherapy arm and the on treatment analysis 
showed an inferior response in the monotherapy arm (8).  Based on this limited data, it 
appears as though PI monotherapy may be more valuable when used as a switch strategy 
rather than as first -line therapy in treatment naïve individuals.
Although the randomised controlled trials to date have all been performed with lopinavir, 
other PIs may be effective in maintaining viral suppression when used as monotherapy. In a 
non-randomised trial, ACTG 5201, 33 patients who had achieved undetectable VL on triple-
therapy with boosted atazanavir, discontinued nucleosides and remained on atazanavir
monotherapy. At week 24, 3 patients had virological rebound, one of whom re-suppressed
spontaneously on monotherapy. The other 2 patients had undetectable blood atazanavir 
levels and were presumably non-adherent to treatment. None of the patients developed
resistance mutations to atazanavir (9). In a non-randomised trial conducted in Sweden, 5 of 
15 patients who switched from stable triple-therapy (either an NNRTI-based or triple NRTI 
regimen) to boosted atazanavir monotherapy had VL rebound between weeks 12 to 16 (2 
samples above 20 copies/ml) (10). The high proportion of patients who experienced rebound 
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may perhaps be explained by residual CYP3A4 enzyme-inducing effects of NNRTI reducing 
atazanavir levels in the period immediately following the switch, which might be avoided by 
continuing the NRTIs for the first few weeks (11). The study has also been criticised because 
two of the patients that failed used acid-suppressing drugs (ranitidine and lansoprazole) 
which are known to decrease atazanavir levels and were specifically contraindicated in the 
protocol (11).  Of note, none of the 5 patients with VL rebound developed PI resistance, and 
all re-suppressed VL with re-introduction of triple -therapy (10).
There are currently two ongoing randomised controlled trials and one ongoing uncontrolled 
trial investigating PI monotherapy for patients who have achieved undetectable VL on 
existing treatment. The highly -active ART (HAART) followed by maintenance with
monotherapy - Kaletra study (MAIMOKA study; ISRCTN45284754) is comparing lopinavir 
monotherapy to standard-of-care triple-therapy for patients who have achieved undetectable 
VL on treatment. The recruitment target is 240 patients with an anticipated study end date 
of October 2008. The primary endpoint is therapy failure (defined as VL >400 copies/ml) at 
96 weeks. A phase III study of darunavir monotherapy is currently underway, and will 
randomise 250 patients with undetectable VL on triple-therapy to take darunavir alone, or 
take triple-therapy including darunavir (NCT005 13513). The primary endpoint is maintained 
suppression of VL <50 copies/ml at 48 weeks. The study is designed as a non-inferiority
study (12% margin), and will report at end 2008/ early 2009 (12).
The Only REYataz (OREY) study (NCT00337467) is an uncontrolled study of atazanavir 
monotherapy in 62 patients who have achieved undetectable VL on their previous
combination therapy. The primary endpoint is the proportion of patients who have virological 
rebound at Week 48. 
2.4  Rationale and objectives of this trial
2.4.1 Why is this long-term strategy trial needed?
Although the trials of PI monotherapy described above are encouraging, this research is 
driven by the pharmaceutical industry with a typical short-term focus. A definitive trial
focused on long-term outcomes is lacking. This trial is different in a number of respects from 
the previously completed or ongoing pharma-sponsored studies: 
(i) Whereas other studies examine the effect of PI monotherapy per se, this trial will 
examine the effect of a strategy  that includes prompt switch back to standard-of-
care when PI monotherapy does not maintain full virological suppression of <50 
copies/ml.
(ii) Whereas previous or ongoing studies are focused on specific PI drugs and 
specified comparator regimens, this trial allows drug selection according to
patient/ physician preference and selection or switching of PIs for maximising 
tolerability; it is therefore more relevant to clinical practice. 
(iii) Whereas other studies are of relatively short duration of one to two years, this 
trial has relatively long-term follow-up (up to 5 years) which is important for 
assessing long-term consequences of this strategy.
(iv) Whereas other studies focus on short-term VL endpoints (reflecting their
commercial origin and single drug focus), this trial has an endpoint of clinical
drug resistance, chosen to be most relevant to the long-term goal of maintaining 
effective treatment regimens.
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(v) This trial is of sufficient size and, therefore, power to answer questions reliably.
(vi) This trial will collect relevant health care utilisation data for determining cost 
implications.
It is very unlikely that there will be a pharma-initiated study looking at long-term use of this 
strategy, and the trial we propose is likely to be the definitive long-term randomised 
controlled trial that addresses this important strategic option for long-term HIV therapy. 
The trial objectives are:
1. To determine whether a strategy of switching to PI monotherapy is non-inferior
to continuing triple drug therapy (the standard-of-care) in terms of the proportion 
of patients who maintain all their available drug treatment options after at least 3 
years of follow-up.
2. To compare the safety and toxicity of PI monotherapy with standard -of-care
triple-therapy over 3 to  5 years.
3. To assess the health economic benefits of use of PI monotherapy.
2.5 Risks and benefits of the PI monotherapy strategy used in this 
trial
2.5.1 Risk of side effects from treatment
The patients recruited into this trial will be, by definition, stable on their current standard -of
care treatment regimen of 2 NRTIs and an NNRTI or PI. Patients who are taking this 
regimen will, in general, be free from major side effects on this regimen, as they would have 
otherwise changed therapy prior to enrolment. Patients who are randomised to the
intervention arm will in some cases start a new PI to which they have not been exposed 
previously. Although the PIs that are in contemporary use are in general well tolerated, there 
is a risk that some patients will experience new side effects from the selected PI. Side effects 
of PIs include gastro -intestinal disturbances (including diarrhoea, nausea, vomiting,
abdominal pain, flatulence), anorexia, hepatic dysfunction, pancreatitis; blood disorders 
including anaemia, neutropenia, and thrombocytopenia; sleep disturbances, fatigue,
headache, dizziness, paraesthesia, myalgia, myositis, rhabdomyolysis; taste disturbances;
rash, pruritus, Stevens-Johnson syndrome, hypersensitivity reactions including anaphylaxis, 
metabolic disturbances such as hyperglycaemia, hypertriglycerideaemia and
hypercholesterolaemia and visceral fat accumulation.
A recent epidemiological study identified an association between treatment with a PI  and 
the risk of myocardial infarction, although the effect appears modest (relative risk per year of 
exposure 1.16) especially when compared to the risks associated with other cardiovascular 
risk factors (increasing age 1.39; male sex 1.91; current smoking 2.83; history of
cardiovascular disease 4.3) (13) (14). The association between PI treatment and risk of 
myocardial infarction was further reduced by adjusting for serum lipid levels. The overall 
incidence of myocardial infarction in patients exposed to PI treatment for more than 6 years 
was only 0.6% per year, which is small. To address this issue, this trial will include formal 
assessment of cardiovascular risk as part of the screening criteria, and will not enroll patients 
with very high level of background risk. Lipid levels will be measured periodically, and 
clinicians will be encouraged to manage lipid elevations fastidiously according to current 
BHIVA treatment guidelines. The protocol also allows switching to other protease inhibitors, 
some of which have minimal effects on lipid levels. Other modifiable risk factors (e.g. high 
blood pressure and diabetes) will also be sought actively and managed according to
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guidelines, and patients who smoke will be encouraged to stop. With these measures, any 
increased risk of myocardial infarction in those patients who switch to a protease inhibitor for 
the first time is expected to be very low. 
The PIs used in the trial will all be licensed drugs which have been used in many thousands 
of patients with HIV disease. Therefore risk of adverse events is quantifiab le and known to 
be relatively small. Furthermore, the inclusion and exclusion criteria identify patients at risk 
of metabolic problems and more serious side effects and such patients will not be enrolled 
into the trial. Physicians and patients will be allo wed to select the PI best suited to that 
patient, and, if necessary, to switch to an alternative PI if there are tolerability or toxicity 
problems. Patients will be monitored carefully during the intervention for known and
unknown side effects of PIs allowing effective and appropriate management of these effects. 
Lastly, the protocol allows switch back to triple therapy (with or without a PI) in the event of 
unmanageable toxicity occurring in the PI monotherapy arm.
2.5.2 Risk of virological failure with resistance
There is a risk of virological failure with development of resistance.  Patients selected for 
participation in this trial will be stable on their current standard-of-care regimen, with a 
relatively low probability of treatment failure in the long-term. Patients who are randomised 
to the intervention arm will have standard-of-care triple-therapy changed to PI monotherapy. 
Based on studies to date, it is likely that a small proportion of patients will not maintain full 
viral suppression on PI monotherapy, and if not addressed, there is the risk that ongoing 
viral replication may lead to the development of resistance mutations. In order to minimise 
the risk of developing resistance, patients who are known to have resistance to PIs or who 
have any evidence of failure on a PI-containing regimen will not be included. Most patients in 
the UK are now tested for resistance prior to starting therapy, but in those who have not 
been tested the risk of harbouring transmitted PI resistance is low (1.8% in 2005, data 
obtained from the UK HIV Drug Resistance Database) and so it is not a major concern if a 
baseline test was not done. Thus patients in the intervention arm should enjoy the full 
activity of the PI monotherapy. The fact that the trial is recruiting patients with stable 
undetectable VL (as opposed to initiating patients on PI monotherapy) means that patients 
will not be exposed to high levels of viral replication when they start the PI (hence the risk of 
developing de novo resistance is very low). Furthermore, patients will be monitored closely in 
the initial three months after treatment switch with regular VL testing, and patients who do 
not maintain virological suppression will be switched back promptly to triple-therapy. The 
protocol also includes early therapeutic drug monitoring as an additional safety measure to 
identify patients who have inadequate drug levels to maintain viral control. Given these 
conditions, it is very unlikely that patients will develop significant resistance to the PI even if 
they experience a short period of low level viral replication between the protocol-mandated
testing points. 
There is a small risk that patients who do not successfully maintain virological suppression 
on a regimen of PI monotherapy may fail to re-suppress even if standard-of-care triple-
therapy is re-introduced. However, if re-induction is required it will likely be from a starting 
point of relatively low level of viral replication on PI monotherapy, and the re-introduction of 
standard-of-care triple-therapy in this situation is unlikely to be associated with significant 
risk of new mutations developing in the triple-therapy regimen. The previous PI
monotherapy studies described above all report successful re-induction in patients who are 
not fully suppressed with PI monotherapy. The largest of these studies, OK 04, that adopted 
a less stringent protocol for switching back to triple -therapy than the one used in this study, 
found no excess resistance developing in the PI monotherapy arm (15).
In the studies of Kaletra monotherapy reported to date, virological failure has been almost 
entirely related to poor adherence. We anticipate that there will not be major problems with 
adherence in this trial. The trial will recruit HIV-infected patients who have been established 
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on ART for at least 6 months and will, in most cases, have been taking therapy for many 
years. Such patients have been repeatedly counselled about the importance of achieving and 
maintaining a high level of adherence to therapy, since this is known to be essential for 
successful HIV treatment. We will be recruiting patients who have had consisten tly
undetectable VL measurements, and thereby selecting patients who have demonstrated an 
ability to sustain high levels of treatment adherence. 
2.5.3  Risk of viral rebound in the genital compartment and increased HIV 
transmission
Whereas NRTIs are concentrated in genital secretions, and NNRTIs reach approximately the 
same concentration as in plasma, the concentration of PIs in genital secretions is variable 
and not fully known for the newer PIs (16). There is therefore a risk of sub-optimal drug 
levels, ongoing viral replication and development of resistance in the genital tract with PI 
monotherapy, even though plasma VL may be rendered undetectable. For the minority of 
individuals who are not practising safe sex, there will also be a theoretical risk of transmitting 
the resistant virus to others.
2.5.4 Risk of viral rebound in the central nervous system and neurocognitive 
decline
The penetration of PIs into the central nervous system (CNS) is variable and generally 
inferior to that of the other main drug classes. However, it appears that control of plasma 
viral replication is usually sufficient to control viral replication in the CNS. Furthermore, 
treatment with drug regimens that have limited CNS penetration does not appear to be 
associated with poor neurocognitive performance (17). One small study that measured VL in 
the cerebrospinal fluid in patients taking PI monotherapy (boosted atazanavir) found that 3 
out of 20 patients had elevated VL in CSF despite VL suppression in plasma (18). This raises 
the theoretical concern that monotherapy (with some or all of the PIs) may lead to decline in 
neurocognitive function in a proportion of patients over time, although this has not been 
reported in any of the trials conducted to date. In this trial we will exclude patients who have 
evidence of significant neurocognitive impairment at screening, and neurocognitive function 
will be monitored throughout the study. If a patient shows evidence of decline in
neurocognitive function they will be able to switch back promptly to triple therapy. 
2.5.5 Benefits for trial participants and society 
The benefits for trial participants who are randomised to take PI monotherapy are that they 
may have a reduced risk of long-term toxicity by using PI monotherapy (due to cessation of 
NRTIs and, in some cases, NNRTIs), a possible reduced risk of long -term failure because of 
the high genetic barrier to resistance (compared with NRTIs and NNRTIs), and a better 
profile of preserved drug options for the future. This counterbalances the small risk from 
new PI toxicity or development of resistance during viral load rebound as described above. 
All participants may benefit from the rigorous standard-of-care and increased attention to 
detail that are associated with participation in a clinical trial, and may appreciate some of the 
additional clinical measurements that are conducted as part of the trial (e.g. neurocognitive 
and quality of life assessments). 
The benefits of the trial for society are that it may demonstrate the effectiveness of using PI 
monotherapy as treatment strategy, thereby increasing the number of strategies available 
for the long-term management of this chronic disease. This will represent an improvement in 
the care of HIV infected individuals. The trial may also identify a more economical approach 
to therapy and, in a setting of a healthcare system with finite resources; this would in turn 
benefit society by freeing up resources that could be deployed to other aspects of HIV care, 
or to other disease areas. 
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3. SELECTION OF CENTRES & CLINICIANS
The trial will be conducted at approximately 40 sites in the UK and 4 international sites. A list 
of the selected UK sites is shown in Appendix 4.
3.1 Criteria for selection of trial sites & clinicians 
• The clinical trial site is involved in the treatment of HIV patients.
• The site has the potential to recruit at least 10 patients within the 12-18 month
recruitment period. 
• The investigator has appropriate experience of conducting trials according to Good 
Clinical Practice.
• Clinical trial staff are familiar with the appropriate use of investigational products, as 
described in the protocol. 
• The clinical trial site has an adequate number of qualified staff and adequate
facilities, for the foreseen duration of the trial, to conduct the trial properly and 
safely.
3.2 Site responsibilities 
• The site must have a signed written agreement between the Trust and the MRC that 
will outline details of the trial governance, obligations of parties, liabilities and 
indemnity.
• The site must conduct the trial in accordance with the current protocol and changes 
will only be made when necessary to protect the safety, rights and welfare of
patients.
• The site must conduct the trial in compliance with the International Conference on 
Harmonisation (ICH) GCP and applicable regulatory requirements. 
• The site must ensure that all staff assisting with the trial are adequately informed 
about the protocol and the investigational products and aware of their trial related 
duties.
• The site must permit monitoring and audit of source documentation. Direct access to 
all trial related sites documents, reports and data must be available.
• The site must maintain a trial master file, which contains all essential documents for 
the conduct of the trial.
• The site must submit all trial data in a timely manner, and as described in the 
protocol.
• The site must submit promptly all serious adverse events reports and follow-up with 
detailed written reports as appropriate.
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• The site must not disclose any trial related data without the approval of the Trial 
Steering Committee.
• The site must retain all trial-related documents for 15 years after the completion of 
the trial. 
3.3 Site approval 
It is expected the site will submit the trial documentation for local research and development
approval promptly, and at the latest 6 weeks following ethics approval. The site should begin 
trial-related screening activities no later than 4 weeks following the receipt of all necessary 
trial approvals and documentation. 
A site initiation meeting with the MRC must occur before a site can be approved to 
randomise patients. The following documentation should be forwarded to the MRC CTU:
• Local research ethics committee approval of the protocol, patient information sheet 
and informed consent form, together with translations (if required).
• CV for Principal Investigator and co-investigators.
• Delegation of Authority log.
• Copy of local p harmacy dispensing SOP.
• Approval of the institution’s local Research and Development office, if required.
For each clinical trial site, the responsibilities and contact details (phone, fax and email 
address) of each person working on the trial must be documented on the Delegation of 
Authority  log. Clinical trial sites must notify the MRC CTU of any subsequent changes to trial 
personnel and/or their responsibilities. A current copy of the log must be stored in the trial 
master file at the clinical trial site and also at the MRC CTU. 
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4. SELECTION OF PATIENTS
Patients will be considered eligible for enrolment in the trial if they fulfil all of the inclusion 
criteria and none of the exclusion criteria defined below.
4.1 Patient inclusion criteria
1. Documented HIV infection on ELISA and confirmatory test.
2. Male or female patients, aged 18 years or more. 
3. Receiving combination ART for at least 24 weeks with a regimen comprising 2 NRTIs 
and either an NNRTI or a PI (boosted or un-boosted).
4. No change in ART drugs in the 12 weeks prior to screening.
5. Plasma VL <50 copies/ml for at least 24 weeks prior to screening (must have at least 1 
documented result <50 copies/ml at more than 24 weeks prior to screening, and at 
least 1 documented result <50 copies/ml taken within 12 weeks prior to screening). A 
patient who has had one VL “blip” to <200 copies/ml in the 24 weeks prior to screening
may be included, provided that the 2 VL tests that immediately preceded the blip and 
the 2 VL tests that immediately followed the blip all gave results <50 copies/ml. 
6. CD4+ count >100 cells/mm3 at screening.
This criterion is included because immune reconstitution is a priority in patients with 
very low CD4+ counts, and there is currently insufficient data to assess whether PI 
monotherapy will lead to equivalent rates of CD4+ recovery as standard -of-care
treatment.
7. Willing to continue unchanged o r to modify, antiretroviral therapy, in accordance with 
the randomised assignment.
8. Likely to be resident in the UK for the full duration of the trial and willing to comply with 
trial visit schedule throughout the follow-up period. 
9. Willing to provide written informed consent. 
4.2 Patient exclusion criteria
1. Known major protease resistance mutation(s) documented on prior resistance testing if 
performed (prior resistance testing is not mandatory for trial participation). 
2. Evidence of previous failure while taking a PI-containing regimen (defined as failure to 
achieve VL <50 copies/ml within 24 weeks after starting a PI-containing regimen, or 
having 2 VL >50 copies/ml after having achieved a VL <50 copies/ml on the PI-
containing regimen).
This criterion is included to avoid pre-existing PI resistance that might compromise 
efficacy of PI monotherapy.
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3. Evidence of previous failure on an NNRTI-containing regimen (defined as in 2, above), 
unless a successful viral sequence (resistance test) was obtained following failure and 
within 60 days prior to the date of switching to a new fully suppressive regimen.
This criterion is included to minimise the chances that patients enter the trial with 
unrecognised/undocumented drug resistance which would diminish the accuracy of 
determining the primary endpoint of new drug resistance, should rebound occur during 
the trial.
4. Previous allergic reaction to a PI.
5. Patient currently using or likely to require use of concomitant medication with known 
interaction with PI s including rifampicin, amiodarone, flecainide, bupropion, clozapine, 
ergotamine, mexilitine, midazolam, pethidine, pimozide, quinidine, sertindole, sildenafil, 
voriconazole, zolpidem, St John’s Wort.
6. Patient requiring treatment with radiotherapy, cytotoxic chemotherapy, or is anticipated 
to need these during the trial period. 
7. Treatment for acute opportunistic infection within 3 months prior to trial screening.
8. Pregnant or trying to become pregnant at the time of trial entry. 
9. History of active substance abuse or psychiatric illness that, in the opinion of the
investigator, would preclude compliance with the protocol, dosing schedule or
assessments.
10. History of HIV encephalopathy with current deficit >1 in any domain of the
Neuropsychiatric AIDS Rating Scale (see Appendix 8).
11. Past or current history of cardiovascular disease, or 10 year absolute coronary heart 
disease risk of >30% (calculated from the Framingham equation (19), and assessed 
using the Joint British Societies cardiovascular ris k prediction charts, Appendix 11).
12. History of insulin-dependent diabetes mellitus.
13. Patient currently receiving interferon therapy for Hepatitis C virus infection or considered 
likely to need such therapy during the course of the trial. 
14. Co-infection with hepatitis B, defined as Hepatitis BsAg positive at screening or at any 
time since HIV diagnosis. 
This criterion is included to avoid the risk of a flare of Hepatitis B with NRTI withdrawal.
15. Any other active clinically significant condition, or findings during screening medical 
history or examination that would, in the opinion of the investigator, compromise the 
patient’s safety or outcome in the trial.
16. Anaemia (haemoglobin <9.5g/dl), neutropenia (absolute neutrophil count <1000/mm3)
or thrombocytopenia (platelet count <50,000 /mm3) at trial screening.
17. ALT or alkaline phosphatase greater than 3 times the upper limit of normal at trial 
screening.
18. Fasting plasma glucose >7.0mmol/L at trial screening.
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19. Fasting plasma triglyceride level >3mmol/L at trial screening despite the use of lipid 
lowering drugs.
20. Fasting plasma total cholesterol >6.2mmol/L at trial screening despite the use of lipid 
lowering drugs.
4.3 Screening procedures and pre-randomisation investigations
4.3.1 Pre-screening check 
Prior to the screen ing visit, a check of medical and drug history should be performed to 
ensure that the patient meets the basic medical eligibility criteria. Patients will be given 
adequate information about the trial together with a Patient Information Sheet  (see
Appendix  1) and given an opportunity to ask questions about the trial. 
4.3.2 Screening visit 
Potentially eligible individuals can be screened between 1 and 4 weeks before trial entry (i.e. 
Week -4 to Day 0) but results from the screening must be available prior to randomisation.
The screening visit will be scheduled to occur in the morning due to the need for fasting 
blood tests. Patients should be instructed to not eat or drink anything (except plain water) 
from midnight before the visit, although they may take any necessary routine medication. 
At the screening visit patients will be asked to verify that they have read the Patient 
Information Sheet and will be given a further opportunity to ask questions about the trial. If 
the patient is willing to proceed, the patient and Investigator must both sign 3 copies of the 
main trial Consent Form (see Appendix 2) (one copy to be given to the patient, one copy for 
the patient’s clinic notes and one copy for the trial file) before any trial-specific screening 
procedures are carried out. All individuals screened must have their name, date of birth and 
clinic number recorded in the Trial Register against the next available trial number. This will 
then become their allocated trial number. The Trial Register must be stored by the
investigator in a secure place only accessible to appropriate clinic staff. If an individual is not 
subsequently randomised the reason should be recorded in the register. 
Screening assessments will be performed as listed below and as summarised in the trial
schedule (see section 1.3):
• Review of medical history (including previous and current clinically important
diseases and medications) and recording demographic information 
• Review of symptoms 
• Physical examination (including measurement of blood pressure)
• Assessment of cardiovascular risk factors and estimation of 10 year absolute
coronary heart disease risk using charts based on the Framingham equation (19).
• Resting 12 -lead electrocardiogram (ECG). The results of an ECG performed during
the previous 6 months will be acceptable, provided that the printout is filed and 
available for review in the patients’ case record. The ECG may be performed on or 
after the day of screening, but results must be available at the randomisation visit 
which needs to occur within 4 weeks following the screening visit.
• Laboratory tests: 
o HIV viral load 
o CD4+ count
o Full blood count (haemoglobin, white cells, neutrophils, lymphocytes and
platelets)
o Biochemistry (sodium, potassium, urea, creatinine, bilirubin, ALT, alkaline
phosphatase)
o Bone profile (calcium, phosphate) 
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o Fasting glucose
o Fasting lipids (total cholesterol, triglycerides, LDL, HDL) 
o Urine protein / creatinine ratio
o Hepatitis B surface antigen test and hepatitis C antibody test. The results of tests 
performed during the previous 6 months will be acceptable
o Urine (or serum) pregnancy test for women of childbearing potential 
o Plasma storage (2 X 4ml EDTA tube)
DOI: 10.3310/hta20210 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 21
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Paton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
81
MRC PIVOT Trial
Version 1.1, 25 March 2008 24
5. RANDOMISATION & ENROLMENT
5.1 Randomisation visit (Baseline; Day 0)
The randomisation visit should be scheduled for 1-4 weeks following the screening visit, but 
the results of all the screening assessments (including ECG) must be available prior to 
randomisation. There is no requirement for fasting at this trial visit. 
For trial entry, all eligibility criteria must be fulfilled. These include the results of the
evaluations carried out at screening which must be reviewed prior to the randomisation to 
make sure that the patient meets the criteria for trial entry. The research team should 
confirm that the patient continues to consent to enter the trial. The patient will be advised to 
inform their general practitioner of their trial participation, but this will not be a pre-requisite
to enrolment. If the patient consents for their GP to be informed about participation (see 
Appendix 2) a letter should be sent to the GP (see Appendix 3).
Baseline assessments will be performed as listed below and as summarised in the Trial 
Schedule (see section 1.3).
• Review of medical and drug history since the screening visit
• Review of symptoms 
• Review of concomitant medications
• Adherence to ART (patient will be asked about the number of missed doses in the 
previous 2 weeks, and in the previous 3 months) 
• Targeted physical examination (as needed to evaluate symptoms; at this visit will 
include measurement of blood pressure, body weight, waist and hip-circumference,
assessment of facial lipoatrophy and peripheral neuropathy)
• Neurocognitive assessment 
• Review of healthcare resource utilisation (covering 3 months prior to randomisation 
visit) by patient self-report and review of case sheet
• MOS-HIV quality of life questionnaire (self-completed by patient)
• EQ-5D health status questionnaire (self-completed by patient) 
• Laboratory tests: 
o HIV viral load 
o CD4+ count
o Full blood count (haemoglobin, white cells, neutrophils, lymphocytes and 
platelets)
o Biochemistry (sodium, potassium, urea, creatinine, bilirubin, ALT, alkaline 
phosphatase)
o Plasma storage (1 X 4ml EDTA tube) 
5.2 Procedure for randomisation
To randomise a patient the completed randomisation pages of the CRF must be faxed to the 
MRC CTU while the patient is present in the clinic. 
RANDOMISATION
Tel:  +44(0)20 7670 4843 (Mon - Fri, 09:00 – 17:00)
Fax: +44(0)20 7670 4817
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Eligibility will be checked and if there are queries regarding the CRF the MRC CTU will 
contact the site by phone. Randomisation will be performed using a computer-generated
randomisation list and the details of the patient’s treatment allocation will be notified to the 
trial team at the site by fax and by phone within one hour of the receipt of the randomisation 
form. The patient’s trial number, treatment allocation and the date of randomisation will be 
entered into the Trial Register at the MRC CTU, and these details should also be entered into 
the Trial Register at the site. 
5.3 Post-randomisation procedures and follow-up
The clinician will complete a prescription with the patient’s details and trial medication as 
allocated. The prescription will be for 3 months, or until the next protocol-mandated trial visit 
(see section 6.4). 
Trial visit schedules will be sent by email or fax to the site at the time of randomisation. 
Patients should be followed on the same schedule even if their trial medication is
discontinued. The target dates for trial visits are determined by the date of randomisation 
and are not affected by subsequent events. The schedule defines visit dates (with windows) 
necessary for data collection, but the patient may be seen more frequently for clinical care 
as needed.
Patients will also be given a card with the contact details for the trial research team. 
Patients in the PI monotherapy arm will be asked to return in 4 weeks (visit window ±2
weeks). The Week 4 visit should be scheduled for the morning, and patients should be 
instructed not eat or drink anything (except plain water) from midnight before the visit. They 
should also be instructed to omit any morning dose of PI medication, and bring the
medication with them to the clinic. They may take any other necessary dose of routine 
medication as usual. 
Patients randomised to continue triple-therapy will be asked to return in 12 weeks. The 
Week 12 visit should be scheduled for the morning, and they should be instructed not eat or 
drink anything (except plain water) from midnight before the visit. They may take all their 
medication as usual. 
5.4 Co-enrolment guidelines
Patients may not participate in any other clinical intervention trial while on this trial. 
Participation in other trials that do not involve an intervention may be permitted, but this 
should be discussed first with the Chief Investigator of this trial. 
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6. TREATMENT OF PATIENTS
6.1 Introduction
Patients will be randomised to a strategy of switching to a regimen comprising a single 
ritonavir-boosted PI or continuing triple drug therapy. 
6.2 Control arm
Patients randomised to the control arm will continue to take their standard-of-care triple-
therapy regimen. They will have regular viral load and other safety monitoring according to 
the standard-of-care as described in the assessment section and schedule of assessments 
table (VL testing every 12 weeks). 
Changes of therapy can be made for virological failure or drug-related toxicity as clinically 
indicated, but patients will be expected to remain on the strategy of receiving standard-of-
care triple-therapy for the duration of the trial. The choice of drugs for use in the triple-
therapy strategy is left to the discretion of the physician and patient. 
6.3 PI monotherapy arm
6.3.1 Commencing PI monotherapy
Patients who are receiving an NNRTI-based regimen at baseline will discontinue the NNRTI 
and start a single ritonavir-boosted PI immediately following the randomisation visit. The two 
NRTIs will continue for a further 2 weeks after randomisation and then stop, so that from
that point the patient will take only PI monotherapy. Consideration should be given to 
prescribing anti-diarrhoeal medication (e.g. loperamide) for the initial period of following PI 
initiation, if considered clinically appropriate to do so. 
Patients who are receiving a PI-based regimen at baseline will discontinue the two NRTIs 
immediately following the randomisation visit. They will continue on a single ritonavir -
boosted PI only, which may be the same or a different PI from the one they were taking at 
baseline.
6.3.2 Choice of protease inhibitor 
This is a strategic trial and hence the choice of protease inhibitor will be left to physician and 
patient discretion. Any licensed, ritonavir-boosted PI will be permitted. Switches to
alternative PIs will be permit ted during the trial to avoid or minimise drug-related toxicity, to 
minimise the risk of interactions with any necessary concomitant medication, to create a 
more acceptable treatment schedule, or to take account of changes in current opinion of the 
relative merits of protease inhibitors in this therapeutic setting. 
The trial team at the MRC CTU will endeavour to provide investigators with relevant
information, updates and any data from other trials of PI monotherapy that enters the public 
domain during the course of this trial so that investigators may use these to guide their 
choice of protease inhibitor monotherapy. 
Any change in PI should be followed by a viral load at 4 weeks to verify that undetectable 
viral load is maintained. 
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6.3.3 Dose adjustment usin g therapeutic drug monitoring 
A blood sample will be taken at Week 4 for measurement of the concentration (as close as 
possible to a trough level) of the PI (see section 7.3.1), and the results will be made 
available to the treating clinician prior to the Week 8 trial visit. The drug levels will be 
compared with the concentration-based cut-off values for efficacy (C trough) given in
international guidelines (20):
• Atazanavir 150 ng/mL
• Fosamprenavir 400 ng/mL
• Indinavir 100 ng/mL
• Lopinavir 1000 ng/mL
• Nelfinavir 800 ng/mL
• Saquinavir 100 ng/mL
• Tipranavir 20500 ng/mL
The cut-off value for darunavir will be taken as 550 ng/mL based on protein binding 
corrected EC50 in-v itro (21).
If the concentration of the PI is below the specified threshold, adjustments to the dose of 
the PI, the boosting dose of ritonavir, or the dose frequency may be made if thought to be 
clinically appropriate by the treating physician. The possibility of drug interaction with any 
concomitant medication the patient may be taking should also be considered prior to dose 
adjustment (see section 6.6). Expert advice will be available to the treating physician from 
the trial research team that includes an experienced clinical pharmacologist. All requests for 
such advice will be directed through the MRC CTU. If the P I concentration is below the 
stated threshold at week 4, up to 2 further therapeutic drug monitoring assays may be 
performed up to week 12, either to re-check a borderline low concentration, or to re-check
the concentration after dose adjustment. 
6.3.4 Virological monitoring and switching strategy
Patients in the PI monotherapy strategy arm will have VL testing performed at Weeks 4, 8 
and 12, and every 12 weeks thereafter (see trial schedule, section 1.3). Additional VL testing 
will be performed in the event of a confirmed virological rebound, as described in section 
7.2.1.
Patients who develop virological rebound after switching to PI monotherapy (defined as 2 
consecutive VL values above 50 copies/ml taken 4-6 weeks apart, with the first being 
confirmed by a repeat assay on the same sample) will switch promptly back to a triple-
therapy regimen. Exceptionally, upon receiving the second detectable VL result investigators 
may choose to switch to an alternative PI drug or dosing schedule if they consider that there
is a strong chance that VL control could be re-established rapidly (e.g. by switching from 
once daily to twice daily PI). A further VL must be obtained within 4 weeks of this switch, 
and if this is detectable, patients must switch back to triple-therapy immediately.
6.3.5 Strategy for stopping or interrupting treatment with PI monotherapy 
In addition to the virological rebound criteria given above, patients may be withdrawn 
(temporarily or permanently) from treatment with PI monotherapy for any of the following
reasons at the discretion of the investigator: 
• Disease progression while on therapy
• Unacceptable toxicity (e.g. insulin dependent diabetes developing de novo)
• Need for concomitant medication that has known interactions with the PI (and that 
cannot be avoided by switching to an alternative PI) 
• Serious intercurrent illness or any change in the patient’s condition which justifies the 
discontinuation or interruption of treatment in the clinician’s opinion
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• Pregnancy
• Patient withdraws consent
PI monotherapy should be resumed as soon as possible, if considered clinically appropriate 
to do so (e.g. toxicity resolves, patient is no longer pregnant, or requirement for
contraindicated concomitant medication ends).
6.3.6 Strategy for switching back to triple-therapy
In the event that triple-therapy needs to be resumed, this should be the regimen that the 
patient was taking at trial entry. However, alternatives will be allowed if there is a strong 
preference for choosing alternative drugs (e.g. patients may have experienced relief from 
efavirenz-related neuropsychiatric side effects and may wish to continue on the PI), if there 
is a good clinical reason why change is indicated, or if the results of any resistance tests 
performed suggest that a particular combination would be preferable to that originally taken 
at baseline. 
After returning to triple -therapy, changes of drugs can be made for subsequent virological 
failure or drug related toxicity as clinically indicated. Patients will be expected to remain on 
the strategy of receiving triple -therapy for the remaining duration of the trial, unless the 
interruption was temporary for one of the reasons listed in section 6.3.7. Resumption of PI 
monotherapy after a temporary suspension should be followed by VL testing after 4 weeks.
6.4 Management of drug toxicity and adverse events 
Toxicity will be managed in both arms according to standard clinical practice. Wherever 
possible, any side effects will initially be managed by symptomatic measures and
administration of appropriate (non-contraindicated) medication. In particular, Grade I-II
gastrointestinal side effects such as nausea (with or without vomiting), and diarrhoea will be 
managed by anti-emetics and or antidiarrhoeal agents in the first instance. See Appendix 7 
for details of toxicity grading. Interruption of or changes in ART will be avoided except in the 
event of Grade III or IV toxicity that is considered at least possibly related to one or more of 
the ART drugs. Wherever possible, alternative ART drugs will be selected that maintain the 
patient’s randomised treatment strategy. 
6.5 Management of cardiovascular disease risk factors
Cardiovascular risk factors (smoking status, blood pressure, fasting serum lipids and glucose) 
will be evaluated at baseline and annually during the trial. 
At each of these annual assessments patients who report that they continue to smoke will be 
advised to give up smoking. This should be particularly emphasised in patients who have 
other factors that elevate cardiovascular risk. Patients who indicate that they are willing to 
attempt to stop smoking will be provided with contacts for smoking cessation programmes, 
or other counselling and assistance as appropriate. 
Elevated blood pressure will be managed according to standard treatment guidelines.
Elevated lipid levels will be evaluated according to standard thresholds for treatment and 
managed according to current treatment guidelines. Management decisions should be based 
on fasted results. If elevated triglyceride or cholesterol results are obtained from a non-
fasting blood sample, the test should be repeated after an overnight (10-hour) fast before 
management changes are instigated. Management will initially involve counselling to make 
appropriate changes in diet and exercise routine. Subsequently, if indicated, anti-
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hyperlipidaemia medication may be used. If treatment with a statin is indicated, a drug that 
is not metabolised by the CYP3A4 pathway should be prescribed e.g. pravastatin (but
consider possible interaction with darunavir), atorvastatin, or rosuvastatin (but consider 
possible interaction with lopinavir or darunavir). Up-to-date information on drug interactions 
should be sought (see reference sources in section 6.6, below). If these measures fail to 
provide adequate control of lipids, changes in ART may be considered (e.g. switching to an 
alternative PI or NNRTI that is considered to be less prone to cause hyperlipidaemia). Every 
attempt should be made to maintain the patient within the allocated treatment strategy and 
consideration should be given to discontinuing a PI only if lipid levels cannot be adequately 
controlled with these measures. 
Diabetes will be diagnosed by standard approaches, and managed according to current best 
clinical practice. Management decisions should be based on fasted results. If elevated 
glucose levels are obtained from a non-fasting blood sample, the test should be repeated 
after an overnight (10-hour) fast before management changes are instigated. Management 
may involve initial referral for counselling and initiation of a diabetic diet, and prescription of 
oral hypoglycaemic agents. Switching to an alternative PI (or NNRTI) that is considered to be 
less prone to cause diabetes may be considered. Every attempt should be made to maintain 
the patient within the allocated treatment strategy and consideration should be given to 
discontinuing a PI only if the blood sugar cannot be adequately controlled with these 
measures. However, for patients who develop insulin dependent diabetes de novo following 
switching to a PI, it would be appropriate to consider early switching to an alternative ART 
regimen if available. 
6.6 Concomitant medication 
A large number of drugs have interactions with ART, and before prescribing any concomitant 
medication in this trial investigators should check with the drug interaction information listed 
in the current BNF (http://www.bnf.org) or current summary of product characteristics in the 
electronic medicines compendium (http://emc.medicines.org.uk), or with the detailed
information on drug interactions provided in the University of Liverpool HIV drug interactions 
website (http://www.hiv -druginteractions.org).
In this trial, particular attention needs to be paid to avoid prescribing concomitant
medications that are known to reduce PI drug levels, such as rifampicin, anticonvulsants, St 
John’s Wort and acid -reducing agents. These interactions may differ between the individual 
PIs and the particular medications with drug classes, and details should be checked on the 
University of Liverpool HIV drug interactions website (http://www.hiv -druginteractions.org).
A number of other medications may have serious interactions with one or more PIs, including 
warfarin, calcium channel blockers, ergot derivatives, benzodiazepines, and antifungals. 
The latest summary checklist of PI drug interactions from the University of Liverpool HIV 
drug interactions website (http://www.hiv -druginteractions.org ) will be sent to investigators 
at the start of the trial.
6.7 Drug supply, dispensing and accountability
Patients will be given a three month drug supply at each visit, corresponding to the protocol 
mandated frequency of follow-up. Prescriptions will be written on standard hospital forms, 
and drugs will be supplied from the hospital pharmacy. The local pharmacy dispensing SOP 
will be followed, including a record of the batch numbers of antiretroviral drugs dispensed.
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6.8 Measures of adherence
Patients will be asked several simple questions regarding adherence (number of missed 
doses since last trial visit, number of missed doses in previous 2 weeks) as part of trial visits 
and the answers will be captured on the visit CRF.
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7. ASSESSMENTS & FOLLOW-UP
7.1 Routine Follow-up
The trial will run for 5 years, with recruitment being completed within the first 12-18 months. 
All patients will continue follow-up to a common closing date. 
The assessments are listed in the trial schedule (see section 1.3). Trial visits and
assessments will correspond closely to routine clinical care, with 12-weekly visits throughout 
the trial. Patients randomised to the PI monotherapy arm will have additional visits at Week 
4 and Week 8. Additional visits for VL testing will be required at 4-6 weeks following any 
confirmed VL rebound (see section 7.1.6). Data will be entered on the CRF at each visit.
7.1.1  Week 4 
This visit is only required for patients randomised to the P I  m onothera py a rm .
The visit window is ±2 weeks from the target visit date. The visit will be scheduled to occur 
in the morning due to the requirement for fasting blood tests. Patients should be instructed 
to not eat or drink anything (except plain water) from midnight before the visit. They should 
be instructed not to take any  morning dose of PI medication (other medication can be taken) 
until after the blood has been drawn. The following assessments will be performed: 
• Review of symptoms 
• Review of concomitant medications 
• Adherence to ART (no. of missed doses in previous 2 weeks and since last visit)
• Targeted physical examination (as needed to evaluate reported symptoms)
• Laboratory tests:
o HIV viral load 
o Full blood count (haemoglobin, white cells, neutrophils, lymphocytes and 
platelets)
o Biochemistry (sodium, potassium, urea, creatinine, bilirubin, ALT, alkaline 
phosphatase)
o Fasting glucose
o Fasting lipids (total cholesterol, triglycerides, LDL, HDL) 
o PI drug concentration (trough level preferred, or at least 4 hours from last 
dose)
o Plasma storage (1 X 4ml EDTA sample) 
7.1.2 Week 8 
This visit is only required for patients randomised to the P I  m onothera py a rm .
The visit window is ±2 weeks from the target visit date. The patient should be instructed not 
to take any morning dose of PI medication (other medication can be taken) until after they 
have been assessed in the clinic, in case a repeat PI drug level concentration may be 
required. If the trough level result at Week 4 is known to be above the threshold, then the 
patient can be instructed prior to the visit that the morning PI dose can be taken as 
scheduled (because a repeat drug concentration level will not be needed at Week 8).
Adjustment to PI dose, ritonavir dose or drug schedule may be made at this visit depending 
on the results of PI levels measured at Week 4 (these will be available at this visit). 
The required assessments at this visit are: 
• Review of symptoms 
• Review of concomitant medications 
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• Adherence to ART
• HIV viral load 
Optional:
• PI drug concentration (trough level preferred, or at least 4 hours from last dose).
This is only indicated if the Week 4 drug concentration was below the threshold and 
the clinician thinks it appropriate to recheck the level.
7.1.3 Week 12 
This visit is required for a ll pa tients .
The visit window is ±2 weeks from the target visit date. The visit will be scheduled to occur 
in the morning due to the requirement for fasting blood tests. Patients should be instructed 
to not eat or drink anything (except plain water) from midnight before the visit. 
Patients on PI monotherapy arm who had a low PI concentration at Week 4 and for whom 
the clinician has decided that a further check on drug levels is warranted (for example if a 
dose adjustment has been performed at week 8) should be instructed not to take any 
morning dose of PI medication (other meds can be taken) until after the blood has been 
drawn. All other patients can take their morning medication as scheduled. The following 
assessments will be performed: 
• Review of symptoms 
• Review of concomitant medications 
• Adherence to ART (no. of missed doses in previous 2 weeks and since last visit)
• Targeted physical examination (as needed to evaluate reported symptoms)
• Neurocognitive assessment
• Review of healthcare resource utilisation since last visit (patient self-report and 
review of case sheet) 
• EQ-5D health status questionnaire (self-completed by patient)
• MOS-HIV quality of life questionnaire (self-completed by patient) 
• Laboratory tests:
o HIV viral load 
o CD4+ count
o Full blood count (haemoglobin, white cells, neutrophils, lymphocytes and
platelets)
o Biochemistry (sodium, potassium, urea, creatinine, bilirubin, ALT, alkaline 
phosphatase)
o Bone profile (calcium and phosphate; only required for patients taking 
tenofovir)
o Fasting glucose
o Fasting lipids (total cholesterol, triglycerides, LDL, HDL) 
o Urine protein / creatinine ratio (only required for patients taking tenofovir)
o Plasma storage (1 X 4ml EDTA sample) 
Optional:
• PI drug concentration (trough level preferred, or at least 4 hours from last dose). 
This is only indicated for patients in the PI monotherapy arm in whom the Week 4 
drug concentration was below the threshold and for whom the clinician thinks it 
appropriate to recheck the level.
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7.1.3  Subsequent 12-weekly visits (excluding “annual” visits and final trial visit)
These visits are required for a ll pa tients .
The visit windows are ±4 weeks from the target visit date. There is no requirement for
fasting or drug scheduling for these visits.  The following assessments will be performed: 
• Review of symptoms 
• Review of concomitant medications 
• Adherence to ART (no. of missed doses in previous 2 weeks and since last visit)
• Targeted physical examination (as needed to evaluate reported symptoms)
• Review of healthcare resource utilisation since last visit (patient self-report and 
review of case sheet) 
• EQ-5D health status questionnaire (self-completed by patient)
• Laboratory tests:
o HIV viral load 
o CD4+ count
o Full blood count (haemoglobin, white cells, neutrophils, lymphocytes and 
platelets)
o Biochemistry (sodium, potassium, urea, creatinine, bilirubin, ALT, alkaline 
phosphatase)
o Bone profile (calcium and phosphate; only required for patients taking 
tenofovir)
o Urine protein / creatinine ratio (only required for patients taking tenofovir)
7.1.4  “Annual” visits (week 48, 96, 144, 192, 240) and final trial visit
These visits are required for a ll pa tients .
The visit windows are ±4 weeks from the target visit date. Patients should be instructed to 
not eat or drink anything (except plain water) from midnight before the visit. The following 
assessments will be performed: 
• Review of symptoms 
• Review of concomitant medications 
• Adherence to ART (no. of missed doses in previous 2 weeks and 3 months)
• Targeted physical examination (as needed to evaluate reported symptoms; at 
this visit will include measurement of blood pressure, body weight, waist and hip-
circumference and assessment of facial lipoatrophy; the final trial visit will also 
include an assessment of peripheral neuropathy) 
• 10-year cardiovascular  risk assessment 
• Neurocognitive assessment
• Review of healthcare resource utilisation since last visit (patient self-report and 
review of case sheet) 
• EQ-5D health status questionnaire (self-completed by patient)
• MOS-HIV quality of life questionnaire (self-completed by patient) 
• Laboratory tests:
o HIV viral load 
o CD4+ count
o Full blood count (haemoglobin, white cells, neutrophils, lymphocytes and 
platelets)
o Biochemistry (sodium, potassium, urea, creatinine, bilirubin, ALT, alkaline 
phosphatase)
o Bone profile (calcium and phosphate; required for all patients at this visit) 
o Fasting glucose
o Fasting lipids (total cholesterol, triglycerides, LDL, HDL) 
o Urine protein / creatinine ratio (required for all patients at this visit)
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o Hepatitis B and C serology (if clinically indicated) 
o Plasma storage (1x  4ml EDTA at annual visits; 2x  4ml EDTA at final trial visit)
7.1.5 Additional visits for virological rebound
These visits are required for a ll pa tients .
In the event that the patient has a VL rebound >50 copies/ml, and this result is confirmed 
(by repeat laboratory test ing on the same sample), an additional visit will be required and 
this should be scheduled to occur at 4-6 weeks following the date of the visit at which the 
sample with VL rebound was obtained. 
For this repeat visit, patients in the PI monotherapy arm should be instructed not to take 
their morning dose of PI medication (other medications can be taken) until after the blood 
has been drawn. All other patients can take their morning medication as scheduled. The 
following assessments will be performed at this visit: 
• Review of concomitant medications 
• Adherence to ART (no. of missed doses in previous 2 weeks and 3 months)
• Laboratory tests:
o HIV viral load
o Resistance testing (store until VL test result available and only proceed if >50 
copies/ml on the second sample)
o Plasma storage (2x 4ml EDTA sample for later batched tests which may 
include PI drug levels) 
If the second VL test shows an undetectable VL, follow-up will resume according to the next 
routine visit in the trial schedule. If the patient has another VL result >50 copies/ml later in 
the trial, the same procedure (re-run of the same sample, followed by repeat VL testing if 
confirmed detectable on the first sample) will be followed again.
7.1.6 Additional visits following ART change
This visit is required  for a ll pa tients .
For patients in either treatment arm who change therapy as a result of VL rebound, an 
additional visit should be scheduled at 4-6 weeks following the date of therapy change. 
Review of symptoms, concomitant medication and treatment adherence will be performed. 
The only required laboratory assessment at this visit is VL testing, but additional laboratory 
tests may be performed as clinically indicated. Follow-up should then resume according to 
trial schedule, but further unscheduled visits may be arranged if considered appropriate for 
clinical management.
7.2 Procedures for assessing efficacy
7.2.1 Viral load
VL testing will be performed at the local site laboratory with the standard assay for detecting 
low levels of VL that is routinely used at the site. The site laboratory will be required to 
demonstrate satisfactory participation in a recognised quality control program for VL testing. 
Any VL result >50 copies/ml will be initially confirmed by re-testing the same sample on a 
separate laboratory run. If the result is confirmed as >50 copies/ml, the patient will be 
recalled for a repeat sample. This second assay need be run only once. 
In order to be able to extrapolate the findings beyond the 5 year period of the trial, it will be 
important to document that the patients on PI monotherapy who remain virologically 
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suppressed during the trial have full virological suppression (to the same extent as patients 
on triple-therapy). Therefore, additional testing using a very low copy assay (<5 copies/ml) 
will be performed at the central virology laboratory on the stored plasma sample from the 
final visit in all patients who have VL <50 copies/ml on conventional testing at the final v isit.
7.2.2 CD4+ count
CD4+ counts will be measured at the local site laboratory using the standard flow cytometry 
method used by the site. The site laboratory will be required to demonstrate satisfactory 
participation in a recognised quality control programme for CD4+ count testing.
7.2.3 Resistance testing
Drug resistance is the key component of the primary endpoint, and hence the detection of 
new resistance mutations needs to be pursued fastidiously in this trial. 
All patients who have virological rebound more than 50 copies/ml on 2 consecutive readings 
(taken at least 4 weeks apart) will have a sample sent for genotypic resistance testing (from 
the sample that gave the highest VL result, or if there is less than 50 copies/ml difference in 
the VL results, the later of the two samples will be chosen in preference). Resistance testing 
will be performed by the local laboratory that is normally used by the site. A designated 
referral laboratory, normally used by the site for performing resistance testing at low VL 
levels, may be used also. In the event that sequencing is unsuccessful, the sample will also 
be tested by the study central resistance laboratory at UCL/UCLH. All the sequences will be 
analysed using the Stanford algorithm, and the level of resistance to individual drugs will be 
classified as none (susceptible), potential low level, low level, intermediate level, high level. 
Comparison will be made with the drug resistance profile obtained from any other previous 
sequences available for that patient (pre-treatment resistance testing is commonly
performed at most centres in the UK, and prior resistance testing is mandated in the trial 
entry criteria for patients who have failed previous ART). If a patient develops virological 
rebound with resistance during the course of the trial but does not have a prior resistance 
test result for comparison, attempts will be made to identify a stored (pre-treatment) sample 
and if available this sample will be tested to determine whether transmitted resistance was 
present prior to antiretroviral therapy. 
As a further measure to make the best possible  comparison of the two treatment strategies 
in terms of drug resistance development, stored samples from patients who have rebounded 
(VL >50 copies/ml) will be tested using a minority species resistance assay at the central 
virology laboratory at the end o f the trial. 
7.2.4 Quality of Life (QoL) assessment
This will be assessed using the Medical Outcomes Study HIV Health Survey (MOS-HIV), a 30-
item QoL questionnaire based on the SF36 which has been validated for use in patients with 
HIV infection (22) (see Appendix 6). The questionnaire takes about 5 minutes for patients to 
self-complete, and this will be done at baseline, at 12 weeks, and annually during the trial.
7.2.5 Neurocognitive assessment
Neurocognitive function will be assessed at Baseline, Week 12, annual visits and the final 
trial visit using a series of simple neuropsychological tests that can be administered by a 
clinician or research nurse without specific neuropsychological training, and that will take 
about 20 minutes to perform. The most common neurocognitive impairments seen in HIV-
infected individuals are those that affect frontal sub-cortical functions (23-25). Therefore, the 
tests have been chosen to detect changes in these functions such as psychomotor speed, 
memory, executive functions (e.g. processing instructions) and fine motor speed. The
following simple, well-established tests will be performed (details provided in Appendix 13): 
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• Hopkins Verbal Learning Test - Revised. This assesses verbal learning and
memory. The examiner reads 12 words and the participant is asked to recall them 
immediately. The exercise is performed a further two times in exactly the same 
way. The free recall trials are followed by a recognition test where the examiner 
read s aloud a list of 24 words and the participant must answer yes or no for each
of them depending if the word was or was not included in the original list of 12 
words. Finally, after performing the remaining tests listed below and completing 
the MOS-HIV quality of life questionnaire (i.e. after about 15-20 minutes), the 
initial free recall test is repeated (without the examiner repeating the list again) to 
assess delayed memory. A final score based on the number of words recalled or 
recognised in each part of the test will be calculated (a separate score for
immediate and for delayed memory will be produced). 
• Trail making tests (two parts). These assess psychomotor speed and cognitive 
flexibility within the executive functioning domain (26).  In Part A, participants will 
be asked to connect a series of encircled numbers in numerical order. In Part B 
they will be also asked to connect 25 encircled numbers and letters in numerical 
and alphabetical order in an alternating fashion. The score is the time to 
completion of each of the tasks.
• Grooved Pegboard test. This assesses psychomotor speed and fine motor function. 
It is a manipulative dexterity test consisting of 25 holes with randomly positioned 
slots. Pegs have a key along one side and they must be rotated to match the hole 
before they can be inserted. Participants are asked to insert the pegs into the slots 
as rapidly as possible, and the test will be performed with both the dominant and 
the non-dominant hand. The score is the time to completion of the task (each 
hand scored separately).
The participant will be given their raw test scores if so desired. The investigator will be 
provided with a table in which raw scores are categorised as average, above average, well 
above average based on standard population data so that some interpretation of the
participant’s score can be made, if the participant wishes results to be expressed in that way. 
The final evaluation of each participant’s neurocognitive function will be done centrally to 
calculate a neurocognitive function summary score, as described in section 9.5.2. 
7.3 Procedures for assessing safety
A symptom evaluation and targeted physical examination will be performed at each visit. 
Body composition changes will be evaluated at baseline and annual visits as follows: 
• Waist circumference will be measured between the lower border of the ribs and 
the iliac crest, in a horizontal plane.
• Hip circumference will be measured at the widest point over the buttocks. 
• Patients will be asked about any loss of fat in the face, and asked to say whether 
they consider that these changes are easily noticed by others (classified as 
severe). The physician will confirm on examination whether the patient has readily 
noticeable facial lipoatrophy (classified as severe). 
Cardiovascular risk factors will be assessed at annual trial visits, and risk will be quantified 
using charts based on the Framingham equation (19) (see Appendix 11).
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Blood will be drawn at trial visits to assess laboratory safety parameters according to 
standard-of-care as indicated in the sched ule of trial assessments (see section 1.3).
Additional safety blood tests or investigations will be performed to investigate symptoms or 
monitor emergent laboratory test abnormalities as clinically indicated. 
All adverse events will be reported on the case report form. Adverse events (clinical and 
laboratory) will be graded using the 1992 Division of AIDS toxicity grading scale (see 
Appendix 7). Serious adverse events will be defined according to the EU Directive
2001/20/EC Article 2 based on ICH GCP, and will be reported to the MRC CTU according to 
standard timelines (see section 11). 
Diagnostic criteria for selected serious AIDS and non-AIDS events are defined in the protocol 
(see section 9.2.2 and Appendices 8 and 9), and sites will be encouraged to investigate
patients in a way that allows determination of whether patients meet the specified diagnostic 
criteria. An independent endpoint review committee will review these endpoints to ensure 
that they satisfy the criteria. 
7.3.1 Procedures for Therapeutic Drug Monitoring
Patients in the PI monotherapy arm will have a blood sample taken at Week 4 (and possibly 
repeated at W eek 8 or 12) for measurement of PI concentration. The sample should be a 
trough sample (i.e. taken at the time when the next dose of medication would ordinarily be 
due) if at all possible, or obtained at the very least 4 hours following the last dose. The time 
of the last dose of PI taken will be recorded. 
Samples will be sent from sites using the normal procedures for dispatching samples for
therapeutic drug monitoring which is performed in the UK by Delphic Diagnostics. Results will 
be made available to the sites within approximately 2 weeks of sample collection. When a 
trough sample was not available, population pharmacokinetic data will be used to predict the 
trough level. Advice on whether dose modification of the PI may be indicated will be 
provided with the result.
PI concentration will also be measured in patients who have a confirmed VL rebound, to 
assist with the interpretation of the causes of rebound. These samples may be stored for 
later testing in batches. The results will not be essential for clinical care because the patient 
will have switched back to triple -therapy. The results will be reported to the treating clinician 
but this may not be in real time. 
7.4 Procedures for assessing health economics
The trial will measure all the costs (from an NHS perspective) of participants in the trial 
regardless of why costs were incurred, starting 3 months prior to randomisation and
continuing for the duration of follow-up. Data on service receipt (resource utilisation) will be 
collected at each trial visit by asking patients about visits to HIV clinics or GPs, days off work 
due to illness, and any periods of hospitalisation since the previous trial visit (or during the 3 
months prior to randomisation). The duration of hospitalisation and main diagnosis will be 
recorded (verified if possible by reference to a hospital discharge summary). Patients will 
complete the EQ-5D questionnaire (see Appendix 5) at each trial visit to permit cost-utility
analysis (27).
7.5 Trial closure
All patients will be followed according to the trial schedule until a common trial closing date. 
The trial will be closed after all data queries have been resolved.
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8. LOSS TO FOLLOW-UP & WITHDRAWAL
8.1 Patient transfers
For patients moving from the clinical site, every effort should be made for the patient to be 
followed-up at another participating trial centre and for this trial centre to take over
responsibility for the patient. MRC CTU should be informed and a copy of the patient CRFs 
will need to be provided to the new site. The patient will have to sign a consent form at the 
new site, and until this occurs, the patient remains the responsibility of the original centre.
8.2 Loss to follow-up
A patient will be regarded as ‘lost to follow-up’ if they have not been seen in clinic for more 
than 8 months. After this time, a check will be performed  through disease databases or 
death registers (e.g. Office for National Statistics, CDSC Colindale). Consent will be obtained 
for this when the patient enters the trial (see Appendix 2). Subsequently, if the patient 
attends clinic and a CRF is received by the MRC CTU, the ‘lost to follow-up’ status will be 
reversed.
8.3 Withdrawal of consent
In consenting to the trial, patients are consenting to treatment according to the allocated 
treatment strategy as well as to trial follow-up visits and data collection. If a patient wishes 
to withdraw from the trial treatment strategy, the doctor/nurse will explain the importance of 
remaining on trial follow-up or, failing this, of allowing routine clinic follow-up data to be 
used for trial purposes. 
If the patient explicitly states their wish not to contribute further data to the trial, the trial 
doctor should inform the MRC CTU in writing (i.e. a withdrawal CRF should be completed). 
Data up to the point of withdrawal can be included in the analysis. Further data i.e. vital
status can only be obtained through NHS databases and registers (as above).
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9. STATISTICAL CONSIDERATIONS
9.1 Method of randomisation
Patients will be randomised using a computer-generated algorithm based on random
permuted blocks.
9.2 Outcome measures
Analyses will compare the PI monotherapy and standard treatment arms on the following 
outcome measures: 
9.2.1 Primary outcome measure 
• Loss of future drug options
Defined as the first occurrence of intermediate to high level resistance to any one or 
more of the standard antiretroviral drugs (limited to licensed drugs in contemporary 
use) to which the patient’s virus was considered to be sensitive at trial entry (i.e. 
excluding drug resistance that was known to be present on previous resistance 
testing).
9.2.2 Secondary outcome measures
• Serious drug or disease-related complication
Defined as the first occurrence of one of the following in any individual patient:
o Death from any cause
o Serious AIDS-defining illness (see diagnostic criteria, Appendix 8) 
o Serious non-AIDS defining illness (see diagnostic criteria, Appendix 9)
Acute myocardial infarction
Coronary artery disease requiring invasive procedures
Cirrhosis
Acute liver failure 
End-stage renal disease
Stroke
Clinical acute pancreatitis
Severe lactic acidaemia
Severe facial lipoatrophy 
Severe peripheral neuropathy
Non-AIDS malignancy
• Adverse events
Defined as the total number of Grade III and IV adverse events.
• Virological rebound
Defined in two ways using the “Time to loss of virologic response” (TLOVR) algorithm
(28):
o Two consecutive tests, taken at least 4 weeks apart, with VL more than 50 
copies/ml (the first test must also be confirmed by re-testing the same blood 
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sample). Patients who have virological rebound in the PI monotherapy arm, 
but re-suppress VL to <50 copies/ml with re-introduction of NRTIs, will not 
count as failures; OR
o As above, with at least one of the samples giving a VL result more than 400 
copies/ml.
• CD4+ count change
Defined as change from baseline in absolute CD4+ count.
• Health-related Quality of Life change 
 Defined as change from baseline in the mental and physical health summary scores.
• Neurocognitive function change 
Defined as change from baseline in the neurocognitive function summary score.
• Cardiovascular risk change 
Defined as change from baseline in the risk of cardiovascular disease calculated from 
the Framingham equatio n (19).
• Health care costs 
Defined as the total cost of health care resources utilised per patient year.
9.2.3 Health economic analysis 
A full health economic analysis will be conducted to determine the relative cost-effectiveness
of the alternative management approaches.
9.3 Sample size
As the strategy of PI monotherapy is likely to offer a major advantage in terms of cost 
(approximately 50% cost reduction from standard-of-care) and possible advantages in terms 
of long-term tolerability compared to standard-of-care, the trial aims to demonstrate that PI 
monotherapy is non-inferior to the standard-of-care by a pre-defined amount in terms of the 
primary endpoint (non-inferiority trial).
The estimation of the sample size is based on the following assumptions using a time-to-
event analysis (29):
1. 90% of patients on the standard-of-care arm will maintain all future drug options (i.e. 
remain free of new resistance mutations) over three years. This figure is based on an 
analysis of resistance development during subsequent follow-up for patients who
have taken an established NNRTI-based regimen for at least 12 months in the UK 
CHIC study, following the methodology used by Phillips et al (30).
2. The PI monotherapy arm will be considered “non-inferior” if the upper limit of the 
95% confidence interval (2-sided) for the difference in the proportion of patients who 
maintain all future drug options over three years (standard-of-care – PI
monotherapy) is less than 10%. This is consistent with the majority of HIV non-
inferiority trials that use a cut-off of 10-15% and with FDA guidelines which 
recommend a cut-off of 10-12% (28, 31).
3. 85% power to detect non-inferiority according to criterion 2. 
4. Recruitment occurs at a uniform rate over 18-24 months.
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5. Total trial duration of 60 months. 
6. Cumulative loss to follow-up is approximately 10% by 5 years.
Under these assumptions a total of 388 patients (194 per arm) are required. We therefore 
plan to recruit a total of 400 patients to yield approximately 40 events. 
9.4 Interim monitoring and analyses
An Independent Data Monitoring Committee (IDMC) will be established to monitor the trial. 
A charter for the IDMC will be developed prior to starting the trial. The IDMC will meet 
around the time of trial initiation to establish terms of reference, after the first 100 patients 
recruited have reached 12 months of follow-up and at yearly intervals thereafter. The IDMC 
will also review safety data at each meeting, and may make recommendations about the 
conduct of the trial should any safety concerns be identified. 
9.5 Analysis plan 
A full statistical analysis plan will be developed before the trial is analysed. It will be based 
on the following summary:
9.5.1 Primary analysis
The primary analysis will compare the two groups as allocated (intention to treat, ITT) in 
terms of loss of future drug options (see precise definition of primary outcome measure, 
above). Time-to-event methods (Kaplan-Meier plots and Cox proportional hazard regression) 
will be used for this comparison.  Although non-inferiority trials often place especial emphasis 
on a per-protocol analysis, this is less relevant for a strategy trial (such as this) than for an 
explanatory trial comparing the therapeutic efficacy of two drugs. However, we will conduct 
a sensitivity analysis excluding patients who switch from their randomised allocation within 3 
months where this is due to personal preference rather than any clinical indication.  In both 
ITT and per-protocol analyses patients who have died or who are lost to follow-up will be 
censored at their last viral load measurement.  If non-inferiority is demonstrated, an analysis 
for superiority of the PI monotherapy arm will be performed.
9.5.2 Secondary analyses
The primary analysis will be extended to tabulate individual ART drug options and ART class 
options which are lost due to the development of resistance. Time-to-event methods will be 
used to analyse the rate of serious drug- or disease-related complications and for viral load 
rebound. Also, the frequency of grade III and IV adverse events will be tabulated by body
systems and randomised group and the groups will be compared using the X2 test. Repeated 
measures analysis will be used to compare change in CD4+ cell count from baseline in the 
allocated strategies. 
Patient responses on the MOS-HIV questionnaire will be converted to scores on 11
subscales, ranging from 0 to 100, with higher scores indicating better health (32). The 
scores are then synthesised into a physical health summary score (PHS) and a mental health 
summary score (MHS). A general linear mixed model will be used to compare the two groups 
in terms of changes from baseline in the summary PHS and MHS quality of life indexes over 
the follow-up period. 
The scores on each of the neurocognitive tests will be standardised using demographic-
adjusted normative means. This procedure will adjust the data for gender, age, level of 
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education and ethnic background. Briefly, standard scores will be calculated by subtracting 
the appropriate normative mean from the raw score and then dividing by the appropriate 
normative standard deviation to give a z score (33). The patient’s individual z scores on each 
test will be averaged to give the patient’s neurocognitive function summary score at each 
visit. A general linear mixed model will be used to compare the two groups in terms of 
changes from baseline in the neurocognitive function summary score.
Changes from baselin e in the 10-year cardiovascular risk score will also be compared 
between the two groups using a general linear mixed model. 
Economic analysis
An economic evaluation will be conducted from the health services perspective. Costs will 
cover the use of medication and laboratory tests as well as hospital, primary care and 
community health services. Unit costs will be attached to resource use, using the best 
available estimates of long run marginal opportunity cost, to obtain a cost per patient over 
the period of follow-up. Routinely available national unit costs will be used where possible 
(e.g.  NHS Reference Costs, UK DoH 2005), with local estimations where necessary. 
For the within-trial analysis, the differential cost of the treatment interventions will be related 
to their differential outcomes in terms of the primary outcome. The relative cost -
effectiveness of the alternative forms of management will then be assessed using standard 
decision rules (34) and a full stochastic analysis will be undertaken. A cost-utility analysis will 
also be conducted based on EQ-5D health states. For each state, a utility is assigned as an 
adjustment factor for quality of life. Utility weights range from 0 to 1 where 0 represents 
death and 1 signifies perfect health. The total utility of a particular state is made up of the 
length of time spent in a state multiplied by the utility of that state. This will offer a simpler 
decision rule and allow explorations of cost per quality -adjusted life-year gained (QALY) (35).
A cost consequence analysis will estimate, by randomised group, mean cost per patient and 
changes in EQ-5D ‘utility’.  Regression modelling will be used to explore variation in costs 
and utilities according to patient characteristic s and by location of treatment (36) (37).
The within-trial analysis will be augmented by extrapolation beyond the trial follow-up using 
decision-analytic modelling (38). The aim of this analysis will be to predict the implications of 
any difference in clinical endpoints (in terms of drug therapy options, VL and viral
sequencing for resistance mutations) in the trial for subsequent quality-adjusted survival 
duration and long-term resource costs. This will inform the question of whether any short-
term savings in drug costs within the trial period are offset by additional costs or health 
decrements in the long-term. The model will probably take the form of a state transition 
model and is likely to be based on a model currently in development as part of the OPTIMA 
(www.optimatrial.org/uk) trial. The ultimate outputs of the economic evaluation will be 
estimates, by treatment group, of long-term quality-adjusted survival duration and costs 
including the presentation of incremental cost per quality adjusted life year as necessary. In 
addition, probabilistic methods will be used to present the probability that the two forms of 
management are cost-effective in the long-term. Scenario analysis will be used to explore 
the range of structural assumptions used in the analysis.
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10. TRIAL MONITORING
10.1 Risk assessment
The trial will use only licensed drugs, and the risks and management of drug -related
toxicities are known. The trial is classified as low risk and the monitoring plan has been 
designed accordingly. 
10.2 Monitoring at MRC CTU
Data stored at MRC CTU will be checked for missing or unusual values (range checks) and 
checked for consistency within participants over time.  If any such problems are identified, 
the site will be contacted and asked to verify or correct the entry. Any data which are 
changed should be crossed through with a single line and initialled. Changes should be made 
on the original CRF and a copy of the amended page(s) will be sent to the MRC CTU by fax 
or post.  MRC CTU will send reminders for any overdue and/or missing data.
10.3 Clinical site monitoring
On-site monitoring will be conducted at all sites at a frequency of at least one visit per year. 
The first monitoring visit for each site will be performed after 4-6 patients have been 
enrolled or at 6 months following the date the site received approval to enrol patients, 
whichever occurs first. The CRFs of all patients enrolled will be reviewed at the first 
monitoring visit. For high-recruiting sites, a sample of no less than 5 patients will be selected 
by the MRC CTU for review at subsequent visits. Priority will be given to selecting patients 
for whom the CRFs have not been previously monitored. 
MRC monitors will:
• verify completeness of Trial Master File
• confirm adherence to protocol
• review eligibility verification and consent procedures
• look for missed event reporting
• verify completeness, consistency and accuracy of data being entered on CRFs 
• provide additional training as needed 
The monitors will require access to all patient medical records including, but not limited to, 
laboratory test results and prescriptions. The investigator (or delegated deputy) should work 
with the monitor to ensure that any problems detected are resolved. 
10.4  Data quality assurance
Data will be entered into the trial database at the MRC CTU from a copy of the CRF faxed or 
sent from the site. The site will retain the original CRF. Where possible de-identified
laboratory reports (labelled with patient trial identification number) will be faxed to the MRC 
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CTU. All data recorded in each CRF will be entered on to the trial database, and then printed
reports directly obtained from the database will be checked by different data-entry
personnel.
10.5 Confidentiality of trial documents and patient records
The investigator must assure that patients’ anonymity will be maintained and that their 
identities are protected from unauthorised parties. Patients will be assigned a trial
identification number and this will be used on CRFs, patients will not be identified by their 
name. The investigator will keep securely a patient trial register showing identification 
numbers, names and date of birth. 
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11. SAFETY REPORTING
ICH GCP requires that both investigators and sponsors follow specific procedures when 
notifying and reporting adverse events/reactions in clinical trials.  These procedures are 
described in this section of the protocol. Section 11.1 lists definitions, section 11.2 gives 
details of the institution/investigator responsibilities and section 11.3 provides information on 
MRC CTU responsibilities.
11.1 Definitions
The definitions of the EU Directive 2001/20/EC Article 2 based on ICH GCP apply in this trial 
protocol.  These definitions are given in Table 1.
Table 1: Safety Reporting Definitions
Term Definition
Adverse Event (AE) Any untoward medical occurrence in a patient or clinical trial subject 
to whom a medicinal product has been administered including 
occurrences which are not necessarily caused by or related to that 
product.
Adverse Reaction (AR) Any untoward and unintended response to an investigational 
medicinal product related to any dose administered.
Unexpected Adverse 
Reaction (UAR)
An adverse reaction, the nature or severity of which is not consistent 
with the information about the medicinal product in question set out 
in the Summary of Product Characteristics (or Investigator Brochure) 
for that product.
Serious Adverse Event 
(SAE) or Serious Adverse 
Reaction (SAR) or 
Suspected Unexpected 
Serious Adverse Reaction 
(SUSAR)
Respectively any adverse event, adverse reaction or unexpected 
adverse reaction that:
• result s in death
• is life-threatening*
• requires hospitalisation or prolongation of existing 
hospitalisation**
• results in persistent or significant disability or incapacity
• consists of a congenital anomaly or birth defect 
11.1.1 Clarifications and Exceptions
*The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the 
patient was at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe.
**Hospitalisation is defined as an inpatient admission, regardless of length of stay, even if 
the hospitalisation is a precautionary measure for continued observation.  Hospitalisations for 
a pre-existing condition (including elective procedures that have not worsened) do not
constitute an SAE. 
Medical judgement should be exercised in deciding whether an AE/AR is serious in other 
situations.  Important AE/ARs that are not immediately life-threatening or do not result in 
death or hospitalisation but may jeopardise the subject or may require intervention to 
prevent one of the other outcomes listed in the definition above, should also be considered 
serious.
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11.2 Institution/Investigator responsibilities
11.2.1  Investigator Assessment 
(a) Seriousness
When an AE/AR occurs, the investigator responsible for the care of the patient must first 
assess whether the event is serious using the definition given in Table 1. 
(b) Causality
The Investigator must assess the causality of all serious events/reactions in relation to the 
trial therapy using the definitions in Table 2.  There are 5 categories: unrelated, unlikely, 
possible, probable and definitely related.  If the causality assessment is unrelated or unlikely 
to be related the event is classified as a SAE.  If the causality is assessed as either possible, 
probable or definitely related then the event is classified as a SAR. 
Table 2: Definitions of causality
Relationship Description Event Type
Unrelated There is no evidence of any causal relationship SAE
Unlikely There is little evidence to suggest there is a causal relationship 
(e.g. the event did not occur within a reasonable time after 
administration of the trial medication).  There is another 
reasonable explanation for the event (e.g. the patient’s clinical 
condition, other concomitant treatment).
SAE
Possible There is some evidence to suggest a causal relationship (e.g. 
because the event occurs within a reasonable time after 
administration of the trial medication).  However, the influence 
of other factors may have contributed to the event (e.g. the 
patient’s clinical condition, other concomitant treatments).
SAR
Probable There is evidence to suggest a causal relationship and the 
influence of other factors is unlikely.
SAR
Definitely There is clear evidence to suggest a causal relationship and 
other possible contributing factors can be ruled out.
SAR
(c) Expectedness
If the event is a SAR the Investigator must assess the expectedness of the event.  The 
definition of an unexpected adverse reaction (UAR) is given in Table 1.  If a SAR is assessed 
as being unexpected it becomes a SUSAR. 
(d) Notification 
P lea s e a ls o refer  to the s a fety  reporting f low cha rt on the follow ing pa ge
All AEs/ARs, whether expected or not, should be graded using the toxicity table in Appendix 
7 and should be then recorded in the toxicity (symptoms) section of the appropriate visit 
CRF. This should be sent to the MRC CTU within one month of the form being due. 
All non-treatment-related SAEs and all expected treatment-related SAEs (SARs) are
exempted  from expedited reporting i.e. only SUSARs require expedited reporting. (Adverse 
drug reactions to licensed PIs will continue to be reported by the investigator to the The 
Yellow Card Scheme run by the MHRA and Commission on Human Medicines). 
All SAEs/SARs, whether expected or not, should be graded using the toxicity table in 
Appendix 7 and should be then recorded on an Event CRF. Investigators should record all 
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SAEs occurring from the time of randomisation until 30 days after the last protocol treatment 
administration.
A Safety Reporting Flowchart (Figure 2) is given at the end of this section to help explain the 
classification and reporting of events. Any questions concerning this process should be
directed to the MRC CTU in the first instance. The notification procedure is as follows: 
1. The Event CRF must be completed by the investigator (clinician named on the
Delegation of Authority  log who is responsible for the patient’s care), with due care 
being paid to the grading, causality and expectedness of the event as outlined above.
In the absence of the responsible investigator, the form should be completed and signed 
by a member of the site trial team.  The responsible investigator should subsequently 
check the Event CRF, make changes as appropriate, sign and then re-fax to the MRC 
CTU as soon as possible.  The initial report shall be followed by detailed, written reports 
as appropriate.
2. Send the Event CRF by fax to the MRC CTU, fax number: + 44 (0)20 7670 4817.
3. Follow-up: Patients must be followed-up until clinical recovery is complete and
laboratory results have returned to normal or baseline, or until the event has stabilised.
Follow-up should continue after completion of protocol treatment if necessary.  Follow-
up information should be noted on a further Ev ent CRF by ticking the box marked 
‘follow-up’ and faxing to the MRC CTU as information becomes available.  Extra, 
annotated information and/or copies of test results may be provided separately.  The 
patient must be identified by trial number, date of birth  and initials only.  The patient’s 
name should not be used on any correspondence.
4. Staff at the institution must notify their local research ethics committee (LREC) of a 
SUSAR event (as per the institution’s standard local procedure). 
11.3 MRC CTU responsibilities
Medically qualified staff at the MRC CTU will review all event reports received.  The causality 
assessment given by the local investigator at the hospital cannot be overruled and in the 
case of disagreement, both opinions will be provided in any subsequent reports.
The MRC CTU is undertaking the duties of trial sponsor and is responsible for the reporting 
of SUSARs and other SARs to the regulatory authority (MHRA) and the research ethics 
committees according to standard procedures and within standard timelines.
The MRC CTU will keep all investigators informed of any safety issues that arise during the 
course of the trial. Every 6 months the CTU will write to the investigators listing all SUSARs,
providing information on the event, date of occurrence and body system. In addition, upon 
request of the TSC, the MRC CTU will inform investigators of any safety issues identified by 
the IDMC in their report(s) to the TSC. 
SUSAR NOTIFICATION
Within one working day of becoming aware of an SUSAR, please
fax a completed Event CRF to the MRC Clinical Trials Unit on:
Fax: +44 (0)20 7670 4817
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Definitely, Probably, Possibly
YES
NO
NO
Please
Grade
Unrelated or 
Unlikely  to 
be related
Adverse Event/Adverse Reaction
Was the event serious?
-Resulted in death
-Life-threatening
-Required inpatient hospitalisation or prolongation of    existing 
hospitalisation
-Persistent or significant disability/incapacity
-Congenital anomaly/birth defect
What is the causal relationship to 
protocol medication?
AE/AR: Grade I & II
Record on a routine visit 
CRF and send to the MRC 
CTU within one month of 
the CRF due date
SAE
Record on an Event CRF 
and send to the MRC CTU 
within one month of the 
CRF due date
SAR
Record on an Event CRF
and send to the MRC CTU 
within one month of the 
CRF due date
SUSAR
Record on an Event CRF
and notify the MRC CTU 
within one working day of 
site becoming aware of the 
event
CRF: Case Report Form IB: Investigator’s Brochure
SAE: Serious Adverse Event SAR: Serious Adverse Reaction
SmPC: Summary of Product Characteristics SUSAR: Suspected Unexpected Serious Adverse Reaction
Was the SAE one of the expected 
undesirable effects of the trial 
medication (i.e. listed in the Summary of 
Product Characteristics)?
YES AE/AR: Grade III & IV
Record on an Event CRF
and send to the MRC CTU 
within one month of the 
CRF due date
Figure 2: Safety Reporting Flowchart 
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12. ETHICAL CONSIDERATIONS & APPROVAL
12.1 Ethical considerations
12.1.1  Risks and benefits to trial participants 
See section 2.3 for detailed discussion of risks and benefits of the PI monotherapy strategy 
used in this trial. The risks include the risk of side effects arising from the change in 
medication, which are known and quantifiable since the trial will only use licensed drugs. 
There is a very small increased risk of cardiovascular disease that may be partially abrogated 
by medication to treat hypercholesterolaemia, a potential increased risk of virological failure 
with the development of drug resistance, and the poten tial risk of virological rebound in the 
genital compartment with the theoretical increased risk of HIV transmission to others. These 
risks are all very small. 
The benefits may be a potential reduced risk of long-term toxicity resulting from withdrawal 
of other medications, and the potential reduced risk of virological failure and drug resistance 
thereby leading to better preservation of future drug options. The trial may benefit society 
by finding an alternative long -term HIV disease management option. 
12.1.2  Burden of investigations 
The trial will use only licensed drugs, and the risk and management of drug -related toxicities 
are known. There is no placebo used. The protocol allows for switches within strategy. Apart 
from 2 extra monitoring blood tests in th e first 6 months after enrolment in the PI
monotherapy arm, the remainder of the trial visits coincide with the usual frequency of visits 
for routine clinical care, and the amount of extra blood taken is modest. Hence there are no 
ethical issues with the b urden of investigations. 
12.1.3 Informing potential trial participants of possible benefits and known risks
Participants will be informed fully of known risks and possible benefits by means of a patient 
information sheet and this will be reinforced by discussions with the trial research teams at 
the individual sites prior to enrollment. 
12.1.4  Confidentiality
Patients’ confidentiality will be maintained throughout the trial. Data submitted to MRC CTU 
and samples sent to central testing facilities will be identified only by the trial number and 
patient initials. 
12.2 Ethical approval
The protocol will be submitted for ethical approval to an independent research ethics 
committee (REC) in the UK and for Site Specific Assessment at each of the participating 
sites. A copy of local R&D approval and the Patient Information Sheet and Consent Form on 
local-headed paper should be forwarded to the MRC CTU before the first patient is enrolled 
at site. 
Each patient’s consent to participate in the trial will be obtained after a fu ll explanation has 
been given of the treatment options. The right of the patient to refuse to participate in the 
trial without giving reasons must be respected. 
After the patient has entered the trial, the clinician must remain free to give alternative 
treatment to that specified in the protocol, at any stage, if he/she feels it to be in the best 
interest of the patient. However, the reason for doing so should be recorded and the patient 
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will remain within the trial for the purpose of follow-up and data analysis according to the 
treatment option to which they have been allocated. Similarly, the patient must remain free 
to withdraw from the trial medicine or trial follow-up, at any time, without giving reasons 
and without prejudicing his/her further treatment.
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13. REGULATORY ISSUES
This trial will be reviewed by an independent research ethics committee (REC) in the UK. The 
trial will be registered with the Competent Authority, the Medicines and Healthcare products 
Regulatory Agency (MHRA) UK. 
This trial has been granted a UK Clinical Trial Authorisation (CTA), reference 2007-006448-
23.
Investigators may not enrol patients into this trial until: 
• The necessary notification or approval of the protocol and any amendments has 
been given by the MHRA.
• The approval of the protocol and any amendments has been given by the REC. 
• The approval of the institution’s local ethics committee and R&D has been 
obtained.
During the course of the trial the MHRA or REC may request review of trial and data on 
patients involved  in the trial.
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14. INDEMNITY
The MRC is the sponsor of the trial. The MRC and NHS are both publicly funded bodies and 
are not allowed to purchase advance insurance to cover indemnity because they are backed 
by the resources of the Treasury. 
14.1 Liability
14.1.1  Circumstances where MRC will accept liability
The MRC is willing to accept liability in cases where:
(i) it sponsors the research: namely where it takes responsibility for initiating, managing 
and having day-to-day oversight of the research in question (including any research 
carried out by its Units); and 
(ii) the MRC, or any of its employees, or any person formally acting with Council’s 
authority, have been negligent or have failed to adhere to the relevant
guidelines/guidance, legislation or procedure on good practice in relation to medical 
research; and 
(iii) that negligence or failure to adhere to legislation, etc has caused or has materially 
contributed to the harm suffered by the individual making the claim.
Except in cases where a no-fault compensation scheme has been established with respect to 
a specified clinical trial, where there has been no negligence and no lapse in procedures or 
adherence to relevant legislation or accepted best practice on the part of the MRC, the MRC 
will not accept legal liability for any injury or harm suffered by a participant of a research 
project (in other words the MRC will not accept that the MRC is legally required to make any 
payment in respect of any injury or death arising from a research project). In such
circumstances, the MRC will, on a voluntary basis, be prepared to consider making an ex
gratia payment to any individual who suffers harm as a result of being involved in the 
research, but only if:
(iv) the MRC is the sponsor of the research (as in 14.1.1 (i) above); and
(v) where the MRC is a joint sponsor of the research, the harm has not occurred due to 
the negligence or other fault of the other sponsor(s) - in such cases the MRC would 
expect that the other sponsor would provide indemnity.
Requests for compensation or ex gratia payments in such circumstances will be considered 
on a case-by-case basis in relation to the MRC policy on such payments.
14.1.2  Circumstances where MRC will not accept liability
Where medical research is carried out in a care organisation, whether the NHS or another
organisation, that care organisation will continue to owe the same duty of care to patients 
who are also participants in research that it owes to any other patients. This duty is not 
affected by patients agreeing to participate in such research or th e fact that the MRC may be 
the sponsor of such research. Care organisations (and not the MRC) continue to be
responsible for any breaches of that duty of care with respect to participants of research. 
Similarly, responsibility for the quality of investigat ional products (e.g. investigational
medicinal products, investigational devices) lies with the manufacturer of the product.
If the patient is harmed as a result of negligence of NHS staff while participating in this trial, 
then they may be able to seek compensation. In this situation indemnity is provided by NHS 
indemnity schemes and professional indemnity schemes. 
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15. FINANCE
The trial is funded by the NIHR Health Technology Assessment Programme. The HTA
programme is part of the National Institute for Health Research. It produces independent 
research information about the effectiveness, costs and broader impact of healthcare
treatments and tests for those who plan, provide or receive care in the NHS.
The trial will be coordinated by the MRC CTU. A written agreement with the site Principal 
Investigator and/or the Investigator’s institution and the MRC CTU will outline the funding 
arrangements to sites.
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Clinical Trials Unit
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16. TRIAL COMMITTEES
16.1 Trial Management Group 
A trial management group (TMG) that will include the MRC CTU trial physician and/or chief 
investigator, the trial statistician, the MRC trial manager and data manager will be formed to 
conduct the day-to-day management of the trial. A charter will be developed to describe the 
functioning of the TMG. 
16.2 Trial Steering Committee 
A Trial Steering Committee (TSC) will be formed to provide overall supervision for the trial. 
This will include an independent Chairman, two other independent clinicians, a community 
representative, the Chief Investigator, external clinical principal investigator and the trial 
statistician. A charter will be developed to describe the functioning of the TSC. 
16.3 Independent Data Monitoring Committee 
An Independent Data Monitoring Committee (IDMC) will be formed comprising two clinicians, 
a community representative, and a statistician, none of whom have direct involvement with 
the trial. The IDMC will report to the TSC. A charter will be developed to describe the 
functioning of the IDMC.
16.4 Endpoint Review Committee 
An Endpoint Review Committee (ERC) will be formed to review the documentation relating to 
reported serious drug or disease-related clinical events, in order to ascertain whether these 
meet the criteria for this secondary endpoint. The ERC will consist of two clinicians, one of 
whom will not be directly involved with the trial. 
Figure 3: Diagram of relationships between trial committees
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17. PUBLICATION
It is anticipated that a number of opportunities will arise for publication during the course of, 
and following completion of this trial. In order to avoid disputes regarding authorship, it is 
important to establish a consensus approach that will provide a framework for all
publications derived in full or in part from this clinical trial. The following approach is derived 
from the Lancet an d from the publication policies used in OPTIMA and ESPRIT studies: 
• All publications are to be approved by the TMG and TSC before submission for
publication. The TMG and TSC will resolve problems of authorship and maintain the 
quality of publications.
• Trial findings will be submitted to journal(s) that support open access publication within 
the time frame specified by the MRC policy. All publications will acknowledge the HTA 
and any other appropriate funding sources. 
• For all publications, the TSC will either nominate a chairperson or approve an
individual’s request to chair a manuscript writing committee. The chair will usually be 
the primary or senior author. The chairperson is responsible for identifying fellow 
authors and for determining with that group the order of authorship that will appear on 
the manuscript. The proposed writing committee will be submitted to the TSC for
ratification prior to the first draft of the manuscript. 
• The chairperson of any writing committee will also provide the TSC with a list of 
investigators to be presented in an appendix at the end of the paper. This list will 
include investigators who contributed to the investigation being reported but who are 
not members of the writing committee. In principle, sub-study reports should include 
all investigators for the main study, although in some instances where a smaller 
number of investigators have made any form of contribution, it may be appropriate to 
abbreviate the listing. All headline authors in any publication arising from the main 
study or sub -studies must have a made a significant academic/project management 
contribution to the work that is being presented. “Significant” must be defined by a 
written declaration of exactly what the contribution of any individual is believed to have 
been. In addition to fulfilling the criteria based on contribution, additional features that 
will be considered in selecting an authorship group will include the recruitment of
patients who contributed data to any set of analyses contained in the manuscript, and 
/or the conduct of analyses (laboratory and statistical), leadership and coordination of 
the project in the absence of a clear academic contribution.
• The data derived from this clinical trial are considered the property of the MRC. The 
presentation or publication of any data collected by the participating investigators on 
patients entered into this trial is under the direct control of the TMG and TSC. This is 
true whether the publication or presentation is concerned directly with the results of 
the trial or is associated with the trial in some other way. However, although individual 
participating investigators will not have any inherent right to perform analyses or
interpretations or to make public presentations or seek publication of any of the data 
other than under the auspices of and with the approval of the TMG and TSC, they will 
be encouraged to develop sub-studies or propose analyses subject to the approval by 
the TMG and TSC. 
• Outcome data by treatment group will not be revealed to the participating investigators 
until the data collection phase of the trial has been completed. This policy safeguards 
against possible bias affecting the data collection. The IDMC will be monitoring the 
outcome results and may recommend that the trial be stopped for safety reasons or if 
a definitive answer is reached earlier than the scheduled end of the trial.
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APPENDIX 1: PATIENT INFORMATION SHEET
 [To be presented on local-headed paper]
Patient Information Sheet – Part 1
Version 1.1, 25 March 2008
1. Study title
PIVOT: Protease Inhibitor monotherapy Versus Ongoing Triple-therapy in long -term
management of HIV disease 
EUDRACT: 2007-006448-23
ISRCTN04857074
2. Invitation
You are being invited to take part in a research study. Before you decide whether to take 
part it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it with 
others if you wish. 
• Part 1 tells you the purpose of this study and what will happen to you if you take part.
• Part 2 gives you more detailed information about how the study will be carried out.
Ask us if there is anything that is not clear or if you would like more information. Take time 
to decide whether or not you wish to take part. Thank you for reading this.
3. What is the purpose of the study?
Currently, we use a combination of three drugs to treat HIV. These drugs are called anti-
retroviral treatment o r ART. The drugs that usually make up ART are:
• two nucleoside reverse transcriptase inhibitors (NRTIs) 
• one non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI)
These drugs seem to be very effective and do not cause many side effects in the short-term,
but they do need to be taken life-long and may be associated with side effects after many 
years. It is possible that there are alternatives to triple therapy that are just as effective and 
have less long-term side effects. It is also possible that there are alternatives that, in the 
long run, will be less susceptible to develop drug resistance and so will preserve more 
treatment choices for the future.
One possible long-term treatment option is to simplify treatment to just one drug, a PI, 
instead of the standard triple therapy. There is some evidence from previous clinical trials 
that patients who are stable on triple-therapy can simplify their treatment to PI monotherapy 
(one drug) and successfully maintain undetectable viral load as well as experience less side 
effects when they stop their NRTIs. 
The purpose of this study is to find out whether a strategy of trying PI monotherapy, with 
the plan of switching back to triple therapy if viral load control is not adequate, is just as 
good as continuing standard triple -therapy in long-term treatment of HIV disease.
4. Why have I been chosen?
You have been chosen for this study because you are taking standard combination ART, 
described above, and you have had an undetectable viral load for at least the last 6 months. 
Overall 400 patients like you will take part in the study. 
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5. Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time and without giving a reason. A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard -of-care you 
receive.
6. What will happen to me if I take part?
S tudy screening and entry
Before you join the study, we will need to review your medical history and do some tests to 
make sure you are suitable. You will need to come to the clinic in the morning with an empty
stomach (nothing to eat or drink from midnight before the visit, other than water and your 
medication) so that we can measure your cholesterol and glucose as well as some other 
routine blood tests. We will also need to perform an ECG (an electrical recording of your 
heart). Some of these tests may not need to be repeated if you have had them done in the 
previous 6 months. If these tests do not show any major abnormalities and you meet all the 
criteria for the study, then will be able to participate in the study.
S tudy trea tm ent 
The study is a randomised controlled clinical trial. This means that once you have agreed to 
enter the trial, you will be allocated by chance to either the standard triple-therapy group or 
the PI monotherapy group. Everyone has an equal chance of being in either group.
Allocating treatment this way means that the groups of people getting each treatment 
should be similar, so that if there are any differences between how the groups do we know it 
will be due to the treatment allocation.
If you are allocated to the standard treatment group, you will carry on with your current 
treatment and continue to have regular monitoring as described in the next paragraph. You 
will be able to change your therapy in the future if there is a good clinical reason to do so 
(for example, if you develop viral load rebound or side-effects from the drugs), but if you 
change therapy it should be according to current guidelines (i.e. should consist of at least 3 
drugs which are effective against HIV). 
If you are allocated to the PI monotherapy group, you will stop all your current ART drugs 
that are not PIs, and will start or continue on just a boosted PI (boosted means it is given 
with a small dose of ritonavir, another PI, to increase the level of the main PI and to allow 
less frequent dosing). There are several PIs that may be considered for use as monotherapy, 
and the choice of which PI to take will be left up to you and your clinic doctor to decide. 
Your clinic doctor will be able to advise you on the relative merits of the different PIs, as 
they may differ in terms of the dose frequency, potential side effects, and possibly in 
effectiveness. You will be able to change to an alternative PI as monotherapy during the 
study if you develop any side-effects or if there are other reasons why you, or your doctor,
believe that an alternative PI might be better for you. You will be expected to continue 
treatment with PI monotherapy until the end of the study, but you will be able to return to 
standard triple therapy if there is a good clinical reason to do so (for example you develop 
viral load rebound, or you develop side effects from the PI that you are on that cannot be 
controlled satisfactorily with additional medication or by switching to an alternative PI). If 
you do need to return to taking standard triple-therapy that will usually be the same 
combination that you were taking when you entered the study. During the study you will 
continue to have regular monitoring as described in the next section.
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S tudy a s s es s m ents  a nd follow-u p
You will be involved in the study for about 3 to 5 years (depends on how long the study has 
already been running when you join), during which time you will need to visit the clinic on a 
regular basis to check how you are doing. However, the clinic visits are at approximately the 
same frequency that you would be coming to the clinic anyway for routine care, even if you 
were not taking part in the study. The visits will be at Day 0 (the day you enter the study 
and that you change to PI monotherapy, if allocated to that option) and then approximately 
every 12 weeks up to the end of the study. 
At each of these routine visits the research nurse and/or your doctor will ask you a few 
questions about your medication and whether you have any symptoms, and may perform a 
brief examination. They will ask you to complete a checklist of your health status (takes less 
than 1 minute to do)  and will draw some blood for routine blood tests (viral load, CD4 
count, full blood count, kidney and liver function tests). These routine visits (which account 
for most of the visits in the study) are very similar to what you would have done anyway as 
part of your normal care. 
At the week 12 visit, the  annual study visits (every 48 weeks) and the last study visit, you 
will need to come in the morning with an empty stomach (nothing to eat or drink from 
midnight before the visit, other than water and your medication) so that we can also 
measure the level of cholesterol and glucose in your blood. We will also take an extra tube of 
blood at this visit to store in case future tests are needed. In addition to the assessments 
done at the routine visits, we will also do some neurocognitive (brain function) tests that 
involve testing your memory and reaction times, and ask you to fill in a quality of life 
questionnaire. These simple tests will take about 15 minutes in total. 
If you are allocated to the PI monotherapy group, you will also need to come for two extra 
visits, at 4 weeks and 8 weeks after you start on your new treatment. For the week 4 visit, 
you will need to come in the morning with an empty stomach (nothing to eat or drink from 
midnight before the visit, other than water and your non-ART medication) and postpone your 
morning dose of PI medication until after the blood has been drawn. At this visit the
research nurse or doctor will review how you are getting on with the new treatment, and will 
draw some blood for routine tests (including viral load, full blood count, kidney and liver 
function, cholesterol and glucose) and to measure the concentration of the PI in your blood. 
We will also take 1 extra tube of blood for storage in case of the need for future tests. At the 
week 8 visit, you will just have a blood sample taken for measurement of viral load (and 
possibly to check the PI concentration again, if the levels were low on the first test). 
The total amount of blood needed for these routine tests will be about 40ml at screening, (8 
teaspoons), 25ml (5 teaspoons) at day 0 and for most of the routine 12 weekly visits, and 
35ml (7 teaspoons) at the week 12, annual and final study visits. For the week 4 and week 8 
visits for those in the PI monotherapy group only, the amount of blood needed will be about 
35ml (7 teaspoons) and 10ml (2 teaspoons) respectively . Almost all these blood samples 
would need to be drawn anyway for your routine care and the total amount of additional 
blood taken for specific research-related tests will average no more than 15ml (3 teaspoons) 
per year during the study. 
In addition to  these routine visits, if you have a rebound of viral load while you are in the 
study you will be recalled for a repeat viral load test at between 4 to 6 weeks from the date 
of the previous test. If this test confirms a rebound of viral load your clinic doctor will discuss 
with you the need to change your treatment. If you are in the PI monotherapy arm, this will 
mean restarting triple -therapy. If you have viral load rebound, the sample will also be sent 
for a resistance test, the results of which may guide you and your doctor as to the best 
choice of medication for you. At the end of the study all samples with viral load rebound will 
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be tested again using a very sensitive resistance test at a central laboratory to give the best 
information possible on resistance. All these results will be provided to your doctor. 
You will not be paid to take part in the study, but your clinic may be able to reimburse 
reasonable travel expenses.
7. What do I have to do?
There are no particular lifestyle or dietary restrictions required for participating in this study, 
other than those associated with taking your medication each day. You will be expected to 
adhere to your study medication according to your allocated treatment group for the
duration of the study, and to come for the clinic visits according to the study schedule. You 
will need to tell your doctor before you take any other medication or herbal treatments as 
some of these may interact with the PI or your other HIV medications. 
8. What are the alternatives for treatment?
The alternative for treatment, if you don’t participate in this trial, is to simply carry on with 
your usual combination HIV therapy, or to switch to other alternative treatments based on 
combinations of currently -licensed ART drugs. If you are experiencing unpleasant side 
effects from your current therapy then you should discuss with your doctor about switching 
to an alternative triple -therapy for at least 3 months before entering this trial. You should not 
enter the study if the side effects of your current therapy are so bad that they mean you 
would not be prepared to continue the treatment you are currently on for the duration of the 
study (which will be at least 3 years) if you were allocated to the combination therapy group.
9. What are the side-effects of any treatment received when taking part?
Both standard therapy and PI monotherapy may cause side effects during the course of this 
study. The side effects of PIs vary according to the particular drug taken, but the PIs that 
are most often prescribed now are generally well tolerated. The commonest side effects are 
gastrointestinal intolerance (such as diarrhoea or nausea), metabolic disturbances (such as 
high cholesterol and high blood sugar) and increased bilirubin level (which is harmless, but 
produces a yellow discoloration in the eyes). These side effects are mainly associated with 
particular drug(s), and can usually be managed by taking additional medication (e.g. to 
lower cholesterol) or by switching to an alternative PI. Your doctor will discuss with you the 
possible side effects of the PI that you choose to use, and will advise you on the appropriate 
management of any side-effects.
If you do develop any symptoms you should report them to your doctor. If you experience 
any serious side effects you should contact a member of the study team according to the 
contact details given on the emergency contact card.
10. What are the possible disadvantages and risks of taking part?
Possible risks and discomforts include the development of local bruising and discomfort 
where needles are inserted into a vein to collect blood, although you would be having blood 
taken as part of your routine care with approximately the same frequency even if you were 
not participating in this study. 
If you are not taking a boosted PI-containing combination when you enter the study, there is 
a risk that you will develop new side effects if you are allocated to the PI monotherapy group 
and need to start a boosted PI. However, these side effects (outlined in quest ion 9) can 
usually be controlled with changes in dose, switch to an alternative PI medication, or use of 
additional medication (e.g. to reduce cholesterol).
We expect that a small proportion of patients will experience low level viral load rebound 
when they switch to PI monotherapy (likely no more than 5-10%). Those who do rebound 
will need to switch promptly back to triple-therapy. It is almost certain, based on scientific 
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knowledge and results from other studies, that reintroduction of combination therapy will be 
successful in suppressing viral load to undetectable levels again. The risk of developing 
clinical resistance to the PI during this short time with a low level of viral load is very small. 
Overall, the risk of developing drug resistance appears to be no greater with PI monotherapy 
treatment than it is with triple-therapy. If you do develop resistance during the study, there 
are likely to be several other options available to you for treatment that have a high chance 
of success, and your clinic doctor will discuss these with you.
If you are taking PI monotherapy there is a theoretical risk of developing viral rebound and 
drug resistance in parts of the body where PIs do not achieve high levels (such as the brain 
and genital tract), even though the treatment is working well in suppressing viral replication 
in your blood. There is no evidence to date that this is associated with any adverse clinical 
consequences for you. If you have detectable viral load in genital secretions, there is a 
theoretically increased risk that you might transmit HIV to someone else if you do not 
practise safe sex. You should consider this risk to others carefully and we suggest that you 
discuss this with any regular sexual partner(s) before deciding whether or not to participate
in this study .
If you are a woman who is pregnant, you should not enter this study. This is because 
current guidelines recommend that pregnant women should take combination therapy (PI 
monotherapy has not been tested) to prevent transmission to their unborn child. Although 
pregnant women have taken PIs in the past without harming the baby, it is possible that 
taking a PI during pregnancy may harm the unborn child. If you find that you have become 
pregnant while taking part in the study, you should immediately tell your study doctor. Any 
necessary changes to your ART combination during the pregnancy are permitted in this 
study.
If you have private medical insurance you should check with the company before agreeing to 
take part in the trial to en sure that your participation will not affect your medical insurance. 
In this situation you also need to consider whether disclosure of your HIV status may also 
affect your insurance.
11. What are the possible benefits of taking part?
If you take part and are allocated to the PI monotherapy group, you may have a reduced 
risk of long-term side effects by stopping the drugs you were taking as part of your triple 
combination therapy. The long-term side effects that you may be spared depend on the 
particular drugs that you stopped. They may include things like kidney damage, liver 
damage, nerve damage, loss of fat in the face, arms and legs and other long-term unwanted 
side-effects, both known and unknown, associated with NRTIs; metabolic disturbances (e.g. 
high cholesterol) and chronic neuropsychiatric problems (e.g. sleep disturbance, memory 
loss, poor concentration) associated with NNRTIs (especially efavirenz). 
There is also a possibility that you may have less drug resistance and maintain more future 
long-term treatment options at the end of the study if you take PI monotherapy (because PI 
drugs are generally less prone to develop resistance). 
You may also appreciate or benefit from some of the extra testing that is done as part of this 
study, for example the neurocognitive tests, the PI drug level testing (in the PI monotherapy 
group), the more detailed drug resistance testing as well as the extra attention to details of 
your care that is associated with participation in a clinical trial. 
If you take part in this study, you’ll be helping us to learn more about the best ways to treat 
people with HIV. Having people like you join a randomised  controlled trial is the only way 
that we can find out for sure whether PI monotherapy is as good as (or perhaps better than) 
conventional combination treatment for the long-term management of HIV disease. If the 
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study does show that PI monotherapy is at least as good as conventional treatment then this 
will be an important finding. It will increase the number of treatment options available for 
long-term management of HIV disease and this may be of benefit to you and other people 
like you in the future. PI monotherapy is more economical than triple-therapy, so if it works 
as well as triple-therapy, we’ll be able to free up healthcare resources that could be used to 
improve other aspects of HIV care. 
12. What happens when the research study stops?
When the study ends, you will still be able to continue to access medication and continue to 
be monitored as part of routine clinical care. If you are doing well on PI monotherapy you 
could continue this if you and your doctor wish to do so, or switch back to combination 
triple-therapy while you wait to hear about the results from the trial. If you are on 
combination therapy, it would be sensible to continue this while you wait for the results of 
the trial. When the results of the trial are available your doctor will talk with you about which 
option would be the best for you in the long-term.
13. What if there is a problem?
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed individually. Detailed information on this is given in 
Part 2 of the information sheet.
14. Will my taking part in this study be kept confidential?
Yes, all the information about your participation in this study will be kept confidential. The 
details are included in Part 2.
15. Contact for Further Information
If you have any further questions about this study please discuss them with your doctor. You 
may also find it helpful to contact the i-Base Treatment Information phone line: 0808 800 
6013 (open Mon-Wed 12-4pm), or website: www.i-base.org.uk
If you would like further information on this study please ask:
……………………………………………………… who can be contacted at ……………………………………….
or …………………………………………………...at …………………………………. who is the local principal 
investigator.
This completes Part 1 of the Information Sheet.
If the information in Part 1 has interested you and you are considering
participation, please continue to read the additional information in Part 2 before 
making any decision.
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[To be presented on local-headed paper]
Patient Information Sheet – Part 2
Version 1.1, 25 March 2008 
1. Study title
PIVOT:  Protease Inhibitor monotherapy Versus Ongoing Triple-therapy in long-term
management of HIV disease
EUDRACT: 2007-006448-23
ISRCTN04857074
2. What if relevant new information becomes available?
Sometimes, during the course of a research project, vital new information becomes available
about the treatment that is being studied. If this happens, your study doctor will tell you 
about it and discuss with you whether you want to, or whether you should, continue with the 
study. If you decide not to carry on, your study doctor will make arrangements for your care 
to continue. If you decide to continue in the study you will be asked to sign an updated 
consent form. 
Also, on receiving new information your study doctor might consider it to be in your best 
interests to withdraw you from the study treatment. Your study doctor will explain the 
reasons and arrange for your care to continue. If the study is stopped for any other reason, 
you will be told why and your continuing care will be arranged. 
3. What will happen if I don’t want to carry on with the study?
You can decide that you no longer wish to receive study treatment at any time. We would 
however like to keep in contact with your doctor so that we can continue to receive
information about your progress. If you do not wish us to have access to further information 
about your progress please inform your doctor. If you stop study treatment your doctor will 
continue to provide you with the best available care. 
4. What if there is a problem?
In the event that something goes wrong and you are harmed during this study there are no 
special compensation arrangements. However, The Medical Research Council, UK (MRC) as 
the legal sponsor of this study, will give sympathetic consideration to claims for non-
negligent harm suffered by a person as a result of a study, or other work supported by MRC. 
The hospital continues to have a duty of care to you, whether or not you are participating in 
an MRC supported study. The MRC does not accept liability for any breach in the hospital’s 
duty of care, or any negligence on the part of employees of hospitals. Negligence of NHS 
staff will be indemnified by the NHS or professional indemnity schemes. If you are harmed 
due to someone’s negligence, then you may have grounds for a legal action but you may 
have to pay fo r your legal costs.
If you wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms should be available to you. Participation in this study does not affect 
your normal rights to complain about any aspect of your treatment and care (contact
number details can be obtained from your hospital).
If you have private medical insurance you should consult with your insurer before agreeing
to take part.
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
124
MRC PIVOT Trial
Version 1.1, 25 March 2008 67
5. Will my taking part in this study be kept confidential?
All information which is collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital/surgery will have 
your name and address removed so that you cannot be recognised from it.
If you agree to join the study, some parts of your medical records and the data collected for 
the study will be looked at by authorised persons from the MRC. They may also be looked at 
by representatives from the regulatory authorities to check that the study is being carried 
out correctly. 
We will, if you give permission, contact your GP to notify them of your participation in the 
trial. We may also, if you give permission, contact other medical practitioners not involved in 
the research who are otherwise involved with your treatment to notify them of your
participation in the trial. 
We will ask if we can flag your records with the Office of National Statistics or trace them via 
the NHS Central Register so that if you move away or decide not to continue with the trial 
we will still be able to find out how you are doing. You will be asked a question about this on 
the consent form that you will have to sign before you are entered into the study. 
6. What will happen to any samples I give?
Blood samples will be taken at clinic visits to monitor your progress and to check for any side 
effects as well as for the special tests required in the study protocol. At some visits we will 
specifically take an extra blood sample to keep in reserve in case future tests are needed. 
Any leftover blood and these extra blood samples will be stored securely and confidentially 
using a study number that will be assigned to you, rather than your name or other 
information that could identify you. As part of the consent we are asking for your permission 
to store these specimens for a period of 3 years after the study has finished so that we are 
able to use them for possible other tests in the future. These samples would be gifted by you 
to the research team. Until the study has been completed we will not know for sure what 
tests might usefully be done on these specimens. However, future tests would not involve 
any tests on your genes (DNA). Any fu ture research on these samples taken will require 
further ethical review.
The researchers do not plan to contact you or your doctor with any results from future 
studies done on your stored specimens - this is because test are often experimental and 
should not be used to make decisions on treating your disease. Thus, while you will not 
benefit directly from any future research done, any results could be used to improve the 
treatment of HIV and its complications.
If you decide to provide blood for future research but change your mind later, you should 
inform your clinic that you do not want your samples used in future research. Your samples 
will then no longer be used.
7. What will happen to the results of the research study?
The results of the study will be published in a medical journal and on the website of the MRC 
Clinical Trials Unit – www.ctu.mrc.ac.uk.  Interim results may be presented at clinical
conferences. You will not be identified in any study report or publication. 
A summary of the overall study results for patients who have participated will be produced 
once the study has been completed and analysed. A copy of the final publication will also be 
available to you through your study doctor. 
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8. Who is organising and funding the research?
The research is funded by the NHS Health Technology Assessment (HTA) programme, and is 
sponsored and conducted by the Medical Research Council. 
The clinic you attend will be reimbursed for the additional costs incurred to them by your 
involvement in the study, such as the costs of blood tests and research nurse time. There 
will be no personal payments made to any member of staff for including you in this study.
9. Who has reviewed the study?
The study has been reviewed by the NHS HTA and the MRC. The study has also been given 
a favourable ethical opinion for conduct in the NHS by the Cambridgeshire 4 Research Ethics 
Committee.
10. Contact for Further Information
If you have any further questions concerning the study or if any problems arise during the 
study, please contact:
…………………………………………………………on telephone number…………………………………………..
 and 24-hour telephone contact number ………………………………………………………………………….
You may also find it helpful to contact i-Base, an independent information agency Treatment 
Information phone line 0808 800 6013 (open Mon-Wed 12-4pm). www.i-base.org.uk
Once again, we would like to thank you for taking the time to read this
information and for considering taking part in this study.
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APPENDIX 2: CONSENT FORM
(To be presented on local-headed paper)
Version 1.1, 25 March 2008
PIVOT: Protease Inhibitor monotherapy Versus Ongoing Triple -therapy in long-
term management of HIV disease 
EUDRACT: 2007-006448-23
ISRCTN04857074
Please initial box to agree
1. I confirm that I have read and understand the information sheet 
dated 25 March 2008 (Version 1.1) for the above study and have 
had the opportunity to ask questions and discuss it with my doctor.
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my
medical care or legal rights being affected.
3. I understand that sections of any of my medical notes may be
looked at by responsible individuals involved in the running of the 
study or from regulatory authorities where it is relevant to my 
taking part in research . I give permission for these individuals to 
have access to my records.
4. I give permission to be followed up through usual NHS mechanisms 
(e.g. Office for National Statistics). 
5. I agree to take part in  PIVOT, the PI monotherapy study.
6. (Optional) I agree that any left over blood stored during the study
can be used by the research team in future tests. I understand that 
this will not involve any tests on my genes (DNA). These samples 
are gifted to the research team.
7. (Optional) I agree to my GP being informed of my participation in 
this study.
_______________________ ____________________________________
Name of Participant Date Signature
_________________________ ____________________________________
Name of Person taking consent Date Signature
(if different from researcher)
________________________ ____________________________________
Researcher Date Signature
________________________ ____________________________________
Witness (if applicable) Date Signature
3 copies: 1 for patient, 1 for researcher, 1 to be kept with hospital notes
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APPENDIX 3: GP LETTER
(To be presented on local-headed paper)
[Date]
PIVOT: Protease Inhibitor monotherapy Versus Ongoing Triple-therapy in long-term
management of HIV disease
EUDRACT: 2007-006448-23
ISRCTN04857074
Dear Dr ____________
Your patient, ________________ , has consented to participate in the trial named above and 
given permission to notify you of their participation in the trial. On _____________ they 
were randomised to the _________________ arm of the trial.
This is a randomised controlled clinical trial to compare a strategy of switching to boosted 
protease inhibitor (PI) monotherapy to continuing combination antiretroviral therapy (ART) 
for long-term management of HIV -infected patients. 
This trial aims to determine whether a strategy of switching to PI monotherapy is non-
inferior to continuing triple drug therapy in terms of the proportion of patients who maintain 
all their available drug treatment options after at least 3 years of follow-up.
Please find enclosed a copy of the patient information sheet for this trial and contraindicated 
medication.
You will be kept up-to-date with your patient’s progress but if you have any concerns or 
questions regarding this study please contact the responsible doctor:
Dr _____________________________ at  __________________________(Hospital)
Tel: ______________________________
Kind regards,
[Name]
[Position]
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APPENDIX 4: PARTICIPATING SITES
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Birmingham Heartlands Hospital BSUH NHS Trust
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Boardsley Green East The Elton John Centre
Sussex House
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Birmingham B9 5SS Brighton BN2 1ES
Dr Humphrey Birley Dr Hitendra Thaker
Cardiff Royal Infirmary Castle Hill Hospital
Dept. of Genito-Urinary Medicine Infectious Diseases
Newport Road Castle Hill Road
Cottingham
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Dr Gary Brook Prof Brian Gazzard
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APPENDIX 7: TOXICITY TABLE
Division of AIDs table for grading severity of adult adverse experiences. Rockville: National 
Institute of Allergy and Infectious diseases, 1992. 
GRADING OF ADVERSE EVENTS
ULN= upper limit of local reference range (“upper limit of normal”)
Grade 1 Grade 2 Grade 3 Grade 4
HAEMATOLOGICAL
Haemoglobin g/dl 9.5-10.5 8.0-9.4 6.5-7.9 <6.5
Leucopoenia 10
9
/l 3.0-3.9 2.0-2.9 1.9-1.0 <1.0
Neutrophils 10
9
/l 1.00-1.50 0.75-0.99 0.50-0.74 <0.50
Platelets 10
9
/l 75-99 50-74 20-49 <20 or diffuse petechiae
Prothrombin time 1.01-1.25x ULN 1.26-1.50x ULN 1.51-3.00x ULN >3x ULN
Partial Prothrombin time 1.01-1.66x ULN 1.67-2.33x ULN 2.34-3.00x ULN >3x ULN
Methaemoglobin 5-9.9% 10.0-14.9% 15.0-19.9% >20%
BIOCHEMISTRY
Hyponatraemia mmol/l 130-135 123-129 116-122 <116 or mental status 
change or seizures
Hypernatraemia 146150 151-157 158-165 >165 or mental status 
change or seizures
Hypokalaemia mmol/l 3.0-3.4 2.5-2.9 or replacement 
required
2.0-2.4 or replacement 
or hospitalisation
<2.0 or paresis or ileus 
or life-threatening
arrhythmia
Hyperkalaemia 5.6-6.0 6.1-6.5 6.6-7.0 >7.0 or life-threatening
arrhythmia
Hypocalcaemia mmol/l
  corrected for albumin
1.99-2.14 1.79-1.98 1.56-1.78 <1.56 or life-threatening
arrhythmia
Hypercalcaemia
  corrected for albumin
2.70-2.93 2.94-3.19 3.20-3.44 >3.44 or life-threatening
arrhythmias
Hypomagnesaemia
  mmol/l
0.60-0.75 0.45-0.59 0.30-0.44 <0.30 or life-threatening
arrhythmias
Hypophosphataemia
  mmol/l
0.64-0.76 0.48-0.63 0.32-0.47 <0.32 or life-threatening
arrythmias
Hypoglycaemia mmol/l 3.1-3.6 2.2-3.0 1.7-2.1 <1.7 or mental status
change or coma
Hyperglycaemia
  (fasting)
6.5-9.0 9.1-14.0 14.1-28.0 >28.0 or ketoacidosis or 
seizures
Bilirubin mmol/l 1.1- 1.5x ULN 1.6- 2.5x ULN 2.6- 5.0x ULN >5.0x ULN
AST or ALT or GGT U/l 1.26-2.5x ULN 2.6-5.0x ULN 5.1-10x ULN >10x ULN
Alkaline phosphatase
  U/l
1.26-2.5x ULN 2.6-5.0x ULN 5.1-10x ULN >10x ULN
Amylase U/l
total or pancreatic
or salivary
1.1-1.5x ULN 1.6-2.0x ULN 2.1-5.0x ULN >5x ULN
Triglycerides (fasting)
mmol/l
1.8- 2.2 2.3-5.6 5.7- 10.0 >10.0
Creatinine µmol/l 1.1- 1.5x UL N 1.6- 3.0x ULN 3.1- 6.0x ULN >6.0x ULN or requires 
dialysis
Urea mmol/l 1.25-2.5x ULN 2.6- 5.0x ULN 5.1- 10.0x ULN >10.0x ULN
CK U/l 1.1-2.0x ULN 2.1-4.0x ULN 4.1-6.0x ULN >6x ULN
URINALYSIS
Proteinuria 1+ or <0.3% or <3g/l or 
<1g/day loss
2-3+ or 0.3-1.0% or 3-
10g/l or 1-2g/day loss
4+ or >1.0% or >10g/l 
or 2-3.5g/day loss
nephrotic syndrome or 
>3.5 g/day loss
Haematuria microscopic only gross, no clots gross + clots obstruction or requiring 
transfusion
GASTROINTESTINAL
Stomatitis/mouth ulcers mild discomfort, no 
limits on activity
some limits on eating or 
talking
eating/ talking very 
limited
requiring IV fluids
Nausea mild discomfort, 
maintains reasonable 
intake
moderate discomfort, 
significantly decreased 
intake
severe discomfort, no 
significant intake
minimal intake
Vomiting transient occasional or moderate orthostatic hypotension 
or IV fluids required
shock or hospitalisation 
required for IV fluids
Diarrhoea transient or up to 4 
loose stools/day
5-7 loose stools/day or 
nocturnal loose stools
orthostatic hypotension 
or >7 loose stools/day 
or requiring IV fluids
shock or hospitalisation 
required for IV fluids
DOI: 10.3310/hta20210 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 21
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Paton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
137
MRC PIVOT Trial
Version 1.1, 25 March 2008 80
Grade 1 Grade 2 Grade 3 Grade 4
Clinical pancreatitis mild abdominal pain, 
amylase <2.5x ULN, 
other causes excluded
moderate abdo. pain, 
amylase <2.5x ULN, 
other causes excluded
severe abdo. pain, 
amylase >2.5x ULN, 
hospitalised
severe abdo. pain, 
shock/ hypovolaemia, 
amylase>5x ULN, hosp.
NEUROLOGICAL
Consciousness difficulty in 
concentration or 
memory
mild confusion or 
lethargy <50% waking 
hours
disoriented or stupor 
>50% waking hours
coma or seizures
Mood mild anxiety or 
depression
treatment required for 
anxiety or depression
needs assistance due 
to depression, mania or 
anxiety
acute psychosis or 
incapacitated or 
hospitalised
Headache mild, no treatment transient, moderate, 
requires treatment
severe, responds to first 
narcotic
intractable needing 
repeated narcotics
Activities of daily living mild agitation or 
difficulty concentrating 
or confusion
some limitation ADL
and minimal treatment 
required
treatment and 
assistance needed, 
severe agitation or 
confusion
toxic psychosis or 
hospitalisation
NEUROMUSCULAR
Muscle strength subjective weakness mild objective signs, 
fully functional
objective weakness, 
limited function
paralysis
Clinical myopathy minimal findings moderate myalgia, may 
need NSAID, or 
difficulty climbing stairs 
or rising from sitting 
position, able to walk
moderate to severe 
myalgia needing 
NSAID, needing 
assistance walking or 
for general activities
severe myalgia 
unrelated to exercise 
requiring narcotics, 
unable to walk, or 
necrosis or oedema
Peripheral neuropathy mild paraesthesia, 
numbness, pain or 
weakness, not treated
moderate paraesthesia, 
numbness or pain, 
objective weakness, 
requires analgesic
severe, narcotic 
required, interferes with 
normal activity
intolerable,
incapacitating, unable 
to walk despite 
narcotics, paralysis
RESPIRATORY
Bronchospasm transient, no treatment, 
>70% peak flow or 
FEV1
requires treatment, 
normalises with 
bronchodilator, 50-70%
peak flow or FEV1
no normalisation with 
bronchodilator, 25-50%
peak flow or FEV1
cyanosis or intubated, 
<25% peak flow or 
FEV1
OTHER
Fever, oral, >12 hours 37.7-38.50C 38.6-39.50C 39.6-40.50C >40.50C
Fatigue mild, no decrease in 
activity
25-50% decrease in 
activity
>50% decrease in 
activity, cannot work
unable to care for self
Hypersensitivity pruritus without rash localised urticaria generalised urticaria or 
angioedema
anaphylaxis
Rash erythema or pruritus diffuse, maculopapular
rash, dry desquamation
vesiculation, moist 
desquamation,
ulceration
exfoliative dermatitis, 
mucous membrane 
involvement, or 
suspected Stevens-
Johnson or erythema 
multiforme
Haemorrhage microscopic or occult mild, no transfusion gross blood loss, 
transfused 1-2 units
massive blood loss, 
transfused >2 units
General transient, mild, easily 
tolerated
moderate, discomfort, 
interrupts usual activity
severe, considerable 
interference with usual 
activity
incapacitating or life-
threatening
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
138
MRC PIVOT Trial
Version 1.1, 25 March 2008 81
APPENDIX 8: DIAGNOSTIC CRITERIA FOR
SERIOUS AIDS-DEFINING ILLNESS 
These criteria are based on the 1993 US Centers for Disease Control and Prevention criteria 
for category C disease (ref MMWR 1992; 41 [No RR-17]: 1-19), but excluding oesophageal 
candidiasis and chronic mucocutaneous herpes simplex virus infection. Events that meet 
either the presumptive criteria (if available) or definitive criteria will count as endpoints in 
this trial. 
PRESUMPTIVE CRITERIA DEFINITIVE CRITERIA
CONSTITUTIONAL DISEASE
HIV Wasting syndrome Unexplained, involuntary weight loss >10% from 
baseline (week 0)  PLUS persistent diarrhoea with 
2 or more liquid stools/day > 1 month OR chronic 
weakness OR persistent fever > 1 month.
Should exclude other causes such as cancer, TB, 
MAI, cryptosporidiosis or other specific enteritis.
none
INFECTIONS
Candidiasis of bronchi, trachea or 
lungs
none macroscopic appearance at bronchoscopy 
or autopsy, or histology or cytology/smear 
(not culture)
Coccidiodomycosis, disseminated 
or extrapulmonary
none histology or cytology, culture or antigen 
detection from affected tissue
Cryptococcosis, meningitis or 
extrapulmonary
none histology or cytology/microscopy, culture 
or antigen detection from affected tissue
Cryptosporidiosis none persistent diarrhoea > 1 month, histology 
or microscopy
CMV retinitis Symptomatic or asymptomatic. Typical 
appearance on fundoscopy of discrete patches of 
retinal whitening, spreading along blood vessels, 
associated with vasculitis, haemorrhage and 
necrosis, confirmed by ophthalmologist.
none
CMV end-organ disease none compatible symptoms, plus histology or 
detection of antigen from affected tissue
CMV radiculomyelitis Leg weakness and decreased reflexes or 
syndrome consistent with cord lesion presenting 
subacutely over days to weeks. Myelogram shows 
no mass lesion. CSF shows >5 WBC with >50% 
polymorphs and no other pathogen or persistence 
of symptoms after appropriate treatment for other 
pathogens, OR CMV shown by PCR, antigen or 
culture.
none
CMV meningoencephalitis Rapid (days to 1-4 weeks) syndrome with 
progressive delirium, cognitive impairment  +/ -
seizures and fever (often with other CMV disease 
elsewhere). CT/MRI may show periventricular 
abnormalities with or without contrast 
enhancement. CSF may be normal or show 
evidence of CMV.
none
HSV visceral disease, e.g. 
bronchitis, pneumonitis, 
oesophagitis
none symptoms, plus histology or culture or 
detection of antigen from affected tissue
Histoplasmosis, disseminated or 
extrapulmonary
none symptoms, plus histology or culture or 
detection of antigen from affected tissues
Isosporiasis none persistent diarrhoea > 1 month, histology 
or microscopy
Leishmaniasis, visceral none symptoms, plus histology
Microsporidiosis none persistent diarrhoea > 1 month, histology 
or microscopy
MAC, and other atypical 
mycobacteriosis
Symptoms of fever, fatigue, anaemia or diarrhoea, 
plus AFBs seen in stool, blood, body fluid or tissue 
but not grown on culture, and no concurrent 
diagnosis of TB, except pulmonary
symptoms of fever, fatigue, anaemia or 
diarrhoea, culture from stool, blood, body 
fluid or tissue, except  pulmonary
Tuberculosis, pulmonary Symptoms of fever, dyspnoea, cough, weight loss 
or fatigue, plus AFBs seen in sputum or lavage or 
lung tissue but not grown in culture, plus responds
to standard TB treatment
symptoms of fever, dyspnoea, cough, 
weight loss or fatigue, plus culture from 
sputum or lavage or lung tissue
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PRESUMPTIVE CRITERIA DEFINITIVE CRITERIA
Tuberculosis, extrapulmonary Symptoms, plus AFBs seen from affected tissue or 
blood but not grown in culture, concurrent 
diagnosis of pulmonary TB or responds to 
standard TB treatment
symptoms, plus culture from blood or 
affected tissue
PCP Recent symptoms, plus typical CXR appearance if 
on PCP prophylaxis or any CX R appearance if not 
on prophylaxis and CD4+ <200, negative 
bronchoscopy if already treated for PCP for > 7 
days or not done, no bacterial pathogens in 
sputum, and responds to PCP treatment
microscopy or histology
Extrapulmonary pneumocystis none symptoms plus microscopy or histology
Recurrent bacterial pneumonia Second pneumonic episode within 1 year, new 
CXR appearance, symptoms and signs, diagnosed 
by a doctor
second pneumonic episode with 1 year, 
new CXR appearance, detection of 
bacterial pathogen
PML, Progressive multifocal 
leukoencephalopathy
Symptoms and brain scan consistent with PML, 
and no response to toxo treatment
histology
Recurrent salmonella septicaemia none second distinct episode, culture
Cerebral toxoplasmosis Symptoms of focal intracranial abnormality or 
decreased consciousness, and brain scan 
consistent with lesion(s) having mass effect or 
enhanced by contrast, and either positive 
toxoplasma serology or responds to treatment 
clinically and by scan
histology or microscopy
Other extrapulmonary
toxoplasmosis
none symptoms plus histology or microscopy
NEOPLASMS
KS, Kaposi’s sarcoma Typical appearance without resolution. clinicians 
who have seen few cases should not make 
presumptive diagnoses
Histology
Primary cerebral lymphoma Symptom s consistent with lymphoma, at least one 
lesion with mass effect on brain scan, no response 
clinically and by scan to toxoplasma treatment
B-cell, non-Hodgkin’s lymphoma none histology
Cervical carcinoma, invasive none histology, not carcinoma-in-situ
NEUROLOGICAL
HIV encephalopathy Cognitive or motor dysfunction interfering with 
usual activity, progressive over weeks or months in 
the absence of another condition to explain the 
findings, should have brain scan +/- CSF to 
exclude other causes. should be grade 2 or worse 
in at least 2 domains by NARS (see below) 
excluding abnormal domains at trial entry
none
OTHER
Indeterminate intracerebral 
lesion(s)
Neurological illness with evidence for an 
intracerebral lesion(s) by brain scan where the 
differential diagnosis is either cerebral 
toxoplasmosis, PML, cerebral lymphoma or HIV 
encephalopathy
none
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ABBREVIATED NARS (Neuropsychiatric AIDS Rating Scale) grading for  HIV 
ENCEPHALOPATHY
Adapted from: Price RW, Brew BJ. The AIDS dementia complex. J Infec t Dis 1988; 158 (5): 
1079-83, and Hughes CP, Berg L, Danziger WL. A new clinical scale for the staging of 
dementia. Brit J Psych 1982; 140: 566-92.
Cognitive-Behavioural Domains
Orientation Memory Motor Behaviour Problem
solving
Activities of 
daily living
NARS stage
0.5 fully oriented complains of 
memory
problems
fully ambulatory 
slightly slowed 
movements
normal has slight 
mental slowing
slight
impairment in 
business
dealings
1 fully oriented, 
may have brief 
periods of 
“spaciness
mild memory 
problems
balance, co-
ordination and 
handwriting
difficulties
more irritable, 
labile or 
apathetic,
withdrawn
difficulty
planning and 
completing work
can do simple 
daily tasks, may 
need prompting
2 some
disorientation
memory
moderately
impaired, new 
learning
impaired
ambulatory but 
may require 
walking aid
some
impulsivity or 
agitated
behaviour
severe
impairment,
poor social 
judgement, gets 
lost easily
needs
assistance with 
ADLs
3 frequent
disorientation
severe memory 
loss, only 
fragments of 
memory remain
ambulatory with 
assistance
may have 
organic
psychosis
judgement very 
poor
cannot live 
independently
4 confused and 
disoriented
virtually no 
memory
bedridden mute and 
unresponsive
no problem 
solving ability
nearly
vegetative
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APPENDIX 9: DIAGNOSTIC CRITERIA FOR
SERIOUS NON-AIDS-DEFINING ILLNESS
These criteria are based on those used in long term clinical endpoint trials by the INSIGHT 
research network, with additional criteria for acute liver failure, severe acute pancreatitis, 
severe lactic acidaemia, severe facial lipoatrophy and severe peripheral neuropathy that are 
based on standard toxicity criteria or definitions developed in case -definition studies. 
DIAGNOSTIC CRITERIA
Serious Non-AIDS event
Acute myocardial 
infarction (MI)
A or (B+C) or (B+D): (A) Acute MI demonstrated as the cause of death on autopsy; (B) 
Occurrence of a compatible clinical syndrome, including symptoms (e.g. chest pain) consistent 
with myocardial ischaemia; (C) Development of (i) evolving new Q waves, or (ii) evolving ST 
elevation, based on at least two EKGs taken during the same hospital admission; (D) 
Diagnostic elevation of CK-MB to more than twice the upper limit of normal in the laboratory 
performing the study, or diagnostic elevation of troponin above ULN.
Coronary artery disease 
requiring invasive 
procedures
Written report in medical record detailing procedure performed for treating coronary artery 
disease, including: coronary artery bypass graft, coronary artery stent implant, coronary 
artherectomy, and percutaneous tran sluminal angioplasty.
Cirrhosis (A+B+C) or (A+B+D) or (A+B+E) or F or G: (A) Clinical evidence of cirrhosis, with at least one 
of the following: ascites, hepatic encephalopathy, gastric or oesophageal varices, or signs of 
portal hypertension on endoscopy, without another explanation for these symptoms; (B) At 
least one of the following: Increased PT or INR above ULN, serum AST > serum ALT, platelet 
count <150,000; (C) albumin <3 g/dL or <30 g/L; (D) A positive result on an approved 
diagnostic fibrosis panel, e.g. Fibrosure/Fibrotest; (E) A positive result on transient 
elastography (Fibroscan) consistent with cirrhosis; (F) MRI, CT or ultrasound imaging 
consistent with cirrhosis (e.g. nodular liver, reversal of flow in portal vein); (G) Histologic 
evidence obtained by liver biopsy or autopsy.
Acute liver failure ALT or AST greater than 5 times ULN, with clinical jaundice and encephalopathy.
End-stage renal disease A or B or C: (A) Haemodialysis or pertitoneal dialysis for a period of at least three months,
documented in a clinical note; (B) A kidney transplant, documented in a clinical note; (C) two 
consecutive measurements of serum creatinine clearance rate < 15 ml/min per 1.73 m
2
calculated using the Cockcroft-Gault equation.
Stroke (A+D) or (A+B) or (A+C) or D or E: (A) Acute onset with a clinically compatible course, 
including unequivocal objective findings of a localising neurologic deficit; (B) CT or MRI 
compatible with diagnosis of stroke and current neurologic signs and symptoms; (C) Positive 
lumbar puncture compatible with subarachnoid haemorrhage; (D) Stroke diagnosed as cause 
of death at autopsy; (E) Death certificate or death note from medical record listing stroke as 
cause of death.
Severe acute pancreatitis Severe abdominal pain requiring hospitalisation and blood amylase levels greater than 2.5 
times the upper limit of normal.
Severe lactic acidaemia Two consecutive measures of peripheral blood lactate > 5 mmol/l (45 mg/dl) or demonstrated 
lactic acidosis (arterial blood pH < 7.34, blood bicarbonate < 20 mmol/l and blood lactate levels 
above normal range).
Severe facial lipoatrophy Facial fat loss that is considered to be obvious to both patient and clinician and that is 
considered by the clinician to have the characteristic appearance of HIV-associated
lipoatrophy.
Severe peripheral 
neuropathy
Severe pain, numbness or tingling in the feet and/or legs that interferes with normal activities 
and requires narcotic analgesia for control.
Non-AIDS malignancy 
(excluding Kaposi’s 
sarcoma (KS), lymphoma, 
invasive cervical cancer)
Diagnosis of cancer other than lymphoma, KS or invasive cervical cancer and a written report 
in the medical record from the hospitalisation during which the diagnosis was established, or in 
a pathology report that established the diagnosis, or in an autopsy report.
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APPENDIX 10: PROTEASE INHIBITOR INFORMATION
BNF November 2007 (www.bnf.org)
Cautions
Protease inhibitors are associated with hyperglycaemia and should be used with caution in 
diabetes (see Lipodystrophy Syndrome). Caution is also needed in patients with haemophilia 
who may be at increased risk of bleeding. Protease inhibitors should be used with caution in 
hepatic impairment (BNF Appendix 2); the risk of hepatic side-effects is increased in patients
with chronic hepatitis B or C. Atazanavir, darunavir, fosamprenavir, and tipranavir may be 
used at usual doses in patients with renal impairment, but other protease inhibitors should 
be used with caution in renal impairment (BNF Appendix 3). Protease inhibitors should also 
be used with caution during pregnancy (BNF Appendix 4).
Side-effects
Side-effects of the protease inhibitors include gastro-intestinal disturbances (including
diarrhoea, nausea, vomiting, abdominal pain, flatulence), anorexia, hepat ic dysfunction,
pancreatitis; blood disorders including anaemia, neutropenia, and thrombocytopenia; sleep 
disturbances, fatigue, headache, dizziness, paraesthesia, myalgia, myositis, rhabdomyolysis; 
taste disturbances; rash, pruritus, Stevens-Johnson syndrome, hypersensitivity reactions 
including anaphylaxis; see also notes above for lipodystrophy and metabolic effects
(Lipodystrophy Syndrome), and Osteonecrosis.
Lipodystrophy Syndrome
Metabolic effects associated with antiretroviral treatment include fat redistribution, insulin 
resistance and dyslipidaemia; collectively these have been termed lipodystrophy syndrome. 
Fat redistribution (with loss of subcutaneous fat, increased abdominal fat, ‘buffalo hump’ and 
breast enlargement) is associated with regimens containing protease inhibitors and
nucleoside reverse transcriptase inhibitors. Stavudine, and to a lesser extent zidovudine, are 
associated with a higher risk of lipoatrophy and should be used only if alternative regimens 
are not suitable.
Dyslipidaemia (with adverse effects on body lipids) is associated with antiretroviral
treatment, particularly with protease inhibitors. Protease inhibitors are associated with insulin 
resistance and hyperglycaemia. Plasma lipids, blood glucose and the usual risk factors for 
atherosclerotic disease should be taken into account before prescribing regimens containing 
a protease inhibitor; patients receiving protease inhibitors should be monitored for changes 
in plasma lipids and blood glucose.
Sub-sections:
AMPRENAVIR
ATAZANAVIR
DARUNAVIR
FOSAMPRENAVIR
INDINAVIR
LOPINAVIR WITH RITONAVIR
NELFINAVIR
RITONAVIR
SAQUINAVIR
TIPRANAVIR
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AMPRENAVIR
Interactions Liver disease Avoid oral solution due to high propylene glycol content; 
without low-dose ritonavir, reduce dose of amprenavir
capsules to 450 mg every 12 hours in moderate hepatic 
impairment and reduce dose to 300 mg every 12 hours in 
severe impairment
Renal impairment Mild-moderate: Use oral solution with caution due to high 
propylene glycol content 
Severe: Avoid ora l solution
Pregnancy Avoid oral solution due to high propylene glycol content; 
manufacturer advises use capsules only if potential benefit 
outweighs risk
Indications HIV infection in combination with other antiretroviral drugs in patients previously 
treated with other protease inhibitors
Cautions Rash.  Rash may occur, usually in the second week of therapy; discontinue permanently 
if severe rash with systemic or allergic symptoms or, mucosal involvement; if rash mild 
or moderate, may continue without interruption—rash usually resolves within 2 weeks 
and may respond to antihistamines
Contra -indications Breast-feeding not advised in HIV infection
Side-effects see notes above; also reported, rash including rarely Stevens-Johnson syndrome (see 
also above); tremors, oral or perioral paraesthesia, mood disorders including depression
Dose Agenerase®(GSK)
Capsules, ivory, amprenavir 50 mg. 
Excipients include vitamin E 36 units/50 mg amprenavir (avoid vitamin E supplements) 
Dose  adult and adolescent over 12 years, body -weight over 50 kg, 1.2 g every 12 
hours; adult and adolescent over 12 years, body-weight under 50 kg and child 4–12
years, 20 mg/kg every 12 hours (max. 2.4 g daily)
With low -dose ritonavir, adult and adolescent over 12 years, body -weight over 50 kg, 
amprenavir 600 mg every 12 hours with ritonavir 100 mg every 12 hours 
Oral solution , grape -bubblegum- and peppermint -flavoured, amprenavir 15 mg/mL. 
Excipients include vitamin E 46 units/mL (avoid vitamin E supplements), propylene 
glycol 550 mg/mL (see Excipients)
Electrolytes: K+ 26 micromol/mL, Na+ 174 micromol/mL
Dose  adult and child over 4 years, 17 mg/kg every 8 hours (max. 2.8 g daily); child 
under 4 years not recommended 
Note:  The bioavailability of Agenerase® oral solution is lower than that of capsules; 
the two formulations are not interchangeable on a milligram-for-milligram basis
ATAZANAVIR
Interactions Liver disease Manufacturer advises caution in mild hepatic impairment; 
avoid in moderate to severe hepatic impairment
Pregnancy Manufacturer advises use only if potential benefit outweighs 
risk; theoretical risk of hyperbilirubinaemia in neonate if used 
at term
Indications HIV infection in combination with other antiretroviral drugs in patients previously 
treated with antiretrovirals
Cautions see notes above; also concomitant use with drugs that prolong PR interval; cardiac 
conduction disorders; predisposition to QT interval prolongation (including electrolyte 
disturbances, concomitant use of drugs that prolong QT interval); interactions: BNF 
Appendix 1 (atazanavir)
Contra -indications Breast-feeding not advised in HIV infection
Side-effects see notes above; also peripheral neurological symptoms; less commonly mouth ulcers, 
hypertension, syncope, chest pain, dyspnoea, abnormal dreams, amnesia, depression, 
anxiety, weight changes, increased appetite, gynaecomastia, nephrolithiasis, urinary 
frequency, haematuria, proteinuria, arthralgia, and alopecia; rarely 
hepatosplenomegaly, oedema, palpitation, and abnormal gait
Dose with low -dose  ritonavir and food, adult over 18 years, 300 mg once daily with ritonavir 
100 mg once daily
Reyataz®(Bristol-Myers Squibb)
Capsules , atazanavir (as sulphate) 100 mg (dark blue/white); 150 mg (dark blue/light 
blue); 200 mg (dark blue), 
DARUNAVIR
Interactions Liver disease Manufacturer advises caution in mild to moderate hepatic 
impairment; avoid in severe hepatic impairment—no
information available
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Pregnancy Manufacturer advises use only if potential benefit outweighs 
risk
Indications HIV infection (that has not responded to treatment with other protease inhibitors) in 
combination with other antiretroviral drugs
Cautions see notes above; also sulpho namide sensitivity
Contra -indications Breast-feeding not advised in HIV infection
Side-effects see notes above; also myocardial infarction, transient ischaemic attack, syncope, 
tachycardia, hypertension, flushing, peripheral oedema, dyspnoea, cough, hiccups,
peripheral neuropathy, anxiety, confusion, memory impairment, mood changes, 
abnormal coordination, weight gain, hyperthermia, hypothyroidism, osteoporosis, 
gynaecomastia, erectile dysfunction, dysuria, polyuria, nephrolithiasis, renal failure, 
hyponatraemia, arthralgia, keratoconjuntivitis sicca, salivation changes, mouth ulcers, 
increased sweating, and alopecia
Dose With low -dose ritonavir, adult over 18 years, 600 mg twice daily
Missed dose  If a dose is more than 6 hours late, the missed dose should not be taken 
and the next dose should be taken at the normal time
Prezista®(Janssen-Cilag)
Tablets , orange, f/c, darunavir (as ethanolate) 300 mg
FOSAMPRENAVIR
Interactions Note Fosamprenavir is a pro-drug of amprenavir
Indications HIV infection in combination with other antiretroviral drugs
Cautions see notes above and under Amprenavir
Contra -indications Breast-feeding not advised in HIV infection
Side-effects see notes above and under Amprenavir
Dose with low -dose ritonavir, adult over 18 years, 700 mg twice daily
Note  700 mg fosamprenavir is equivalent to approx. 600 mg amprenavir
Telzir®(GSK)
Tablets , f/c, pink, fosamprenavir (as calcium) 700 mg 
Oral suspension , fosamprenavir (as calcium) 50 mg/mL, (grape-bubblegum-and
peppermint -flavoured) (with 10-mL oral syringe) 
INDINAVIR
Interactions Liver disease Increased risk of nephrolithiasis; reduce dose to 600 mg every 
8 hours in mild to moderate hepatic impairment; not studied in 
severe impairment
Pregnancy Toxicity in animal studies; manufacturer advises use only if 
potential benefit outweighs risk; theoretical risk of 
hyperbilirubinaemia and renal stones in neonate if used at 
term
Indications HIV infection in combination with nucleoside reverse transcriptase inhibitors
Cautions see notes above; also ensure adequate hydration (risk of nephrolithiasis especially in 
children); patients at risk of nephrolithiasis (monitor for nephrolithiasis); avoid in 
porphyria (section 9.8.2); interactions: BNF Appendix 1 (indinavir)
Contra -indications Breast-feeding not advised in HIV infection
Side-effects see notes above; also reported, dry mouth, hypoaesthesia, dry skin, hyperpigmentation, 
alopecia, paronychia, interstitial nephritis (with medullary calcification and cortical 
atrophy in asymptomatic severe leucocyturia), nephrolithiasis (may require interruption 
or discontinuation; more frequent in children), dysuria, haematuria, crystalluria, 
proteinuria, pyuria (in children), pyelonephritis; haemolytic anaemia
Dose 800 mg every 8 hours; child and adolescent4–17 years, 500 mg/m2 every 8 hours (max. 
800 mg every 8 hours); child under 4 years, safety and efficacy not established
Crixivan®(MSD)
Capsules , indinavir (as sulphate), 200 mg; 400 mg, Counselling  Administer 1 hour 
before or 2 hours after a meal; may be administered with a low -fat light meal; in 
combination with didanosine tablets, allow 1 hour between each drug (antacids in 
didanosine tablets reduce absorption of indinavir); in combination with low-dose
ritonavir, give with food
Note  Dispense in original container (contains dessicant)
LOPINAVIR WITH RITONAVIR
Interactions Liver disease Avoid oral solution because of propylene glycol content; 
manufacturer advises avoid capsules and tablets in severe 
hepatic impairment
Renal impairment Avoid oral solution due to propylene glycol content; use 
capsules and tablets with caution in severe impairment
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Pregnancy Avoid oral solution due to high propylene glycol content; 
manufacturer advises use capsules and tablets only if potential 
benefit outweighs risk (toxicity in animal studies)
Indications HIV infection in combination with other antiretroviral drugs
Cautions see notes above; concomitant use with drugs that prolong QT interval; pancreatitis (see 
below); interactions: BNF Appendix 1 (lopinavir, ritonavir)
Pancreatitis  Signs and symptoms suggestive of pancreatitis (including raised serum 
lipase) should be evaluated—discontinue if pancreatitis diagnosed
Contra -indications Breast-feeding not advised in HIV infection
Side-effects see notes and Cautions above; also electrolyte disturbances in children; less commonly 
dysphagia, appetite changes, weight changes, cholecystitis, hypertension, myocardial 
infarction, palpitation, thrombophlebitis, vasculitis, chest pain, oedema, dyspnoea, 
cough, agitation, anxiety, amnesia, ataxia, hypertonia, confusion, depression, abnormal 
dreams, extrapyramidal effects, neuropathy, influenza -like syndrome, Cushing’s 
syndrome, hypothyroidism, menorrhagia, amenorrhoea, sexual dysfunction, breast 
enlargement, d ehydration, nephritis, hypercalciuria, lactic acidosis, arthralgia, 
hyperuricaemia, abnormal vision, otitis media, tinnitus, dry mouth, sialadenitis, mouth 
ulceration, periodontitis, acne, alopecia, dry skin, sweating, skin discoloration, nail 
disorders, rarely prolonged PR interval
Dose Kaletra®(Abbott)
Capsules , orange, lopinavir 133.3 mg, ritonavir 33.3 mg
Dose  adult and child over 2 years with body surface area of 1.4 m2 or greater, 3 
capsules twice daily with food; child over 2 years with body surface area less than 1.4 
m2, oral solution preferred; if oral solution inappropriate and body surface area 0.4–0.75
m2, 1 capsule twice daily, body surface area 0.8–1.3 m2, 2 capsules twice daily
Tablets , yellow, f/c, lopinavir 200 mg, ritonavir 50 mg 
Dose  adult and child with body surface area greater than 1.3 m2 or body-weight 40 kg 
and over, 2 tablets twice daily
Oral solution , lopinavir 400 mg, ritonavir 100 mg/5 mL
Excipients include propylene glycol 153 mg/mL (see Excipients), alcohol 42%
Dose  adult and adolescent, 5 mL twice daily with food; child over 2 years 2.9 mL/m2 
twice daily with food, max. 5 mL twice daily; child under 2 years, safety and efficacy not 
established
Note  5 mL oral solution = 3 capsules = 2 tablets; where appropriate, capsules may be 
used instead of oral solution
NELFINAVIR
Interactions Liver disease No information available—manufacturer advises caution
Renal impairment No information available—manufacturer advises caution
Pregnancy No information available—manufacturer advises use only if 
potential benefit outweighs risk
Indications HIV infection in combination with other antiretroviral drugs
Cautions see notes above; interactions: see BNF Appendix 1 (nelfinavir)
Contra-indications Breast-feeding not advised in HIV infection
Side-effects see notes above; also reported, fever
Dose 1.25 g twice daily or 750 mg 3 times daily; child 3–13 years, initially 50–55 mg/kg twice 
daily (max. 1.25 g twice daily) or 25–30 mg/kg 3 times daily (max. 750 mg 3 times daily)
Viracept®(Roche)
Tablets , blue, f/c, nelfinavir (as mesilate) 250 mg
Oral powder , nelfinavir (as mesilate) 50 mg/g. 
Excipients include aspartame (section 9.4.1)
Counselling  Powder may be mixed with water, milk, formula feeds or pudding; it should 
not be mixed with acidic foods or juices owing to its taste
RITONAVIR
Interactions Hepatic impairment Avoid in decompensated liver disease; in severe hepatic 
impairment without decompensation, use ‘booster’ doses with
caution (avoid treatment doses)
Pregnancy Manufacturer advises use only if potential benefit outweighs 
risk—no information available
Indications HIV infection in combination with nucleoside reverse transcriptase inhibitors; low doses 
used to increase effect of some protease inhibitors
Cautions see notes above; avoid in porphyria (section 9.8.2); pancreatitis (see below); 
interactions: see BNF Appendix 1 (ritonavir).
Pancreatitis  Signs and symptoms suggestive of pancreatitis (including raised serum 
lipase) should be evaluated—discontinue if pancreatitis diagnosed
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Contra -indications Breast-feeding not advised in HIV infection
Side-effects see notes and Cautions above; also diarrhoea (may impair absorption—close monitoring 
required), vasodilatation, cough, throat irritation, anxiety, perioral and peripheral 
paraesthesia, hyperaesthesia, fever, decreased blood thyroxine concentration, electrolyte 
disturbances, raised uric acid, dry mouth, mouth ulcers, and sweating; less commonly 
increased prothrombin t ime and dehydration; syncope, postural hypotension, seizures, 
menorrhagia, and renal failure also reported
Dose initially 300 mg every 12 hours for 3 days, increased in steps of 100 mg every 12 hours 
over not longer than 14 days to 600 mg every 12 hours; child over 2 years initially 250 
mg/m2 every 12 hours, increased by 50 mg/m2 at intervals of 2–3 days to 350 mg/m2 
every 12 hours (max. 600 mg every 12 hours).
Low -dose booster to increase effect of other protease inhibitors, 100–200 mg once or 
twice daily
Norvir®(Abbott)
Capsules , ritonavir 100 mg
Excipients include alcohol 12%
Oral solution , sugar-free, ritonavir 400 mg/5 mL 
Counselling  Oral solution contains 43% alcohol; bitter taste can be masked by mixing 
with chocolate milk; do not mix with water, measuring cup must be dry
With lopinavir: See under Lopinavir with ritonavir
SAQUINAVIR
Interactions Hepatic impairment Manufacturer advises caution in moderate hepatic impairment; 
avoid in severe impairment
Renal impairment severe Dose adjustment possibly required
Indications HIV infection in combination with other antiretroviral drugs
Cautions see notes above; concomitant use of garlic (avoid garlic capsules— reduces plasma-
saquinavir concentration); interactions: BNF Appendix 1 (saquinavir)
Contra -indications Breast-feeding not advised in HIV infection
Side-effects see notes above; also dyspnoea, increased appetite, peripheral neuropathy, convulsions, 
changes in libido, renal impairment, dry mouth, and alopecia
Dose with low-dose ritonavir, adult and adolescent over 16 years, 1 g every 12 hours
Invirase®(Roche)
Capsules , brown/green, saquinavir (as mesilate) 200 mg 
Tablets , orange, f/c, saquinavir (as mesilate) 500 mg
TIPRANA VIR
Interactions See BNF Appendix 1
Indications HIV infection resistant to other protease inhibitors, in combination with other 
antiretroviral drugs in patients previously treated with antiretrovirals
Cautions see notes above; also patients at risk of increased bleeding from trauma, surgery or 
other pathological conditions; concomitant use of drugs that increase risk of bleeding; 
interactions: BNF Appendix 1 (tipranavir).
Hepatotoxicity  Potentially life-threatening hepatotoxicity reported; monitor liver function 
before treatment then on weeks 2, 4 and 8 of treatment, then every 2–3 months (every 
2 weeks for first 3 months then monthly in those with hepatic impairment (BNF Appendix 
2)). Discontinue if signs or symptoms of hepatitis develop or if liver-function abnormality 
develops (consult product literature)
Contra-indications Breast-feeding not advised in HIV infection
Side-effects see notes above; also dyspnoea, anorexia, peripheral neuropathy, influenza-like
symptoms, renal impairment and photosensitivity; rarely dehydration
Dose With low-dose ritonavir, 500 mg twice daily; child safety and efficacy not established
Aptivus®(Boehringer Ingelheim)
Capsules , pink, tipranavir 250 mg 
Excipients include ethanol 100 mg per capsule
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APPENDIX 11: JOINT BRITISH SOCIETIES 
CARDIOVASCULAR RISK PREDICTION CHARTS
BNF September 2006 (www.bnf.org)
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APPENDIX 12: LABORATORY METHODS &
SPECIMEN STORAGE 
Storage specimens
4mls of EDTA blood to be taken for storage at baseline, Week 4 (PI monotherapy arm only), 
Week 12 and then annually. An additional sample will be taken at any visit where a second 
VL test is performed as confirmation of viral rebound.
These samples will be collected in a 1x 4ml EDTA collection tube, processed within 4 hours 
from the time of blood draw. Any leftover blood will be separated, and the plasma stored in 
1ml aliquots at -70°C in case future testing is required. 
Stored blood samples will be labelled with the patient’s trial number and draw date. Samples 
must be processed, stored and documented until collection and centralisation of the samples 
at the central repository at Mill Hill. Shipping of specimens from sites to the central
repository will be conducted annually.
Central resistance testing
In order to be able to extrapolate the findings beyond the 5-year period of the trial, it will be 
important to document that the patients on PI monotherapy who remain virologically 
suppressed during the trial have full virological suppression (to the same extent as patients 
on triple-therapy). Therefore, a single sample will be sent for testing by a very low copy 
assay (<5 copies/ml) at a central laboratory in all patients who have VL <50 copies/ml on 
conventional testing at the last follow-up visit of the trial. 
Therapeutic Drug Monitoring 
Patients in the PI monotherapy arm will have a blood sample taken at the Week 4 visit for 
measurement of the trough level of the PI. Samples in the UK will be sent for TDM
processing via normal hospital procedures to Delphic Diagnostics. Results will be made
available to the sites within approximately 2 weeks  of sample collection.
Arrangements for TDM at non-UK sites are to be confirmed.
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APPENDIX 13: NEUROCOGNITIVE ASSESSMENT 
TOOLS
Hopkins Verbal Learning test-revised (HVLT-R)
For this test the examiner will read aloud a list of 12 words and immediately after finishing 
that, the participant will be asked to freely recall them. The test is performed a further two 
times asking the participant to recall the words immediately after each reading. After the 
third exercise of free recall is completed, the examiner will read aloud a list of 24 words 
which includes the 12 words used for the previous part of the test. The participant will be 
asked to answer “yes” or “no” as the examiner reads each word if s/he recognises that word 
as one of the words included in the original 12 word list used for the first part of the test. 
The list of 24 words to be used in the second part of the test (recognition trial) includes, 
apart from the 12 “target words”, 6 words that are categorically related to the target words. 
It also includes 6 unrelated words. After completing all the other neuropsychological tests 
and the MOS-HIV quality of life questionnaire (i.e. after about 15-20 minutes) the examiner 
will ask the participant to recall the words read at the beginning of the test (without the 
examiner repeating the list again) in order to assess delayed memory. 
Each word recalled is scored during the immediate free recalling section of the test (range 0 
– 36) and during the delayed recall test (range 0 – 12). In addition, the total number of 
correct responses is scored from the recognition section of the test. To control for the effect 
of practising on repeated administration a different version of the test, with different lists of 
words, will be used at each visit. A number of different versions of the test are commercially 
produced (Psychological Assessment Resources Inc). 
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Sample of Hopkins verbal learning test
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Trail Making test: Part A 
Procedure
1) Position the participant at a table.
2) Place the practice sheet for part A flat on the table in front of them.
3) Provide the participant with a pen and explain the test to them showing the elements 
in the practice sheet. Ask the participant to draw a line between number 1 and
number 2, then to draw a line between 2 and 3 and so on, in order, until reaching 
the end (number 8 in the practice sheet). 
4) Ask the participant to not lift the pen from the paper.
5) Ask the participant to complete the practice test.
6) After successful completion of the practice test, show the participant the test sheet.
Explain to the participant that on this page there are more numbers, but the
procedure is the same.
7) Ask the participant to complete the test in the same way s/he completed the practice 
sheet. The participant must draw lines between numbers in numerical order starting 
from number 1 and finishing at number 25.
8) Ask the participant to draw the lines as fast as s/he can, but remind them not to lift 
the pen from the paper.
9) Start timing and continue timing the test even if the patient makes errors until s/he
reaches the end (number 25).
10) If the participant makes an error, say “stop” and return the participant to his or her 
last correct response.
11) Stop timing when the participant reaches number 25 and record the time.
Trail Making test: Part B 
Procedure
1) Place the practice for part B on the table in front of the participant.
2) Explain to the participant that on this sheet there are some numbers and letters. The 
beginning of the task is again number 1. However, this time the participant must 
draw a line from number 1 to letter A, then a line between A and 2, followed by a line 
from 2 to letter B, then a line from B to 3 and from 3 to C and so on. The participant
must continue alternating numbers and letters in ascending numerical and
alphabetical order until reaching the end (letter D on the practice sheet).
3) After successfully completing the practice sheet, show the test sheet to the
participant.
4) Again, explain to the participant that in this sheet there are more number and letters. 
Ask the participant to complete the test in the same way s/he completed the practice 
one.
5) Ask the participant to draw the lines as fast as s/he can, but remind them not to lift 
the pen from the paper until the test is completed.
6) Start timing and continue timing the test even if the participant makes errors until 
s/he reaches the end (letter L). As in part A, if the participant makes an error, return 
the participant to his or her last correct response.
7) Stop timing when the participant reaches letter L and record the time.
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Sample of Trail Making test: Part A 
Sample of Trail Making test: Part B
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
156
MRC PIVOT Trial
Version 1.1, 25 March 2008 99
Grooved Pegboard test 
The Grooved Pegboard (Lafayette Instruments) is a metal board (10 x 10 cm) with 25 holes 
arranged in 5 rows containing 5 holes each. Every hole on the board has a channel or groove 
randomly orientated in different directions. The kit also includes 25 metal round pegs with a 
key or ridge running longitudinally which must be placed in the holes. To do so, the
participant needs to rotate the pegs to the correct position for insertion. 
For the test, the examiner will ask the participant to insert all the 25 the pegs as fast as s/he 
can.
The participant must complete one row before starting a new one. 
The test is timed, so the examiner will start timing when the participant is ready to begin the 
test and will stop timing only when the last peg is properly inserted. The test will be 
performed with each hand starting with the dominant one. Time to completion is scored 
separately for each hand.
Example of Grooved Pegboard:
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